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i
Abstract
The combination of high throughput omics (i.e. genomics or proteomics) and machine
learning oﬀers new possibilities for clinical diagnostics and the detection of biomarkers.
One disease for which no reliable prognostic marker has been found yet is bronchiolitis
obliterans (BO), a clinical manifestation of chronic rejection after lung transplantation.
BO is the major limiting factor for long-term survival after lung transplantation, and
manifests as a chronic bronchiolar inﬂammation accompanied by progressive sub-mucosal
ﬁbrosis leading to gradual obliteration of the bronchiolar lumen. The resulting reduction
in forced expiratory volume per second (FEV1) is deﬁned as the bronchiolitis obliter-
ans syndrome (BOS). As chronic lung transplant failure occurs more frequently than
in other organ transplants, molecular markers for early BO and BOS detection are ur-
gently required to adapt the patients immunosuppressive regimen when airway damage
is minimal. To achieve this goal, gene expression in bronchial epithelial cells (microarray
anaylsis) and on the proteome level in bronchoalveolar lavage ﬂuid (BALF)(mass spec-
trometry proﬁling) were monitored. Analysis of the obtained data sets was performed
using novel and established methods from the ﬁelds of machine learning and statistics.
This thesis also introduces a novel clustering algorithm. In the analysis of gene expres-
sion microarrays one problem is the unsupervised discovery of stable and biologically
relevant patient subgroups. To this end I developed a novel clustering algorithm. This
algorithm focuses on the discovery of a set of patient clusters deﬁned by the consistent
up- and down-regulation of a subset of genes. Assessment of cluster stability is done
using a bootstrap resampling scheme. This makes it possible to rank the genes in ac-
cordance with their clusterwise importance. The algorithm was applied to a publicly
available B-cell lymphoma microarray data set and compared to other commonly used
clustering algorithms.
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Zusammenfassung
Die Kombination aus Hochdurchsatzverfahren und Maschinellem Lernen eröﬀnet neue
Möglichkeiten im Bereich der Biomarker basierten klinischen Diagnostik. Eine der
Krankheiten für die noch kein verlässlicher prognostischer Marker gefunden wurde ist
Bronchiolitis Obliterans (BO). Hierbei handelt es sich um eine klinische Manifesta-
tion der chronischen Transplantatabstoßung nach Lungentransplantation. Bronchiolitis
Obliterans, der wichtigste limitierende Faktor für das langfristige Überleben lungentrans-
plantierter Patienten, manifestiert sich als eine chronische Entzündung. Die begleitende
progressive bronchioläre submukotische Fibrose führt zu einer Obstruktion des bron-
chiolären Lumens. Die daraus resultierende Reduktion der forcierten exspiratorischen
Einsekundenkapazität (FEV1) ist als Bronchiolitis Obliterans Syndrom (BOS) deﬁniert.
Chronisches Transplantatversagen tritt bei Lungentransplantaten deutlich häuﬁger auf
als in anderen Organen. Deswegen sind molekulare Marker zur Früherkennung dringend
erforderlich. Eine solche Früherkennung würde eine Anpassung der immunsuppressiven
Therapie ermöglichen, wenn der Schaden der Atemwege noch gering ist. Um dieses Ziel
zu erreichen wurde die Genexpression in bronchialen Epithelzellen (Microarray Analyse)
und das Proteom der bronchoalveolären Flüssigkeit (BAL) (Massenspektrometrie) un-
tersucht. Die Analyse der dadurch erhaltenen Datensätze erfolgte mittels etablierter und
neuartiger Methoden aus den Bereichen Maschinelles Lernen und Statistik. Desweiteren
wurde im Rahmen der vorligenden Dissertation ein neuer Clustering-Algorithmus en-
twickelt. Ein Problem bei der Analyse von Genexpressions Daten ist die Entdeckung
stabiler und biologisch relevanter Patienten-Untergruppen. Zu diesem Zweck entwick-
elte ich einen Clustering-Algorithmus zur Entdeckung von Patienten Untergruppen, die
durch die hoch- und herunterregulierung einer Gengruppe deﬁniert sind. Die Bewer-
tung der Stabilität einer Gruppe von Genen erfolgt unter Verwendung eines Bootstrap-
Resampling Ansatzes. Dieser Ansatz macht es auch möglich Gene nach ihrer Bedeutung
für die jeweiligen Patienten Cluster zu ordnen. Der Algorithmus wurde an einem öf-
fentlich zugänglichen B-Zell-Lymphom Microarray Datensatz getestet, und mit anderen
häuﬁg verwendeten Clustering-Algorithmen verglichen.
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Chapter 1
Introduction
1.1 Motivation
1.1.1 Integrative Analysis of the Bronchiolitis Obliterans Syn-
drome
The combination of high throughput omics (i.e. genomics or proteomics) and machine
learning oﬀers new possibilities for clinical diagnostics and the detection of biomark-
ers [1,2,3]. One disease for which no reliable prognostic marker has been found yet is
bronchiolitis obliterans (BO) [4], a clinical manifestation of chronic rejection after lung
transplantation (LTx). BO is the major limiting factor for long-term survival after lung
transplantation [5,6,7], and manifests as a chronic bronchiolar inﬂammation accompa-
nied by progressive sub-mucosal ﬁbrosis leading to gradual obliteration of the bronchiolar
lumen. The resulting reduction in forced expiratory volume per second (FEV1) is de-
ﬁned as the bronchiolitis obliterans syndrome (BOS). As chronic lung transplant failure
occurs more frequently than in other organ transplants [4], molecular markers for early
BO/BOS detection are urgently required to adapt the patients immunosuppressive regi-
men when airway damage is minimal. To achieve this goal, gene expression in bronchial
epithelial cells (microarray anaylsis) and the proteome level in bronchoalveolar lavage
ﬂuid (BALF)(mass spectrometry proﬁling) were monitored. Analysis of the obtained
data sets was performed using novel and established methods from the ﬁelds of machine
learning and statistics.
1.1.2 Clustering of High Throughput Data (Block Maxx)
In the analysis of gene expression microarrays one problem is the unsupervised discovery
of stable and biologically relevant patient subgroups. To this end I developed a novel
clustering algorithm. This algorithm focuses on the discovery of a set of sample clusters
deﬁned by the consistent up- and down-regulation of a subset of genes. Assessment of
cluster stability is done using a bootstrap resampling scheme, which also makes it pos-
sible to rank the genes in accordance with their clusterwise importance. The algorithm
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was applied to a publicly available B-cell lymphoma microarray data set and compared
to other commonly used clustering algorithms.
1.2 Publications
The BOS related results obtained from the proteomic data set, as presented in this the-
sis, were published in Transplantation and entitled Proteomic Bronchiolitis Obliterans
Syndrome Risk Monitoring in Lung Transplant Recipients [8]. A manuscript covering
the microarray part of the BOS study is currently in preparation. The Block Maxx
clustering algorithm described in this thesis was partly inspired by another novel biclus-
tering method of mine, which was published at the Sixth IEEE International Conference
on Data Mining - Workshops (ICDMW'06) in 2006 as Global Biclustering of Microarray
Data [9]. I was ﬁrst author in reference [9] and shared ﬁrst author in reference [8]. A
description of the Block Maxx algorithm will be prepared as a manuscript. I was also
involved in the following publications: Proteomic analysis of ﬁeld cancerization in phar-
ynx and oesophagus: a prospective pilot study published in The Journal of pathology
[10], Bronchoalveolar lavage ﬂuid of lung cancer patients: Mapping the uncharted wa-
ters using proteomics technology published in Lung cancer [11], and Multi-parametric
analysis and modeling of relationships between mitochondrial morphology and apoptosis
published in PloS one [12].
1.3 Thesis Outline
In chapter 1 the biological background, existing computational methods and basic topics
are introduced. The focus lies on the bronchiolitis obliterans syndrome (BOS), ensemble
methods in biomarker detection and the basic principles of cluster analysis. Additionally,
basic concepts in transcriptomics and proteomics are presented. In chapter 2, the meth-
ods applied in this thesis are presented, speciﬁcally the developed approach to obtain
suitable biomarkers for the early detection of BOS and the novel clustering approach
referred to as Block Maxx. Chapter 3 depicts the results of this thesis and presents ex-
pression processes related to BOS as well as the performance of Block Maxx on a clinical
microarray data set. The results are discussed and an outlook is given in chapter 4.
1.4 R Programming Language
R is a highly extensible programming language for statistical computing [13]. The soft-
ware is open source and allows for data input, calculation and graphical display. Func-
tionality can be added by extension via packages. R is freely available under the GNU
General Public License and can be obtained via http://www.r-project.org/. Spe-
ciﬁc R package extensions for biological data analysis are oﬀered by the Bioconductor
project [14,15]. Bioconductor is open source and open development. More information
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can be found under http://www.bioconductor.org/. If not speciﬁed otherwise, all
calculations in this thesis were performed using R.
1.5 The Respiratory System
The lung is the primary respiratory organ in mammals and allows the organism to
transport oxygen from the atmosphere into the bloodstream, while enabling the release
of carbon dioxide into the atmosphere. The respiratory tract of the lung (Figure 1.1)
can be divided into the proximal conductive, nonrespiratory airways (nose, pharynx,
larynx, trachea, bronchi, and nonalveolar bronchioles) and the distal respiratory region
(respiratory bronchioles, alveolar ducts, and alveoli). The respiratory tract is covered by
a heterogeneous epithelium. This pseudostratiﬁed epithelium [16] lining the proximal
conductive airways is progressively replaced by a simple cuboid cell layer [17] in the
more distal airways. The alveoli are then covered by a very thin epithelial lining. Fol-
lowing a progressively subdividing system of bronchi and bronchioles these thin walled
airsacks provide an extensive surface, where the gas exchange takes place. The alveolar
epithelium [18] additionally provides a barrier that protects the host from inhaled for-
eign agents and contributes to the maintenance of lung ﬂuid balance. Its regenerative
abilities allow for normal cell turnover and restoration of alveolar function after lung
injury [19].
1.5.1 Study of the Lung Epithelium
In lung pathology the common mean of studying the proteins secreted by the lung
epithelium of the alveolar and distal airways is the sampling of the epithelial lining
(ELF) by bronchoalveolar lavage (BAL) [21]. BAL is a relatively non-invasive diagnostic
procedure for which a ﬂexible ﬁberoptic bronchoscope is inserted into the lung and small
amounts of physiologic solution are injected. The ﬂuid is then aspirated obtaining the
bronchoalveolar lavage ﬂuid (BALF), which consists of cells (both resident alveolar cells
and recruited inﬂammatory cells), their secreted products and proteins from leakage
across the endothelial-epithelial barrier. An alternative method is to directly analyse the
bronchial epithelial cells obtained by bronchial brushing [22] during bronchoscopy. The
molecular analysis of BALF (BALFomics [21]) and bronchial epithelial cells [23,22] oﬀers
great potential [24,25,26,27,28] for research and diagnostics. So far both approaches
have been used to study various lung diseases [24,29,30]. The proteins, genes and other
substances gained from such studies, which oﬀer insights into disease pathogenesis, are
commonly referred to as biomarkers [31].
1.5.2 Lung Diseases
Biomarkers and the insights they oﬀer into disease pathology are urgently needed for the
diagnosis and treatment of various lung diseases. For many of which the only treatment
available to end stage patients is the transplantation of a donor lung [7]. Those diseases
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Figure 1.1. An overview of the complete human respiratory system (http://en.
wikipedia.org/wiki/Respiratory_system)[20]
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with lung transplantation as an accepted treatment option can be divided into four
groups: septic lung disease (i.e. Cystic Fibrosis (CF) [32]), restrictive lung diseases (i.e.
idiopathic pulmonary ﬁbrosis (IPF) [33]), obstructive lung diseases (i.e. chronic obstruc-
tive pulmonary disease (COPD) [34]) and pulmonary vascular diseases (i.e. pulmonary
hypertension [35]).
1.5.3 Lung Transplantation
Today clinical lung transplantation (LTx) remains the ﬁnal therapeutic option for pa-
tients suﬀering from a wide range of progressive lung disorders [7,36]. After several trial
experiments on dogs in the ﬁrst half of the 1950s, the ﬁrst clinical lung transplantation
(LTx) was performed in 1963 by Hardy at the University of Mississippi [37,38]. This
transplantation was initially successful and showed only a low level organ rejection. The
patient died 18 days later from multi organ failure due to a bronchiolar lung tumor.
Further lung transplantations were performed between 1963 and 1974. Of the more
than 40 patients receiving a transplant during this time, only 2 survived the ﬁrst month
post-transplantation. Main causes of death were among others transplant rejection and
respiratory insuﬃciency. Due to those failures programs for lung transplantations were
suspended till the early 1980s. Back then the use of Cyclosporin A as an immunsup-
pressor led to a new age of lung transplantation [39]. An era which began in 1983, when
Dr. Joel Cooper and the Toronto Lung Transplantation Group achieved the ﬁrst long
term success after a single lung transplantation (SLTx)[40]. In 1985 this same group
also performed the ﬁrst long term success in double lung transplantation (DLTx)[41].
After those early successes the number of lung transplantations rose consitently [42],
thus establishing lung transplantations as a treatment of end stage lung diseases [7,36].
Even though quite a few medical advances have been made, organ rejection caused by
the hosts immune system still represents the ﬁnal frontier of lung transplantation [4].
1.5.4 Immune System
The immune system prevents infectious agents like bacteria, viruses and parasites from
causing harm to the body. The main principles behind the immune system can be divided
into the innate and adaptive immune system. Innate immunity provides a ﬁrst line of
defense against many pathogens and starts immediately after a pathogen has entered the
body. The immunological recognition allows for the detection of such infectious agents
(antigens). This recognition step is achieved by leukocytes of the innate immune system,
which are responsible for an immediate immune response, and by the lymphoctes of the
adaptive immune system. The adaptive immune system oﬀers a way to overcome the
limitations of the innate immune system. This is necessary since the innate immune
system provides only limited protection as many pathogens evolve rapidly, altering the
molecular patterns of surface molecules. Adaptive immunity oﬀers a solution to these
limitations as a great diversity of pathogens can be recognized. B lymphocytes (B-cells)
and T lymphocytes (T-cells) are the main eﬀectors of adaptive immunity. Receptors
on their surface allow them to recognize foreign substances. A substance that can be
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recognized by cells of the adaptive immune system is called antigen and the binding
region is called epitope. The most important part of the adaptive immune system is the
immunological memory. This allows a person, who has once been exposed to a speciﬁc
infectious agent, to make a more immediate and stronger response against subsequent
exposure. Further actions required for the containment and elimination of the infections
are provided by the immune eﬀector functions. Members of the immune eﬀector functions
are the complement system of blood proteins, antibodies and lymphocytes among other
involved white blood cells. To prevent the immune system from causing unwanted
conditions such as allergy and autoimmune diseases, the system controls itself by immune
regulation [43].
1.5.5 Autoimmune Diseases
To prevent the immune system from attacking the hosts own cells, central self-tolerance
safeguards have to be put in place. These mechanisms focus the adaptive immune system
on pathogens and steer it away from self [44]. This is essential since the random gene
rearrangment, which occurs during lymphocyte development in the primary lymphoid
organs (thymus and bone-marrow), leads to the generation of lymphocytes (T-cells and
B-cells) with aﬃnity for self antigens. Those potentially dangerous lymphocytes are
removed from the pool or controlled by various mechanisms [43]. In the case of immature
B-cells this immunological tolerance to self is established in the bone marrow. Thus B-
cells recognizing self-molecules present in the bone marrow are removed from the B-cell
repertoire by negative selection (clonal deletion). A much more rigorous selection process
is performed in the case of T-cells, which undergo both positive and negative selection
in the thymus. This makes sure that T-cells selected for survival recognize self-major
histocompatibility complex (MHC) molecules but do not recognize self peptides. The
breakdown of those self tolerance mechanisms leads to an attack on the normal tissues
of the body. This in turn can lead to a variety of immune diseases like systemic lupus
erythematosus [45], autoimmune thyroid disease [46] or type I diabetes mellitus [47]. In
the case of type I diabetes mellitus, the most extensively studied chronic autoimmune
disorder, T-cell mediated destruction of pancreatic islet β-cells occurs. Processes of
organ and tissue destruction, as mediated by the hosts immune system, can also occur
in the case of allograft rejection. In this case a response to nonself antigens of the
transplant occurs [43].
1.5.6 Allograft Rejection
While current advances in immunosuppression proved to be quite eﬀective in the short
term, improvements for long-term graft survival are still an ongoing concern [48]. For
lung transplants the average 5 year graft survival is around 46.3% [4]. This low graft
survival rate is mainly due to the host immune systems recognition of nonself antigens
(allorecogntion) and the resulting immune response mediated injury of the transplanted
tissue (allograft rejection) [49]. The process of allograft recognition is enabled by the T-
cells abillity to recognize genetically diﬀerent MHC (major histocompatibility complex)
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molecules. In literature two diﬀerent pathways (1. direct pathway 2. indirect pathway)
are described [49]. For the direct pathway [50] the intact donor MHC molecules on
APCs (antigen-presenting cells) in the transplanted tissue are recognized by alloreactive
T-cells. In the indirect pathway [51] antigens (Ag) derived from donor MHC molecules
are processed by the host APCs and presented to alloreactive T-cells in a self restrictive
manner. Those processes signal the activation and transition of the lymphoid tissues
naive T-cells into eﬀector cells. In response to the inﬂammatory signals the allograft is
also inﬁltrated by other cells of the immune system (i.e. neutrophils, macrophages, and
natural killer (NK) cells) which promote further injury by proinﬂammatory mechanisms.
The types of rejection occuring after organ transplantation can be grouped into three
categories. Hyperacute rejection is a rare and fatal type of rejection which occurs within
minutes to hours after transplantation. The cause of this rapidly occurring process
are pre-formed antibodies against the donors MHC or ABO blood groups [43]. This
process of complement-mediated injury to the graft epithelium activates inﬂammatory
and coagulative cascades. Those cascades are the cause for the extensive thrombosis
observed in the graft vessels [43]. Another form of rejection is a cellular mediated
immune process referred to as acute rejection [49]. This normally occures within the
ﬁrst months after transplantation. Most patients suﬀer from at least one episode of
acute rejection and even later episodes are still quite frequent [52]. The third rejection
type is chronic rejection, which manifests clinically as bronchiolitis obliterans (BO) [4],
a submucosal ﬁbrosis of the respiratory bronchioles. Chronic rejection is the main cause
for late graft failure and occurs in half of the lung transplant patients within 5 years
after transplantation [4]. This rejection type is believed to be caused by chronic cytokine
production and smooth vascular muscle proliferation [53]. Another type of graft failure
is caused by the graft-versus-host disease (GHVD) [54,43]. The GHVD is essentially
characterized as the reverse of graft rejection [55]. This means that immunologically
competent cells (i.e. mature T-cells) present in the allograft recognize the transplant
recepient as foreign. Thus resulting in a severe inﬂammatory disease. Acute GHVD is,
despite a signiﬁcant amount of donor-derived lymphoid tissue and cells being transfered,
an uncommon and usually fatal occurence after lung transplantation [56,57,58]. GVHD
caused by bone marrow transplantation was found to be a risk factor for bronchioltis
obliterans (BO) development [59]
1.5.7 Bronchiolitis Obliterans Syndrome
In the mid-1980s bronchiolitis obliterans (BO) was ﬁrst described in a small cohort of
heart lung transplant recipients at Stanford University [60]. Today BO, an accepted
pathological manifestation of chronic allograft rejection, is the main reason for trans-
plant dysfunction [4]. Histologically it manifests as a patchy submucosal ﬁbrosis of the
respiratory bronchioles, which results in total or subtotal occlusion of the airway lumen
[4]. This excessive ﬁbropoliferation of the small airways is due to ineﬀective epithe-
lial regeneration and tissue repair after injury and inﬂammation of epithelial cells and
subepithelial structures [61]. In parallel with "injury response", a concept proposed
to explain the chronic dysfunction of various organ allografts, injury to the airways
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may be caused by alloimmune-dependent mechanisms, alloimmune-independent mecha-
nisms or a combination of both [62]. The current opinion is that bronchiolitis obliterans
represents various causes which lead to similar histologic and clinical results [60]. In
addition to the immunological risk factors like repeated acute rejection, human leuko-
cyte antigen (HLA) incompatibility, several non immunological risk factors have been
described [63]. The lung allograft is particularly susceptible to fungal and bacterial in-
fection [64,65,66,67]. Lung allograft airway colonization by fungal aspergillus species and
bacterial pseudomonas aeruginosa have already been associated with BO [68]. A viral
contributor in the form of cytomegalovirus (CMV) pneumonitis has also been correlated
with development of BO [69]. Despite all the research describing the development of BO
the histologic validation is still only feasible in the end stages. This diagnostic prob-
lem is caused by the circumstance that the disease temporarily presents itself only by
cellular inﬁltration of the airways or inactive ﬁbrotic processes. To circumvent those
hindrances the term brochiolitis obliterans syndrome (BOS) was introduced, as opposed
to the term bronchiolits obliterans (BO), which is used when histologic correlation can
be proven [60,4]. BOS is deﬁned as a signiﬁcant decrease in one second capacity (Forced
Expiratory Volume in 1 second, FEV1) in relation to the best FEV1-scores after trans-
plantation. FEV1 scores are usually given as a percentage of the best FEV1 observed
after lung transplantation (baseline). Thus BOS is commonly interpreted as chronic
rejection without histological evidence. The BOS classiﬁcation is divided into 5 stages
(Table 1.1) [70,60].
Table 1.1. BOS-stages
BOS-stage FEV1(%)
0 > 90
0-p 81− 90
1 66− 80
2 51− 65
3 ≤ 50
Of those stages BOS 0-p (potential BOS) was introduced in 2001 to allow for the
early detection of BOS [71 ,72,73] . For all diagnostic stages other factors which also lead
to a decrease in organ function (i.e. acute rejection or infections) have to be excluded as
confounding factors. This diagnostic complexity shows that more accurate biomarkers
for BO and BOS detection are urgently needed.
1.6 Biomarkers and High-Throughput Analysis
Recent advances in the ﬁeld of multi-omics approaches (i.e. genomics, transcriptomics,
sequencing, and proteomics) opened up new worlds of opportunities in biomedical re-
search [31,3,74] and biomarker detection. But due to their giant size and complexity,
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those worlds can only be explored using biostatistics and bioinformatics. One of the trea-
sures to be discovered in the process are new biomarkers for human diseases. Biomarkers
can be deﬁned as a dynamic and informational substance (i.e. nucleic acids-based gene
expression analysis, peptides, proteins) that can be quantitatively linked to pathogenic
progression. Most substance based biomarkers in use today were discovered in blood
(plasma, serum and whole blood)[75] but other ﬂuids and sample types are also gaining
prominence (i.e. cerebrospinal ﬂuid, tissue biopsies, urine, saliva and bronchoalveolar
lavage ﬂuid)[76,24,77,78,10]. While the term biomarker itself has only been established
recently, there have always been diagnostic tools monitoring organ functions or general
changes in biological structures. For instance body temperature is an indicator for fever
[79] or the forced expiratory volume per second (FEV1) a measure of lung function
[7]. Before a molecular biomarker can be used for diagnostic purposes its reliability
has to be stringently validated [31,80]. This is far from trivial, especially in the case
of a biomarker panel composed of several biomakers [81]. To actually put biomarker
research into clinical use, it might be far more feasible to follow an integrative approach
between molecular and established clinical diagnostics [82,83]. In the following, com-
mon approaches for high throughput analysis of gene expression and monitoring of the
proteome are introduced.
1.6.1 Analysis of Gene Expression
The majority of current research is focused on the gene transcription level [84]. This
gene expression analysis, which is often referred to as transcriptomics, is usually based on
the level of mRNA under varied conditions. Of the techniques used for high throughput
transcriptomics microarrays are the most commonly used approach [85,86].
An Introduction to Microarray Technology, Analysis and Validation
Microarrays allow for the measurement of the expression level of a large number (many
thousands) of genes simultaneously, and are based on the concept of hybridization. A
DNA microarray is a chip of microscopic single strand DNA spots (probes) attached
to points on a solid surface. Those DNA (cDNA) strands are complimentary to the
mRNA of a speciﬁc gene, which allows both nucleic acid strands to bind each other by
hydrogen bonds between corresponding nucleotides (Watson-Crick base pairing). For
the experiment the whole RNA of a cell at a speciﬁc time is isolated and multiplied by
polymerase chain reaction (PCR) [84,85,86], with the mRNA or corresponding cDNA
being labeled by ﬂuorescent dyes. Now the samples are spotted and hybridized on the
microarray chip and, after washing of the non hybridized pieces, scanned by a laser. The
intensity of the signal represents the level of a speciﬁc mRNA, since each spot is made
up of many identical probes. The most common microarray types are known as cDNA
and oligonucleotide arrays. For cDNA arrays preampliﬁed cDNA is attached to points
on a solid surface chip. These chips are based on competitive hybridization for which a
reference sample is used. The reference RNA, which is also hybridized to the microarray,
is marked by a diﬀerent dye. Thus the laser scanning results in ratio data which describes
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the diﬀerential expression between both samples. Recently oligonucleotide arrays (i.e.
Aﬀymetrix) gained popularity in the ﬁeld of transcriptomics. Those arrays allow for the
analysis of a single sample, with the probes (sequences of about 25 nucleotides length)
being synthesized directly on the chip. Most microarray data sets are in the form of a set
of experiments which describe the properties of speciﬁc biological entities or conditions
(i.e. patients or cell lines). Each experiment is deﬁned by a set of genes associated with
the entities. Such data can be easily represented as a data matrix A with one row for
each gene and one column for each entity. The matrix entries aij represent condition-
speciﬁc expression levels of a gene. After data normalization, which is essential to achieve
comparability between diﬀerent experiments, various data analysis approaches (i.e. gene
association analyis, network inferration, model building) can be applied to the obtained
data.
Normalization
Results from individual experiments need to be normalized with respect to each other
to account for experimental variation in RNA amounts, speciﬁc activity of probe labels,
and standard handling errors [87]. Individual intensities are adjusted to be able to make
comparisons both within the array as well as between arrays in the experiment. These
adjustments are necessary to remove purely technical diﬀerences that do not represent
biological variation and to be able to identify true diﬀerentially expressed genes [88].
Over many years of microarray experiments various normalization approaches have been
developed [89,90,88,91,92]. After normalization is completed, diﬀerentially expressed
genes or functional groups, classifying the samples into meaningful clusters, can be
identiﬁed [93, 94,95,96].
Quantitative Real Time PCR
High throughput transcriptomic approaches like microarrays and RNA sequencing [97]
oﬀer nearly unrivaled possibilities for whole genome proﬁling. As the obtained expression
proﬁles may vary depending on the applied methods and platforms a further validation
step becomes necessary. For this quantitative-real-time-polymerase-chain-reaction (qRT-
PCR) is the common method of choice. The qRT-PCR is a replication method for nucleic
acids, based on the common PCR (polymerase-chain-reaction), which additionally oﬀers
the possibility for real time quantiﬁcation of a target gene. After cDNA synthesis [98] this
quantiﬁcation is performed using ﬂuorescent reporter probes, which speciﬁcally detect
only DNA fragments containing the target genes sequence of interest. Thus the detected
ﬂuorescence directly correlates with the number of synthesized DNA target sequences.
The main quantiﬁcation step is performed during the exponential phase of the PCR,
for which each cycle shows an exponential increase in the amount of target sequence.
The logarithmized number of cycles after which the ﬂuorescence ﬁrst rises signiﬁcantly
above the background ﬂuorescence is denoted as CT (threshold cycle). In addition to the
gene sequence of interest an internal control gene (housekeeping gene) is also measured,
which can be used to normalize for experimental variability. This can be done using the
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following equation:
∆CT = CTtarget−gene − CTcontrol−gene
The gene expression in a sample can now be described as an n-times expression change
when compared to a reference (i.e diseased vs. healthy reference). For this the ∆∆CT
value is calculated.
∆∆CT = ∆CTdiseased −∆CTreference
From this the expression ratio between a sample and the respective reference can be
calculated.
Ratio = 2−∆∆CT
Thus obtaining a relative quantiﬁcation of gene expression.
1.6.2 Diﬀerential Expression
The identiﬁcation of genes that are diﬀerentially expressed between two distinct exper-
imental conditions has been a major topic in the scientiﬁc community [93]. The easiest
approach is to use the intuitive fold change criterion [95].
Fold Change
The fold change is a number which decribes how much a quantity changes compared to
a reference value. For example a measured value of 200 and a reference value of 100
would be described as a fold change of 2. For microarray studies the fold change (FC)
of a feature (gene) fi is calculated by dividing the mean/median f¯i
class
over all samples
in the class of interest by the mean/median of the reference class f¯i
reference
.
FCfi =
f¯i
class
f¯i
reference
(1.1)
If the genes are equally expressed in both classes, the FC equals 1. For logarithmized
expression values the FC can be calculated by:
log(FCfi) = log2(f¯i
class
)− log2(f¯ireference) (1.2)
In this case the FC equals 0 if the genes are equally expressed in both classes of
interest. While the FC is an established measure of diﬀerential expression in biological
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research [99,100,101], it does not provide a signiﬁcance estimate or take into consid-
eration the level of expression variance. While statistical tests (i.e. t-test, Wilcoxon
rank sum test) are more statistically justiﬁed than the FC [102], they do not take into
consideration that even statistically signiﬁcant changes are unlikely to have a biological
eﬀect if the FC is very low [94]. Further it was shown that for validation purposes genes
exhibiting small degrees of change show lower correlation between microarray and qRT-
PCR results [103]. One solution to the shortcomings of the FC, while still keeping its
advantages, is the rank product (RP) test [94,104].
Rank Product Test
The rank product (RP) test [94,104,105] is a non-parametric statistical test which detects
genes that are consistently found among the most up-regulated (or down-regulated).
For this we assume a data set with two experimental conditions disease (D) and control
(C). Given nD and nC replicates, the expression ratios of each gene are calculated for
all possible comparisons (k = nD × nC) between both conditions:
D1
C1
,
D1
C2
, . . . ,
DnT
CnC
(1.3)
After ranking the gene expression ratios within each comparison, the rank product
for each gene g in k comparisons i = 1, . . . , k can be calculated by
RP upg = (
k∏
i=1
rupg,i)
1/k (1.4)
where rupi,g is the position of gene g in the list of genes in the ith replicate sorted by de-
creasing FC, i.e. rup = 1 for the most strongly up-regulated gene. Analogously RP downg
is calculated from the list of genes sorted by increasing FC, i.e rdown = 1 for the most
strongly down-regulated gene. Genes with small RP (r¯) values are supposed to have the
highest biological relevance for up- and down-regulation respectively. Based on the RP
a signiﬁcance level can be assigned to the diﬀerential expression of each gene. For this
a permutation scheme is used to estimate how likely a given RP value is in a random
experiment. For this we generate p permutations of k rank lists of length n. Then we
calculate the rank products of the n genes in the p permutations and count how often
the rank products of the genes in the permutations are smaller or equal to the observed
rank product. This allows us to determine a p-value. To correct for multiple testing
[106,107] a respective Benjamini-Hochberg false discovery rate (FDR) was associated
with each gene [105]. The FDR adjusted p-value p∗ is calculated for each gene according
to the following procedure:
Benjamini-Hochberg False Discovery Rate
Step 1: Rank the p-values in a decreasing order p1 > p2 . . . > pn
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Step 2: The highest p-value is not adjusted: p∗1 = p1
Step 3: Corrected p-value p2 is calculated by p∗2 = p2(
n
n−1)
Step 4: Corrected p-value p3 is calculated as in Step 3 by p∗3 = p3(
n
n−2)
Continue till all p-values are adjusted. After correction for multiple testing a p-value
cut-oﬀ of α∗ = 0.05 equals a false positive rate of 5%.
Gene Annotation
Even after multiple testing correction [106], microarray studies often return very large
lists of diﬀerentially expressed genes. To allow for the functional analysis such ge-
nomic studies, the functional annotations [108] of numerous genes have been made avail-
able in various online resources [96]. Those annotations are systematically categorized
and describe either hierarchical classiﬁcation systems (i.e. Gene Ontology (GO)[109])
or biochemical pathway representations (Kyoto Encyclopedia of Genes and Genomes
(KEGG)[110] and Biocarta [111]). Those annotation categories can be used to assess
the biological signiﬁcance of a gene list. This type of analysis can be performed us-
ing specialized bioinformatics tools such as the Database for Annotation, Visualization
and Integrated Discovery (DAVID) [112]. DAVID consists of an integrated biological
knowledgebase and analytical tools aimed at systematically extracting biological mean-
ing from gene lists [96]. The DAVID analysis (Figure 1.2) is essentially based on gene
enrichment analysis [96]. This method assumes that if a biological category or pathway
is inﬂuenced in a given study, the co-functioning genes have a higher potential to be
detected as diﬀerentially expressed. The degree of enrichment is assessed by comparison
against a background list. The background list should encompass all the genes that can
potentially be selected for the annotation process, which in most cases is all genes from a
chip. Given that for example 10% of the diﬀerentially expressed genes are kinases vs. 1%
in the background, the signiﬁcance of enrichment can than be tested by established sta-
tistical methods, like chi-squared, Binomial probability and Hypergeometric distribution
[Huang2009a]. In the case of DAVID a Fisher exact test is used with multiple testing
correction being performed using the Bonferroni method [107,106] or several other less
conservative approaches [107,106]. Thus a list of functional groups signiﬁcantly enriched
in a gene list of interest is returned.
1.6.3 Analysis of Protein Expression
In addition to the transcriptomic methods dealing with gene expression, there is also
a wide array of analogous proteomics methods (i.e peptide arrays) measuring the level
of protein in a sample [113,78]. Proteomics is deﬁned as the systematic analysis of all
proteins in any deﬁned biological compartment [114]. This oﬀers a complimentary ap-
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Figure 1.2. The annotation workﬂow as performed by using DAVID [112]
1.6 Biomarkers and High-Throughput Analysis 19
proach to gene chip microarrays, since there is often a poor correlation between mRNA
abundance in a cell or tissue and the quantity of the corresponding functional protein.
A relationship further complicated by the complexity of the proteome, due to alternate
splicing of the transcripts, sequence polymorphism and posttranslational modiﬁcations.
Proteomics is believed to oﬀer great potential for the burgeoning ﬁeld of clinical pro-
teomics [78,81]. This research direction aims to gain insights into the complex processes
of pathobiology by the discovery of clinically relevant protein biomarkers.
Mass Spectrometry
One of the workhorses of biomarker detection [115] are mass spectrometry (MS)- based
technologies. Modern mass spectromic methods make it possible to generate proteome
proﬁles of biological tissues and ﬂuids. There are diﬀerent kinds of mass spectrometers
[116] but the most popular approach of mass spectrometry for biomarker detection in
various body ﬂuids is the MALDI-TOF (Matrix Assisted Laser Desorption and Ionisa-
tion - Time of Flight) method [117]. This method oﬀers easy sample preparation and
acquisition while also being tolerant towards contaminants such as salts, detergents or
common buﬀers [115]. Even though samples can be analyzed in a highly reproducible
[118] fashion by mass spectrometry, reproducibility strongly depends on the sampling
process, standardized measurement and a stringently controlled data analysis [119].
Technical Details
In the case of MALDI-TOF [117] the samples of interest are mixed with a matrix con-
sisting of an UV absorbing compound and spotted as a spot on a steel sample slide. The
spots are dried and the steel sample slide is inserted into the sample chamber under high
vacuum. Laser pulses are ﬁred on the spots and the compound transfers the energy from
the excitation laser to the sample molecules, which vaporises and ionises them. After
the ions stop vibrating the high voltage is turned on, which attracts and accelerates the
ions through the time of ﬂight tube to a detector. The time between the laser pulse
and the arrival of the ions at the detector is measured by a high precision timer. Since
this time is proportional to the mass of the molecule divided by its charge (m/z), the
molecular weight can be calculated. The results from a MALDI-TOF experiment can be
represented as a spectrum where the height (intensity) of a peak represents the number
of ions present for a speciﬁc m/z value.
Mass Spectrometric Data Preprocessing
As shown in [120,121] mass spectrometry can be composed into three components
f(i, j) = b(i, j) + s(i, j) + ε(i, j). (1.5)
where f(i, j) is the observed value, b(i, j) is the baseline value, s(i, j) is the true
signal and ε(i, j) is the noise for ith sample at jth m/z ratio. Noise of MS spectra can
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be caused by many diﬀerent factors such as system artifacts, thus making preprocessing
necessary for a successful data analysis [121,122,123]. The baseline decribes the low
frequency component of the observed signal and is mainly caused by chemical noise and
ion overload.
Baseline Correction
It is often the case that a raw spectrum shows an elevated baseline. Thus baseline
correction was performed by ﬂattening the base proﬁle of each spectrum by removal
of baseline slope and oﬀset [Sauve]. For this the baseline is estimated by partitioning
the m/z range on the logarithmic scale into n equally spaced intervals, ﬁnding the
local minimum within each interval, and smoothing these local minima by either local
regression (loess) or local interpolation. To make sure that the spectrum rests on the zero
horizontal line, this baseline is subtracted from each raw spectrum. Resulting negative
values are set to zero.
Interpolation
The varying m/z resolution and ranges between spectra prevent a straightforward rep-
resentation as a data matrix. Thus, after restricting all spectra to the smallest common
m/z range, a linear interpolation method [124] can be used to approximate the missing
data in spectra positions with low resolution. This makes it possible to represent all
spectra in a single data matrix. See Figure 1.3 for details.
Normalization
Various experimental sources can lead to systemic diﬀerences between spectra. Thus a
normalization method based on the total ion count becomes necessary, which allows for
the comparison of the absolute peak intensities of diﬀerent spectra [125,126]. For this
the area under curve (AUC) of each spectra is calculated for all m/z values [127].
AUC =
n∑
i=1
γi (1.6)
where γi ,the signal at the ith m/z ratio, is used to measure the protein concentration
in mass-spectrometry data. Using this approach all spectra were rescaled by division to
the same AUC value.
Peak Recognition
After normalization it is important to detect peaks in the spectrum [128], which are
likely to represent proteins. For this the mean spectrum over all available spectra is
calculated. This spectrum is then smoothed using the moving average of the k nearest
neighbours [129], which helps to remove spurious peaks. Afterwards a local maximum is
identiﬁed in the smoothed spectrum, which is considerd as a peak when its signal to noise
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Figure 1.3. Resampling of mass spectra: Five spectra are shown exemplary as
lines between the mass range endpoints. The spectra are ordered according to decreasing
resolution (I-V). All spectra are restricted to the same mass range between the largest
starting point (here of spectrum (II)) and the smallest end point (here of spectrum
(V)) of all spectra (I-V). The spectrum with the highest resolution (here spectrum I) is
chosen as the master resolution. All other spectra are interpolated to match this master
resolution [124].
1.7 Data Mining and Machine Learning 22
ratio [130,128] and intensity exceed a user deﬁned threshold. The noise is estimated as
the median of the absolute deviation (MAD) of points within a mass window [129,128],
while the intensity threshold is set to a percentage of the highest peak intensity. After
this step the data can be represented as a data matrix A with one row for each peak and
one column for each entity. The matrix entries aij represent condition-speciﬁc intensity
levels at the highest point of a peak, for a speciﬁc m/z level. The preprocessed data can
now be used by various data analysis approaches.
ELISA
To further validate the results obtained from mass spectrometry, an enzyme linked im-
munosorbent assay (ELISA) is often applied [131,132]. This represents the most reliable
and sensitive protein based testing platform [133] currently available. All ELISA tests
require an especially well-characterized antibody for the detection of the protein of in-
terest (antigen), which is not always available. Those antibodies, previously linked with
an enzyme, bind the protein of interest and the enzyme catalyses a reaction to mark
the presence of the antigen. This reaction processes an added enzyme speciﬁc substrate
and leads to a detectable change in color. This color change signal, as measured by a
photometer, allows for an exact detection of antigen concentration.
1.7 Data Mining and Machine Learning
The ﬁeld of machine learning, which has its roots in artiﬁcial intelligence (AI), deals
with systems that use previous experience to improve performance on a speciﬁc task. In
medical research the applications of interest include diagnosis of patients and the group-
ing of patient cohorts into pathologically relevant subgroups. Those goals are reﬂected
in two main types of data analysis, as deﬁned in [134]:
1.Clustering (Unsupervised Learning) gathers objects into groups (clusters),
such that the objects within a cluster are more similar to each other than they are to
objects belonging to a diﬀerent cluster.
2.Prediction (Supervised Learning) assigns an appropriate label (categorization)
to new objects given their attributes. The model for the respective decision making uses
information extracted from the relationship between attribute values and labels of a set
of sample objects.
First we will take a closer look at the concepts behind clustering (unsupervised
learning).
1.7.1 Unsupervised Learning
If the task of a research project is to partition a collection of unlabeled data into mean-
ingful clusters, methods from the ﬁeld of cluster analysis (unsupervised learning) provide
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an appropriate solution. Cluster analysis as described in [135,134] is the organization of
a collection of patterns (usually represented as a vector of measurements, or a point in a
multidimensional space) into clusters based on similarity. Thus patterns within a cluster
are more similar to each other than they are to a pattern belonging to a diﬀerent cluster.
A pattern pi consists of a vector of d measurements pi = (pi1, . . . , pid). In the case of gene
expression data each gene can be represented as a vector of expression levels under a
number of diﬀerent conditions. Accordingly a condition can be represented as a vector of
genewise expression levels. A large number of algorithms to cluster unlabelled data sets
has been proposed [136,135] and applied to biological data sets [137,138,139]. Among the
most popular methods are hierarchical (agglomerative) clustering [135], k-means [135]
and Partitioning Around Medoids (PAM) [140].
Similarity Measures for Clustering
A measure of similarity between two patterns drawn from the same feature space is
essential for most clustering procedures. The most common way is to measure the
dissimilarity (or distance) between two patterns pi and pj, using a measure deﬁned on
the feature space. The most popular metric is the Euclidean distance:
d2(pi, pj) =
√√√√( d∑
k=1
(pi,k − pj,k)2
)
= ||pi − pj||2 (1.7)
Agglomerative Clustering
The most common approach to microarray data clustering is called agglomerative clus-
tering or hierarchical clustering [135]. The idea behind this is based on a simple principle:
Given n data points, the algorithm starts with n clusters by assigning each point to a
cluster of its own. Then a bottom-up procedure is performed, which at each stage suc-
cessively merges the pairs of clusters (i.e. a set of points) closest to each other. Since
each step returns a clustering solution with one cluster less, all data points are joined
into a single cluster after n−1 operations. This approach creates clustering solutions for
all possible numbers of clusters k, 1 ≤ k ≤ n, which can be represented as a dendrogram
structure by the order of merges.
K-Means Algorithm
K-means [135] is a partitional clustering algorithm which produces a single partition of
the data, for which a ﬁxed number of clusters k has to be predeﬁned. To describe the
algorithm we ﬁrst introduce the concept of a cluster centroid. Given a cluster with n
points (patterns) p1, . . . , pn the cluster centroid is deﬁned as the arithmetic mean µ of
the vectors:
µ =
1
n
n∑
i=1
pi (1.8)
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K-means as described in reference [135]
Step 1: Initialization of k Clusters
Each point p1, . . . , pn is assigned to one of the k clusters C1, . . . , Ck. This is done by
randomly choosing k points as cluster centroids z1, . . . , zk, and assigning the remaining
points to the cluster centroid with the lowest Euclidean distance.
Step 2: Recalculation
For each cluster Cluster Cr the centroid is calculated anew according to equation 1.8.
Step 3: Partitioning
The partitioning is adapted to the new centroids, each point is assigned to the centroid
with the lowest Euclidean distance.
Step 4:
Steps 2 and 3 are repeated until the centroids no longer move.
Each new partitioning reduces the sum of the Euclidean distance from the points to
their respective cluster centroid but the k-means algorithm is not guaranteed to ﬁnd the
optimal solution (global minimum). Depending on the initialization only local subop-
tima are found. Because of that it is rerun several times with diﬀerent starting centroids
and the best solution is selected. It is also possible to use another distance measure than
the Euclidean distance [141,142,143].
PAM algorithm
The PAM clustering algorithm [140] is similar to k-means [135] but operates directly on
a dissimilarity matrix. Before the actual clustering procedure PAM deﬁnes k medoids.
A medoid is usually deﬁned as an object with minimal average distance to all other
objects in the cluster. After the starting medoids are deﬁned, each object in the data
set is assigned to the nearest medoid. Thus putting object i into cluster vi, when medoid
mvi is nearer than any other medoid mw. The algorithm proceeds in two steps:
BUILD-step: This step sequentially selects k centrally located objects to be used
as initial medoids.
SWAP-step: If the objective function can be reduced by interchanging (swapping) a
selected object with an unselected object, then the swap is carried out.
This is continued until the objective function can no longer be decreased. Thus deﬁning
the ﬁnal data partition.
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1.7.2 Supervised Learning (Classiﬁcation and Prediction)
The goal of prediction [144] is to predict a target attribute for new objects based on
the values of the other attributes. The relationship between the target attribute and
those other attributes is then learned from a training set of data, for which the target
attribute is already known. The training data captures an empirical dependency between
the ordinary attributes and the target attribute, for which the data mining technique
builds an explicit model of the observed dependenices. In the case of categorial target
values the prediction is called classiﬁcation. As opposed to continous numerical target
values, for which the prediction is referred to as regression. There are a number of
popular classiﬁcation methods, which have already been applied to problems from the
ﬁeld of biology and medicine [145,121,146].
Cross-Validation
To get an unbiased assessment of a classiﬁers predicitve quality, it is required to test
its performance on an independent data set [147,148]. Since in a clinical setting the
availability of samples is often limited, withholding a substantial proportion of the data
for testing purposes might potentially reduce the quality of the predictive model. Thus
the approach of k-fold cross-validation can be used to predict how well a classiﬁer will
perform in practice. For this the original sample set is divided into k subsamples.
While one subsample is retained as the test data for model validation, the remaining
k − 1 subsamples (training set) are used to learn the classiﬁer. This ensures that the
classiﬁcation result for each sample is unbiased by knowledge of the particular sample.
The validation procedure is repeated k times (the folds), with each subsample being
used exactly once for the validation set. In stratiﬁed k-fold cross-validation, the folds are
selected such that each fold contains roughly the same proportions of class label types.
The classiﬁcation results obtained for each sample, when the particular sample was not
part of the training set, can be used to rate the classiﬁer. Common criteria include
accuracy, sensitivity, speciﬁty and the area under curve (AUC) [149]. Overﬁtting of the
predictor can be a major limitation in supervised learning. One of the main reasons for
cross-validation is to test if the model was not overﬁtted. Overﬁtting means that the
model was optimized for the available test data but poorly predicts independent data.
This happens when the model picks up random variations that do not present true
relationships. Another important thing to keep in mind is that all preprocressing and
feature selection steps using class knowledge should be included in the cross-validation.
Otherwise a substantial bias is introduced to the cross-validation results [150], which
leads to an overestimation of prediction accuracy.
Decision Trees
Classiﬁcation using decision trees such as CART (classiﬁcation and regression trees)[146],
is quite popular in in the Machine Learning Community. A decision tree classiﬁes a pat-
tern by performing a sequence of simple tests, where the tests performed at subsequent
levels depend on the outcome of the previous tests. For the class of binary trees there
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are two types of tests: (i) equality tests for categorial attributes, (ii) inequality tests on a
single real-valued attribute. An example of the ﬁrst type is color = red, and an example
of the second type is length ≥ 24cm. Representing the rules as a tree structure T , each
tree node t represents a rule used for testing a variable Xi from a set of input variables
X1, X2, . . . , XD. Using those rule sets the classiﬁer partitions the input space Rr into
cuboid regions for predicting an output variable Y . Hereby the decision node at the top
of the tree, containing only outgoing edges, is called root node. To predict the output
variable y for a sample x, drop x down T and follow its path till a terminal (leaf) node
is reached. Each leaf node contains only incoming edges and represents a speciﬁc class
which is associated with a certain partitioning based on a sequence of tests. The class
associated with a speciﬁc leaf node is determined by the majority class of samples from
the training set which, according to the rule set, would be assigned to this leaf node. A
new sample assigned to this leaf node is then classifed accordingly. See Figure 1.4 for
an example.
Construction of a tree classiﬁer requires a labelled training set
L = (x1, y2), . . . , (xn, yn) (1.9)
where xn is an object measured in the input variables X1, X2, . . . , XD with n = 1, . . . , N .
The class label of each object is deﬁned by yn which can take a value k ∈ 1, . . . , l. In
the case of a binary classiﬁcation problem an object can belong to either of two classes
i.e. k ∈ 1, 2. The tree model is then constructed by partitioning the training set of
measurement vectors into "purer" subsets. Herefore every possible value of each variable
is considered for each split. The goodness of a split is evaluated by the achieved decrease
in impurity. The most established choice of impurity within a tree node t [146] is given
by the Gini index
IG(t) =
l∑
j=1
pj(1− pj(t)) (1.10)
where we assume that there are l classes and p1, p2, . . . , pl are the proportions of samples
in the l classes. Then the Gini index, as used by CART, is a measure of how often a
randomly chosen element from the set would be incorrectly labelled if it were randomly
labelled according to the distribution of labels in the subset. Thus it is computed by
summing the probability of each item being chosen times the probability of a mistake
in categorizing that item. It reaches its minimum (zero) when all cases in the node fall
into a single target category. Based on the respective impurity function a feature and
split are rated according to the decrease in impurity [146]
4(s, t) = I(t)− h(tL)I(tL)− h(tR)I(tR) (1.11)
where s is a split of node t, h(tL) and h(tR)are the propotions of the samples in the
left and right daughter nodes of node t, respectively. The split that leads to the highest
decrease in impurity is chosen for the tree. By recursively using the node-splitting
procedure, the tree is usually overgrown (too many descendant nodes), which is likely to
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overﬁt the training data. Thus a pruning steps is necessary which removes some nodes
to achieve an optimal bias-variance trade-oﬀ. The decision which nodes to remove is
usually based on an independent test set or cross-validation.
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Figure 1.4. A simpliﬁed decision tree model for the discrimination between plants,
insects and mammals.
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1.8 Ensemble Learning
Decision trees can easily be converted into a set of logical formulae. A property that
is very desirebale since it allows the user to understand how examples are classiﬁed,
which is nearly impossible for many other classiﬁers [146]. Their explanatory power
and the fact that they derive rules that can be expressed as logical formulae is the
main reason why decision trees are used. They are often not competitive with other
classiﬁcation approaches in terms of their classifcation accuracy. This is especially true
for high dimensional data such as microarray or mass spectrometry measurements where
a single tree is not able to reﬂect the inherent complexity. Another disadvantage is the
unstable topology of decision trees. A minor change to the training set might result
in a substantially diﬀerent tree model [151]. To overcome those limitations ensemble
learning methods generate many classiﬁers and aggregate their results [152]. Two well-
known methods are Boosting [153] and Bagging [154] of classiﬁcation trees. In Boosting,
successive trees give extra weight to points incorrectly predicted by earlier predictors.
In the end, a weighted vote is taken for prediction. In Bagging successive trees do not
depend on earlier trees. Each tree is independently constructed using a bootstrap sample
of the data set. A classiﬁcation tree Tk is grown for each perturbation Λk of the learning
set, k = 1, 2, . . . , K; a test observation x is dropped down each tree; and the classiﬁer
predicts the class of that observation by that class that enjoys the largest number of
total votes over all of the trees. Meaning that in the end a simple majority vote is taken
for prediction. An improved variant of the Bagging approach, called random forest [155],
was introduced by Leo Breiman [147,156,157].
1.8.1 Random Forest
Like bagging the random forest[155] tree ensemble constructs each tree using B bootstrap
samples Λb of the learning set Λ. In addtion to this well known randomization scheme
it also introduces a randomization component into tree construction itself, such that for
the tree Tb each node is split using the best split among a randomly chosen subset of m
variables. These are the only two tuning parameters for a random forest: the number m
of variables randomly chosen as a subset at each node and the number B of bootstrap
samples. The procedure is relatively insensitive to a wide range of of values of m and B.
If the class of interest contains only a small proportion of the observations, as is often the
case in a clinical setting, each bootstrap sample will contain only very few of the minority
class observations. To prevent the resulting poor class prediction for the minority class,
the majority class is undersampled (balanced random forest (BRF)) for each bootstrap
sample [158,159]. After classiﬁer construction, a random forest predictor score (RF-
score) based on the percentage of trees voting for a speciﬁc class is calculated. Most
of the time a simple major vote (RF-score ≥ 50%) is used for class assignment. While
the random forest algorithm seems to apply a counterintuitive strategy, it turns out to
perform very well compared to other classiﬁers [160,161] and is robust against overﬁtting
[155]. The random forest methodology framework can even be applied to methods
other than decision trees [162]. Another advantage is an internal unbiased estimation of
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classiﬁer performance similar to cross-validation. At each bootstrap iteration the data
not in the bootstrap sample (out of bag (OOB) data) is used to estimate the error rate.
The mean error estimation over all bootstrap iterations is referred to as the OOB error.
1.8.2 Random Survival Forest
An extension of the random forest method to right censored data is given by random
survival forests [163]. It follows the same principles of constructing an ensemble of base
learners but uses survival trees [163] instead of standard decision trees [146]. Those
survival trees are a special type of decision trees, which are constructed using an obser-
vation data set of time, status, event [164] and associated predictor covariates [165]. For
this we denote survival time and censorship information for each of the n individuals
within h by
(t1, δ1), . . . , (tn, δn) (1.12)
An individual with no event at time tl is considered censored (δl = 0), while an event at
time tl is denoted by δl = 1. The splits at a node h are of the form x ≤ c or x > c. Given
the value xl of x for an individual l = 1, . . . , n, the number of observations assigned to
each of the two daughter nodes created after a split is given by:
n1 = #(l : x1 ≤ c) (1.13)
n2 = #(l : x1 > c) (1.14)
The splits at each node are chosen such that the resulting daughter nodes show a max-
imum survival diﬀerence. One survival based measure of node seperation, which can
be used to choose the best split, is given by the log-rank score test. The best split can
now be chosen according to the log-rank score test [166], which serves as a measure of
node separation. For this we assume the predictor x has been ordered such a way that
x1 ≤ x2 ≤ . . . ,≤ xn. We can now compute a ranking for each survival time tl,
al = δl −
δl∑
k=1
δk
n− δk + 1 (1.15)
where Γk = #{t : Tt ≤ Tk}. The log rank score is deﬁned as
S(x, c) =
∑
k<=c al − n1a¯√
n1(1− n1n )s2a
(1.16)
with the sample mean and sample variance of {al : l = 1, . . . , n} are given by a¯ and
a2s respectively. The resulting measure of node seperation |S(x, c)| is maximized over x
and c, yielding the best split. The tree reaches a saturation point when a terminal node
contains at least 3 events with an unique event free time.
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Ensemble Estimation
Similar to the random forest method, where the predicted class is deﬁned by a majority
vote over all trees, the ensemble cumultative hazard function is produced by the average
over all trees. For each tree the cumultative hazard estimates are calculated terminal
nodewise. For a node h with distinct event times let dl,h and Yl,h be equal to the number
of events and individuals at risk at time tl,h. The cumultative hazard for the node h can
now be deﬁned as:
Hˆh(t) =
∑
tl,h<t
dl,h
Yl,h
(1.17)
The survival rate at a time (t) can then be calculated by the product limit (PL) method
[167]:
Sˆh(t) =
∏
tl,h<t
(1− dl,h
Yl,h
) (1.18)
The rules making up the tree assign each individual i with the predictor xi to a speciﬁc
terminal node, from which the individuals cumultative hazard (Hˆ(t|xi)) is determined.
The estimate described so far is based on one tree only, while the ﬁnal ensemble cumul-
tative hazard is averaged over all trees (b = 1, ..., ntree) in the ensemble. This ensemble
hazard (Hˆe(tx, i) is calculated by:
Hˆe(t|xi) = 1
ntree
ntree∑
b=1
Hb(t, xi) (1.19)
An OOB estimate of the ensemble cumultative hazard (Hˆ∗e ) can be obtained for each
individual by averaging only over those trees for which the individual in question was
part of the OOB set. Ensemble survival rates can be calculated analogously to ensemble
cumultative hazard.
Concordance error rate
The quality of a predictive model is generally reﬂected by its prediction error on a test
set or by cross-validation. In the case of random forests or random survival forests this
can be done using the OOB principle. An important aspect of this procedure is the
measure used to rate the prediction error. In the case of a predictive survival model
this is provided by the concordance index (C-index). The concordance index reﬂects
the probability that, given a randomly selected pair of individuals, the individual that
suﬀers from an event ﬁrst also had the worse predicted outcome. The concordance error
rate is calculated by 1 minus the C-index and takes values between 0 and 1, with 0
reﬂecting perfect concordance. A concordance error of 0.5 represents a prediction not
better than random guessing. To compute the concordance index we ﬁrst have to deﬁne
what constitutes a worse prediction outcome. This can be done using the following
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approach. Let t∗1, . . . , t
∗
N denote all unique event times in the data. Individual i is said
to have a worse outcome than j if
N∑
k=1
Hˆ∗e (t
∗
k|xi) >
N∑
k=1
Hˆ∗e (t
∗
k|xj). (1.20)
The concordance error is calculated as follows [163]:
1: Create all pairs of observed responses over all of the data.
2: Omit those pairs where the shorter event time is censored. Also omit pairs i and j
if Ti = Tj unless γi = 1 and γj = 0 or γi = 0 and γj = 1. The total
number of permissible pairs is denoted by Permissible-Pairs
3: For each permissible pair in which the shorter event time had the worse predicted
outcome, add 1 to the running sum p. If the predictions are tied count
add 0.5 to the sum. Concordance = p now denotes the total sum over
all permissible comparissons.
4: Deﬁne the concordance index (C-index) as
C =
Concordance
Permissible− Pairs (1.21)
and the concordance error by 1 - C
The concordance index can also be applied to uncensored data where it estimates the
Mann-Whitney parameter [168]. In this case it also follos the same idea as the Kendall
rank correlation coeﬃcient [169]. A possible C-index application on uncensored data is
the comparisson of microarray and qRT-PCR results.
1.9 Biclustering
Unsupervised clustering methods are among the most used algorithms in the analysis of
high dimensional data sets. These methods allow for the discovery of unknown patterns
hidden in the data. In the case of microarray data the most common approaches used
include: (1) inferring gene function from clusters of genes similarly expressed across
samples [170] and (2) searching sample groups that show similar expression patterns
across the genes [171]. While the clustering of genes [140] and the clustering of samples
[139] have been been the topic of various research eﬀorts [172], the complexity and high
dimensionality of the data [173] still make it a very challenging problem. This complex-
ity prevents common clustering algorithms like k-means or hierarchical clustering from
discovering the structures of interest [135]. In recent years new approaches i.e unsuper-
vised random forest clustering [174] or trimmed-k-means [175] introduced concepts like
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feature weighting or outlier removal. Another concept, that gained prominence during
the last decade, is biclustering [138]. The term biclustering describes the simultaneos
clustering of the rows and the columns of a data matrix. The ﬁrst biclustering algorithm
was published by Hartigan [176]. Since then numerous new methods were introduced
[138,9,177,178,179]. Most clustering techniques cluster a group of genes according to
their expression levels under multiple conditions or a group of conditions based on a
number of genes. But the clustering of genes and conditions runs into a diﬃculty. The
problem arises from the general principles of cellular processes. Groups of genes that
are co-regulated in a certain subset of experimental conditions can be completely inde-
pendent with respect to other conditions. Such local expression patterns might enable
us to ﬁnd new genetic pathways normally not found by ordinary clustering algorithms.
Such local patterns in microarray data can be found by an approach called biclustering
, where each bicluster is deﬁned by a subset of genes and a subset of conditions. Classic
clustering algorithms cluster the rows and columns independently. The genes are clus-
tered by their expression levels under all conditions. Similarily, each condition is deﬁned
by the activity of all the genes. Biclustering algorithms cluster the rows and columns
simultaneously. Each gene in a bicluster is selected only a subset of the genes. This
enables biclustering algorithms to identify groups of genes that show similar activity
patterns under a speciﬁc subset of the experimental conditions. This is an improve-
ment over conventional clustering, since only a small set of the genes participates in
a cellular process. Additionally a cellular process might be active only in a subset of
the conditions. One major disadvantage of biclustering is that they use random seeds,
which causes inconsistency and results vary considerably even when obtained from the
same dataset [177]. While the new developments in clustering substantially improved
on existing methods, the complex assumptions and models used often make the results
hard to interpret and validate by researchers [180]. An argument known thus far from
discussing the advantages and disadvantages of the fold change compared to more ad-
vanced statistical methods [95,94]. In this thesis the novel biclustering algorithms Block
Maxx is presented. This algorithm combines the advantages of biclustering with the
easier interpretability and usability of conventional clustering approaches.
Chapter 2
Methods
To identify possible prognostic markers for the early detection of the bronchiolitis obliter-
ans syndrome, bioinformatics approaches were applied to high throughtput data obtained
from a collective of lung transplanted patients. The clinical and experimental parts were
performed at the Hannover Medical School (MHH). All patients enrolled gave their in-
formed consent to participate in this study. Approval from the Ethics Committee of
the Hannover Medical School (MHH) has been obtained. BAL and bronchial brushing
was performed by the Department of Respiratory Medicine, MHH [24] following Euro-
pean Respiratory Society Task Force guidelines [181]. The data sets include microarray
expression data from bronchial epithelial cells and mass spectrometry screening of bron-
choalveolar lavage ﬂuid (BALF). Extensive clinical data was provided for all analysed
samples. Due to the complexity of the clinical and high throughput data, machine
learning methods were adapted speciﬁcally to the respective research topics.
2.0.1 Patient Demographics
A total of 77 bronchial epithelial cell samples from 53 patients (26 female, 37 male) were
collected from 372 to 1042 days (611 ± 140) after LTx (4 bilateral, 49 single) during
routine clinical surveillance. Of these patients, 18 were aﬀected by cystic ﬁbrosis, 23
had lung emphysema, 12 pulmonary ﬁbrosis, 9 alpha-1-PI deﬁciency and 15 suﬀered
from various other conditions. See Table 2.1 for details. For the BALF proﬁling 146
samples from 82 patients (42 female, 40 male) were collected 169 to 1000 days (mean
471 days 177) after LTx (73 bilateral, 9 single) during routine clinical surveillance. Of
these patients, 19 were aﬀected by cystic ﬁbrosis, 24 had lung emphysema, 15 pulmonary
ﬁbrosis, 9 alpha-1-PI deﬁciency and 15 suﬀered from various other conditions. See Table
2.3 for details. The majority of patients taking part in this study provided both alveolar
epithelial cell and BALF samples.
2.0.2 Study Design
LTx patients were grouped according to their BOS status. An FEV1 below the Interna-
tional Society for Heart and Lung Transplantation (ISHLT) criteria for BOS (FEV1 ≤
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80% of baseline) was considered persistent, if all consecutive FEV1 measurements over a
period of at least one year also showed an FEV1 ≤ 80%. Thereby, and through compre-
hensive follow-up, other factors (e.g. infection, bronchial stenosis, acute rejection) were
excluded as the main underlying reason for FEV1 decline. Alveolar epithelial cell sam-
ples taken after a persistent FEV1 measurement (≤ 80%) were considered BOS-positive
(19 samples from 13 patients). Alveolar epithelial cell samples were considered BOS-
negative if they were taken at least two years before an irreversible drop to FEV1 ≤ 80%
(35 samples from 24 patients). Samples not complying with these strict criteria were
labeled as BOS-unclassiﬁed (23 samples from 16 patients). BALF samples for which
a FEV1 measurement (≤ 80%) became persistent within one year after bronchoscopy,
were considered BOS-positive (16 samples from 10 patients). Samples were considered
BOS-negative if they were taken at least three years before an irreversible drop to FEV1
≤ 80% (38 samples from 26 patients). Samples not complying with these strict criteria
were labeled as BOS-unclassiﬁed (92 samples from 46 patients). See Table 2.4 for deatils.
Table 2.1. Clinical Data Microarrays (Patients)
Patient demographics Hazard ratio (95% Cl) p-value
Subjects 53
Sex M/F 27/26 1.54 (0.78 - 3.04) 0.22
Age (yr) at Ltx 45 ± 12 1 (0.97 - 1.03) 0.97
Diagnosis pretransplantation
Alpha-1-PI deﬁciency 6 1.48 (0.56-3.88) 0.43
Cystic ﬁbrosis 13 1.35 (0.62-2.94) 0.46
Lung emphysema 16 0.9(0.4-2.02) 0.8
Pulmonary ﬁbrosis 8 0.73 (0.25- 2.11) 0.56
Various conditions 10 0.71(0.25 - 2.04) 0.52
Transplant type
Single 7 0.36 (0.05-2.67) 0.32
Bilateral 70 2.76 (0.37-20.27) 0.32
Known BOS development
No 41
Yes 36
CI, conﬁdence interval; M, male; F, female; BOS, bronchiolitis obliterans syndrome; LTx, lung
transplantation; yr, years.
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Table 2.2. Classwise Clinical Data Microarrays (Samples)
Class distribution
Classes BOS-positive BOS-negative Unclassiﬁed
p-value
(BOS+/BOS-)
(Wilcoxon)
13 24 16
Transplant type
Single 0 3 1
Bilateral 13 21 15
Diagnosis pretransplantation
Alpha-1-PI deﬁciency 1 3 2
Cystic ﬁbrosis 3 5 5
Lung emphysema 5 7 4
Pulmonary ﬁbrosis 2 3 3
Various conditions 2 6 2
Sex M/F 7/6 11/13 9/7
Age (yr) at Ltx 48 ± 13 45 ± 12 42 ± 13 0.27
Samples 19 35 23
days after lung transplant 576 ± 149 615 ± 119 633 ± 163 0.09
M, male; F, female; BOS, bronchiolitis obliterans syndrome; LTx, lung transplantation; yr, years.
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Table 2.3. Clinical Data Mass Spectrometry (Patients)
Patient demographics Hazard ratio (95% Cl) p-value
Subjects 82
Sex M/F 40/42 1.54 (0.78 - 3.04) 0.22
Age (yr) at Ltx 44± 13 0.98 (0.96-1.01) 0.24
Diagnosis pretransplantation
Alpha-1-PI deﬁciency 9 1.66 (0.68-4.03) 0.26
Cystic ﬁbrosis 19 1.86 (0.9-3.84) 0.09
Lung emphysema 24 0.58(0.25-1.34) 0.2
Pulmonary ﬁbrosis 15 0.82 (0.34-1.99) 0.66
Various conditions 15 0.67(0.23-1.91) 0.45
Transplant type
Single 9 1.25 (0.43-3.55) 0.68
Bilateral 73 0.8(0.28-2.29) 0.68
Known BOS development
No 48
Yes 34
CI, conﬁdence interval; M, male; F, female; BOS, bronchiolitis obliterans syndrome; LTx, lung
transplantation; yr, years.
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Table 2.4. Classwise Clinical Data Mass Spectrometry (Samples)
Class distribution
Classes BOS-positive BOS-negative Unclassiﬁed
p-value
(BOS+/BOS-)
(Wilcoxon)
10 27 67
Transplant type
Single 2 2 9
Bilateral 8 25 58
Diagnosis pretransplantation
Alpha-1-PI deﬁciency 1 5 7
Cystic ﬁbrosis 3 6 16
Lung emphysema 3 8 18
Pulmonary ﬁbrosis 2 3 13
Various conditions 1 5 13
Sex M/F 4/6 11/16 34/33
Age (yr) at Ltx 43± 15 44± 12 43± 14 0.92
Samples
days after lung transplant 579± 193 412± 143 477± 179 0.03
M, male; F, female; BOS, bronchiolitis obliterans syndrome; LTx, lung transplantation; yr, years.
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2.1 Gene Expression Proﬁling
First I will introduce the steps performed for the microarray analysis (gene expression
proﬁling).
2.1.1 Bronchial brush specimens
During bronchoscopy epithelial cells were obtained from the airway mucosa using a
sheated bronchial specimen brush. This bronchial brush was advanced through the op-
erating channel of the bronchoscope, and pushed forward and back after being positioned
in a bronchial segment. The brush was retracted into the tip before removal from the
bronchoscope. This procedure was repeated ﬁve times, each time in a diﬀerent bronchial
region. All obtained epithelial cells were removed from the brush by shaking in saline
solution and stored at −80 ◦C [22].
2.1.2 Microarray Proﬁling
RNA was extracted from the epithelial cells and replicated by polymerase chain reaction
(PCR) to obtain a suﬃcient amount of RNA for a high quality gene expression analysis
[182] The expression was measured using two-colour, whole-genome, cDNA microar-
rays, for which RNA (labelled using Cy3) from an epithelial cell sample is co-hybridized
against reference RNA (labelled using Cy5) of the ﬁrst cell sample obtained after LTx
from the respective patient. Thus all expression values are ratios relative to those ﬁrst
samples. These reference samples were taken during the ﬁrst year post lung transplan-
tation. The experiments were performed as described in [183,184,22], using the human
cDNA chips of the Stanford Functional Genomics Faculty [185]. After microarray exper-
iments, the ﬂuorescence intensities of Cy5 and Cy3 were measured on a GenePix 4000
dual-laser scanner (Axon instruments, Foster City, Ca, USA) and the GenePix Pro 4.1
imaging software (Axon instruments). This software allows for the extraction of intensi-
ties for each printed cDNA location from the microarray scan. All 43000 spots, on each
of the chips built using the Resgen Clone set (Stanford Functional Genomics Facility,
Stanford, CA, USA), were quality controlled by the software. The software was able to
ﬂag a spot as having bad quality because of shape, size and several other parameters
based on spot intensity [186]. Only probes ﬂagged as good in more than 50 percent of all
cases were used for further analysis. Normalization was performed using the vsn (vari-
ance stabilization and normalization) method [89]. The non-redundant gene-oriented
UniGene clusters [187] contain GenBank sequences that represent a unique gene [188].
The expression of multiple probes with the same Unigene cluster ID was averaged (me-
dian) to represent genewise expression [189,190].
2.1.3 BOS-Speciﬁc Transcriptome Alterations
To ﬁlter directly for BOS-speciﬁc genome alterations between BOS-positive and BOS-
negative samples diﬀerential expression was assessed using the rank product test [94,104].
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The p-values were adjusted using Benjamini-Hochberg false discovery rate (FDR) [105]
and adjusted p-values≤ 0.05 were considered signifcant. In addition to the p-value, genes
were only considered as up-regulated for a mean and median FC of log2(FC) > log2(1)
(down-regulated for a mean and median FC of log2(FC) < log2(1)).
2.1.4 BOS-Speciﬁc Pathways
After selecting all genes signiﬁcantly regulated between BOS-positive and BOS-negative
samples, a functional analysis was performed using the DAVID online resource [112].
Here KEGG pathway groups were of special interest, since those represent the interac-
tion of a gene set in relation to a speciﬁc biological process or disease. The obtained
results reﬂect the signiﬁcant overrepresentation of KEGG groups [110] among the list of
signiﬁcantly deregulated genes. This was was assessed by comparisson to the entire list
of analysed and annotated genes on the microarray chips.
BOS-Pathway Extension
While the processes causing BOS development might be similar to the detected path-
ways, there are still diﬀerences in the exact genes/proteins involved in disease progres-
sion. I took this idea into consideration by searching for genes functionally related to
the members of the enriched KEGG pathways. This was done using the DAVID func-
tional classiﬁcation tool. In addition to the basic enrichment analysis described so far,
DAVID also implements the functional classiﬁcation algorithm for functional similarity
clustering of genes [191,192]. It uses over 75,000 terms from 14 functional annotation
databases to generate a gene-to-gene similarity matrix of shared functional annotation.
This similarity matrix is used by a heuristic procedure to partition the genes into the
optimal number of k functionally related genes clusters. Genes showing a weak rela-
tionship to the remaining genes are removed by the algorithm. The heuristic follows a
fuzzy [193] approach, allowing a gene to pariticipate in more than one cluster. To give
some guidance in the interpretation of the obtained results an enrichment score is cal-
culated for each cluster. Herefore the geometric mean of the involved functional terms
enrichment p-values is calculated. The minus log transformation of this geometric mean
gives the enrichment score. Even if a high score represents biological importance, it
should not be used for a hard decision concerning a clusters relevance. The ﬁnal decsion
should also take into consideration a more global picture of the expected biology. Using
the prediﬁned quality settings, I selected the clusters which showed a Gene Enrichment
score (GE) above a user deﬁned threshold and contained at least one member of the en-
riched KEGG pathways. Genes from these clusters were used to extend the signiﬁcantly
enriched KEGG pathways ("pathway extension").
2.1.5 BOS Risk Monitoring
BOS-free time was deﬁned as the time diﬀerence between the date of bronchoscopic
sampling and a persistent FEV1 ≤ 80%. For samples taken before an irreversible drop
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to FEV1 ≤ 80%, the mean follow-up time was 573 ± 493 days, and the follow-up for
statistical analysis was limited to 3 years after bronchoscopy. For multivariate analy-
sis of the relation between BOS progression and the respective molecular processes, an
integrative random survial forest (RSF) was constructed [163,194]. This model incor-
porated all KEGG pathway related (direct KEGG members and "pathway extension")
genes and the FEV1 score. The RSF method is an ensemble classiﬁer that consists of
many survival trees. Each tree is independently constructed using a bootstrap sample of
the data. An ensemble cumulative hazard estimate is obtained by combining informa-
tion from all trees. At each bootstrap iteration, the data not in the bootstrap sample is
used to estimate the error rate by concordance error (1 - C-index) [194]. As the KEGG
data base describes interactions of genes in regard to a speciﬁc disease/pathway, the
RSF methodology was perfectly suited to our needs. This is due to the idea that it
automatically models the nonlinear interactions between the variables of interest and
returns a variable importance measure (VIMP) for each feature [194,195,163,196].
Variable Ranking
Analogous to the mean decrease in accuracy(MDA) measure introduced for random for-
est (RF) [155], a variable importance (VIMP) [194,195,163,196] can also be calculated
for random survival forests (RSF). In the original deﬁnition variable importance is cal-
culated by permuting a variable and then calculating the change in prediction error. For
RSF random node assignment is used instead [195,163]. For a variable x, this works as
follows. When a case is dropped down a tree it is randomly assigned to a daughter node
whenever the tree splits on x. The predictions from the randomized trees are obtained
and averaged over the entire forest. Now the VIMP is deﬁned as the prediction error
from the noised up forest minus the error of the original forest. As for standard RF a
positive VIMP indicates an informative variable and is calculated using the OOB error.
The error itself is calculated according to the C-index, which estimates the probability
of correctly classifying two cases. Cases with a higher predicted risk should thus also
show a shorter BOS free time. Variables with a positive VIMP > 0 were considered
potentially informative in regard to BOS progression, while variables with a VIMP ≤ 0
were considered uninformative. A variable with an importance value higher than the
absolute value of the lowest negative-scoring variable was considered signiﬁcantly infor-
mative and important. This is based on the rational that the importance of irrelevant
variables varies randomly around zero [197]. Further for each of the potentially informa-
tive features univariate analysis was performed by univariate Cox proportional hazard
models.
Interactions as Identiﬁed by RSF
It is a recent idea that for discovering biological interactions [198] the interaction pa-
rameters in statistical modeling should be jointly interpreted with the main eﬀects [199].
In traditional parametric modeling these are usually taken to mean the product of two
variables in a model [200]. Random forest and other tree based methods oﬀer the ad-
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vantage that the structure of decision trees gives a broader notion of interaction. For
such trees interaction means the ability to model the outcome diﬀerently over subgroups
deﬁned by a trees partitioning of the data space [200]. As a tree based method random
survival forests can thus be used to rate the interactions between the potentially infor-
mative features (VIMP > 0) of interest [194,195,163,196]. The interaction for a pair of
variables (u and w) is hereby analysed using the concept of a joint VIMP. This joint
VIMP (υf ) is deﬁned as the diﬀerence between the OOB prediction error when both
predictor variables are noised up and the prediction error without noising up. The sum
of the two single variables VIMPs (υu + υw) is called the additive importance or addi-
tive VIMP. A large absolute diﬀerence between the joint VIMP and the additive VIMP
(|(υu+υw)−υf |) indicates a potential interaction between the two variables. In the case
of two highly correlated and inﬂuential variables u and w, the selection of one variable
early in the tree growing process likely precludes the other variable from being selected.
In the example case that 50 percent of the trees were grown using u, with the remain-
ing trees being grown using w. Now noising up u and w individually would inﬂuence
only half of all trees, while noising up both simultaneously would inﬂuence the entire
set of trees. In this case the joint noising up of u and w would lead to a subtantially
higher increase in prediction error, as compared to the additive decrease in prediction
error. Thus the diﬀerence between the joint VIMP and the additive importance would
be positive ((υu + υw) > υf ). A negative diﬀerence, on the other hand, can be observed
if there is a high overlap between the subtrees of u and w. In the case of u being noised
up, the additional noising up of w would not lead to a substantial decrease in prediction
error and vice versa. This is due to the idea that the noising up of a variable u (or w)
already inﬂuences all splits made further down the tree, including splits made on w (or
u). Consequentially in the case of high overlap a negative diﬀerence between the joint
VIMP and the additive importance ((υu + υw) < υf ) would be detected. Thus highly
positive diﬀerences reﬂect the idea that both variables are correlated, while highly nega-
tive values hint to a complementary interaction with respect to BOS progression. This is
due to the idea that after splitting on one variable, a split based on the speciﬁc comple-
mentary variable is most likely to further improve prediction. A concept with is reﬂected
in the overlapping subtrees. The diﬀerences of interest, between the joint VIMP and
the additive importance, were calculated for all pairs of potentially informative variables
(VIMP > 0).
Interpretation of Interactions as Identiﬁed by RSF
A new approach was developed in this thesis to make the concept of variable interaction,
as identiﬁed by a random survival forest (RSF) model, more applicable to biological re-
search. To obtain an interpretable interaction score, the diﬀerences between joint VIMP
and the additive importance were normalised by Z score transformation [201,202,87,203].
Using these interaction scores two graphs [204,205] were constructed. The nodes rep-
resent variables and the absolute values of the interactions scores (|interaction score|)
serve as edge adjacency weights [206]. This was done for positive and negative interac-
tion scores separately. For these graphs only positive (negative) interaction scores were
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considered as edges. In the case of negative (positive) interaction scores no edge was
introduced. The ﬁrst graph (positive interaction scores) helps to represent correlation
between variables with regard to BOS development. The second graph (negative inter-
action scores) allows for the characterization of the complementary information between
predictive variables. The graph backbone [207] composed of the most important edges of
the network can be identiﬁed in the form of a minimum spanning tree [208]. This allows
for the identiﬁcation of the network substructure that best reﬂects the principles behind
BOS development and progression. A spanning tree for each graph, which connects all
the edges together, was constructed using Prim's algorithm for ﬁnding minimum span-
ning trees in weighted graphs [209,206]. The resulting minimum spanning tree showed
a sum over all distance weights ( 1
adjacency
) of the edges in that spanning tree less than
or equal to the sum of distance weights for every other spanning tree [209]. To identify
the most important variables (nodes) in each minimum spanning tree the connectivity
of each node was assessed by its node strength. This is deﬁned as the sum of the ad-
jacency weights of edges connected to the node [210,211]. The nodes with a relative
node strength of ≥ 0.8 , as compared to the node with the highest node strength, were
considered hub nodes of their respective minimum spanning tree. Hub nodes in the ﬁrst
tree graph (positive interaction scores) are considered to be the predictors which best
represent the set of predictive variables. Hub nodes from the second tree graph (negative
interaction scores) oﬀer supplementary information to other predictive variables. The
graph was visualized using the yEd graph editor software (yWorks).
2.1.6 Risk Groups
Both random forest and random survival forest oﬀer the possibility to calculate pairwise
proximities between observations (samples). Two observations are considered similar if
they often fall in the same terminal nodes. Thus a proximity measure can be calculated
by the fraction of two observations being assigned to the same terminal node. After
calculating the distance (1-proximity) between the observations, the partitioning around
medoids (PAM) [174] algorithm was used to cluster the patients (BOS-negative and BOS-
unclassiﬁed) into two risk groups (high risk and low risk)[174,10]. The diﬀerence in BOS
free progression between both groups was visualized using Kaplan Meier curves [164],
with signiﬁcance of diﬀerences in BOS free progression being tested by a log rank test
[164]. For each of the genes selected as potentially informative according to the RSF
model (VIMP > 0), signiﬁcance of diﬀerential expression between the two risk groups
was assessed by a Wilcoxon rank sum test.
2.1.7 Quantitative Real Time PCR
Diﬀerential expression of selected genes was further validated by quantitative real time
PCR (qRT-PCR) (Solaris Assay, Thermo Fisher Scientiﬁc). This procedure, which is
the established method for the validation of microarray results [98], was performed using
a Light Cycler device (version 2.0, Roche, Penzberg, Germany). Detailed information
about the procedure can be found in [Skawran2008a]. The relative quantiﬁcation was
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determined according to the ∆∆ - CT method, using the LightCycler software (version
4.05). The TATA-box binding (TBP) gene was used as an internal control, and the RNA
from the ﬁrst post LTx sample of the respective patient was used as reference. The results
from a fold change based rank product (RP) test were considered validated if the qRT-
PCR values correlated signiﬁcantly with the microarray data (spearman rank correlation
test, rho > 0, p-value ≤ 0.05) and showed a (median) log2(FC) > log2(2) between
the groups of interest. Diﬀerential expression, as detected by a Wilcoxon rank sum
test,was considered validated if the RT-PCR correlated signiﬁcantly with the microarray
data(spearman rank correlation test, rho > 0, p-value ≤ 0.05) and showed a signiﬁcant
diﬀerential expression (Wilcoxon rank sum test, p-value ≤ 0.05) between the groups of
interest. Concordance between RT-PCR and microarray expression values was further
assessed using the concordance index (C-index) [212,194,95]. A C-index around 0.7 was
considered as an acceptably good concordance between the results [213].
2.2 Proteome Screening
This section details the steps performed for the MALDI-TOF mass spectrometry proﬁl-
ing (proteome screening).
2.2.1 MALDI-TOF Proﬁling
After BALF (bronchoalveolar lavage ﬂuid) sample delivery on ice, cells and mucus were
removed by centrifugation. Pellet and supernatant were stored at −80 ◦C. All sam-
ples went through one freeze-thaw cycle before proteomic analysis. Supernatant pro-
teome constituents were isolated using superparamagnetic particles (MB-WCX,Bruker
Daltonics, Bremen, Germany). Samples were processed in duplicate according to mod-
iﬁed manufacturers protocols, taking into account the high salt concentration and low
protein content (mean 0.1 ± 0.08 µg/µL). A linear MALDI-TOF mass spectrometer
(MicroﬂexLT, Bruker Daltonics) was used for proﬁle spectra acquisition. Spectra were
preprocessed, as described in Chapter 1.6.3, using the PROcess R-package [129]. Outlier
spectra showing elevated/decreased intensity sum or variance over all m/z values were
selected by boxplot analysis [214,215]. If visual inspection of these spectra conﬁrmed
the bad quality, these were removed from further analysis [124]. For further anaylsis and
data mining the mean (median) spectrum of the remaining technical replicates for each
sample was calculated [216].
2.2.2 BOS-Speciﬁc Proteome Alterations
BOS normally occurs after the ﬁrst postoperational year [217,218]. Thus I used the
rank product (RP) test [94,104] on samples taken before a persistent FEV1 ≤ 80 per-
cent, comparing those obtained during the ﬁrst postoperational year to samples from
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later years. When ﬁltering directly for BOS-speciﬁc proteome alterations between BOS-
positive and BOS-negative samples. To adjust for the signiﬁcant diﬀerence in time after
LTx between BOS+/BOS- (Table 2.4), comparisons were restricted to samples collected
within a timeframe of one year. The p-values were adjusted using false discovery rate
(FDR) [105], and adjusted p-values of p ≤ 0.05 were considered signiﬁcant.
2.2.3 BOS Predictor Model
For BOS classiﬁcation, I constructed a random forest (RF) predictor model [155,219,220]
based on all signiﬁcantly regulated peaks (BOS-negative vs BOS-positive and after the
ﬁrst postoperational year). The RF method is an ensemble classiﬁer that consists of
many decision trees. Each tree is independently constructed using a subsample of the
data. For our analysis the size of the subsample selected from each group was equal
to 90% of the smallest class (BOS+). Each subsample was drawn without replacement
[221]. A random forest predictor score (RF-score) based on the percentage of trees
voting for a speciﬁc class, was used for classifying a sample. A simple major vote (RF-
score ≥ 50%) deﬁned class assignment. At each bootstrap iteration, the data not in the
bootstrap sample is used to estimate the error rate. The mean error estimation over all
bootstrap iterations is referred to as the out of bag (OOB) error.
Variable Ranking
The random forest method allows for the assesment of a variables importance by looking
how much prediction error increases when the OOB data for that variable is permuted
while all others are let unchanged. The necessary calculations for this mean decrease
in acccuracy (MDA) measure are performed tree by tree. Let Tb be the tree classiﬁer
constructed for the bootstrap sample Λb. First drop the OOB observations correspond-
ing to Λb down the tree Tb, record the resulting classiﬁcations, and compute the OOB
error rate, PEb(OOB). Next, randomly permute the OOB values on the jth variable
Xj while leaving the data on all other variables unchanged. If Xj is important, permut-
ing its observed values will reduce our ability to successfully classify each of the OOB
obseravtions. We then drop the altered OOB observations down the tree Tb, record
the resulting classiﬁcations, and compute the OOB prediction error rate, PEb(OOBj),
which should be larger than the error rate of the unaltered data. A raw Tb-score for Xj
can be computed by the diﬀerence between those two OOB error rates,
rawb(j) = PEb(OOBj)− PEb(OOB), b = 1, 2, . . . , B (2.1)
Finally, we average the raw scores over all the B trees in the forest,thus obtaining
the MDA score for the jth variable:
MDA(j) =
1
B
B∑
b=1
rawb(j) (2.2)
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A high positive MDA value signiﬁes an important variable, while a score≤ 0 describes
uninformative variables. This procedure is repeated for each variable, allowing us to
rank the variables according to their importance in a classiﬁcation setting. A common
procedure is to scale the MDA values by Z transformation [87], but in the context of
this thesis the unscaled values are used. As shown in [222] unbalanced class size can
introduce a bias to the calculated MDA. To make the MDA score unbiased by class
size, a separate MDA for each respective class was calculated. The ﬁnal MDA was then
obtained by averaging (mean) over the classwise MDAs.
Variable Selection
Training the random forest on the BOS-positive and BOS-negative samples, the peaks
were chosen such that the area under curve (AUC) [222] of the random forests out of
bag (OOB) predictions was minimized and peaks considered uninformative according
to their RF-based mean decrease inaccuracy score (MDA ≤ 0 ) were excluded (Listing
2.1). For this an RF model was learned using only the highest ranking (low RP) peaks
from each of the four lists of interest (up/down BOS+/BOS- and up/down after the ﬁrst
postoperational year). Subsequent models were learned on a set of peaks increased by
the next highest ranked peak from each list. This was repeated as long as it also led to
an increase in the AUC of the OOB predictions. Peaks with MDA ≤ 0, according to the
RF model learned using the respective peaks, were removed from the list showing the
highest AUC. The remaining selected peaks were used to learn the ﬁnal RF classiﬁer.
An unbiased estimation of classiﬁer performance was obtained by a speciﬁcally adapted
cross-validation scheme, with all feature selection steps using class information being
included in the validation.
Listing 2.1. This listing describes the algorithm behind the newly developed feature
selection approach.
1
2S e l e c t the f e a tu r e l i s t s o f i n t e r e s t .
3
4Order the f e a t u r e s ( peaks ) in each separa t e l i s t accord ing
5to t h e i r RP sco r e ( from lowest to h i ghe s t ) .
6
7p = 1
8
9S e l e c t the p h ighe s t ranked f e a t u r e s
10from each l i s t o f i n t e r e s t .
11Ca l l t h i s s e t o f f e a t u r e s G .
12
13Fit a random f o r e s t F to the data us ing G .
14Anew = ca l c u l a t e the AUC of F based on the OOBF
15
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16Cal l the best cur r ent f e a t u r e s e t Go
17Go = G
18
19Cal l the best cur r ent random f o r e s t c l a s s i f i e r F o
20F o = F
21
22cont inue = TRUE
23
24whi l e ( cont inue == TRUE)
25
26p = p+ 1
27
28Augment G to in c lude the p h ighe s t ranked
29genes from each l i s t o f i n t e r e s t .
30Ca l l t h i s new s e t G+ .
31
32Fit a random f o r e s t F+ to the data us ing G+ .
33Anew = ca l c u l a t e the AUC
34f o r F+ based on the OOB+F
35
36i f Anew > Aold
37
38Aold = Anew
39Go = G+
40F o = F+
41
42e l s e
43
44cont inue = FALSE
45
46end i f
47
48end whi le
49
50
51Ca lcu la te the unsca led MDA o f each f e a tu r e
52in Go accord ing to F o .
53Remove the genes with MDA ≤ 0 from Go
54Cal l t h i s s e t G∗ .
55
56Fit the f i n a l random f o r e s t F ∗ to the data us ing G∗ .
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Cross-Validation
To get an estimate of classiﬁer performance, I used a cross-validation approach that
included all feature selection steps using class information. At each iteration all sam-
ples from a respective patient (BOS-positive, BOS-negative and BOS-unclassiﬁed) were
not part of the training set. Thus the RF predictor score (RF-score) between 0% (=
BOS-negative) and 100% (= BOS-positive) assigned to each sample (including the ones
labelled as BOS-unclassiﬁed) during cross-validation, is not biased by previous knowl-
edge of the patient/sample in question. Discriminative power of BOS-positive and BOS-
negative classiﬁcation was evaluated using acuracy, sensitivity, speciﬁty and a receiver
operating characteristic (ROC) curve [149]. Since the assigned RF scores were unbiased,
they were used for further validation by risk assessment on the samples taken before an
irreversible drop to FEV1 ≤ 80%.
2.2.4 BOS Risk Monitoring
BOS-free time was deﬁned as the time diﬀerence between date of bronchoscopic sampling
and a persistent FEV1 ≤ 80%. For samples taken before an irreversible drop to FEV1
≤ 80%, the mean follow-up time was 877 days ± 388, and the follow-up for statistical
analysis was limited to 3 years after bronchoscopy. Kaplan-Meier plots were used to
visualize the BOS-free time distributions, and the signiﬁcance of diﬀerences in BOS-free
time was evaluated by log-rank tests. Univariate and multivariate analysis of factors
signiﬁcantly related to BOS-free time was performed using Cox proportional hazard
models.
2.2.5 Identiﬁcation of BALF Proteome Constituents
Mass identiﬁcation was enabled by MALDI-TOF/TOF analysis and in-gel tryptic diges-
tion followed by peptide mass ﬁngerprinting. MALDI-TOF/TOF peptide and protein
fragment analysis was performed with an Ultraﬂex I device (Bruker Daltonics). Iden-
tiﬁcation of masses beyond the MALDI-TOF/TOF technical limit of about 3-5 kDa
was achieved by horizontal SDS-PAGE of BALF samples (precast 12.5% CleanGels,
proprietary neutral SDS buﬀer system; ETC Electrophorese-Technik, Kirchentellinsfurt,
Germany). Gels were stained with colloidal Coomassie (Carl Roth GmbH, Karlsruhe,
Germany) and prominent bands up to 170 kDa excised for in-gel tryptic digestion ac-
cording to standard protocols. Peptide mass mapping using the MASCOT search engine
(Matrix Science, London, UK) complemented by MALDI-TOF/TOF data was used to
analyze the tryptic digests. Peak identiﬁcation was further supported [223] with the
ExPASy TagIdent tool (SIB, Basle, Switzerland) by database search for unique exact
mass matches (pI range 0-14, Mw range 0.5 %). All identiﬁcation results were further
supported by pearson correlation based agglomerative hierarchical clustering.
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2.2.6 Enzyme-Linked Immunosorbent Assay
The diagnostic immunoassay for clara cell protein (CCP) was conducted according to
the manufacturers instructions (BioVendor, Heidelberg, Germany). Each of the mea-
surements was normalized against the baseline value (ﬁrst available sample) for the
respective patient. BALF samples were divided into two groups. Group 1: ISHLT
BOS stage progression in relation to the previous sample (BOS0 -> BOS1 -> BOS2 ->
BOS3). Group 2: No ISHLT BOS stage progression in relation to the previous sample.
For each sample, the percentage of change in protein concentration in relation to the
previous sample was calculated. Signiﬁcance of detected changes was assessed using the
Wilcoxon rank sum test.
2.3 Block Maxx
This thesis presents a novel strategy that clusters the samples based on the consistent
up- and down-regulation of a subset of genes (Figure 2.1). This method, using spectral
bipartite graph partitioning [224,225,226], allows for the removal of genes/samples that
could not be assigned clearly to any of the discovered clusters. My approach is basi-
cally a three step procedure: (1) gene ﬁltering (2) clustering (3) assessment of cluster
stability/importance. Gene ﬁltering is an integral part of cluster analysis, and strongly
aﬀects the clustering results [172]. This is especially important when the number of
genes m is many multitudes larger than the number of samples n [172]. Approaches
to gene ﬁltering are often based on thresholding the mean or variance [227]. Thus an
optimal variance threshold was determined by a combination of hierarchical clustering
and cophenetic correlation [228]. The clustering results are judged by their stability
according to a clusterwise subsampling strategy [229]. This subsampling strategy is also
used to determine each genes importance for a speciﬁc cluster. The method oﬀers su-
perior stability and the results are still easy to visualize as heatmaps. Both properties
enhance its applicability in day to day biological research. To evaluate the algorithm
it was compared to a traditional clustering algorithm (PAM [135,229]), an algorithm
that is able to remove outlier samples (trimmed-k-means [175,230,229]), an approach
using feature weighting (random forest (RF) clustering)[220,174]. All algorithms were
evaluated on a microarray data set of mature aggressive B-cell lymphomas [231].
2.3.1 Data Representation and Gene Filtering
The Block Maxx approach was developed for the analysis of high throughput data sets.
These are usually in the form of a set of experiments that describe the properties of
speciﬁc biological entities (i.e. patients, cell lines). Each experiment is deﬁned by a set
of attributes (i.e. gene expression, protein concentration, gene copy number) associated
with the entities. Such data can easily be represented as a data matrix (Aij) with
one row for each attribute (feature) and one column for each entity. In the following
the attributes (features) used are genes while the entities of interest will be referred to
as samples. Since for most high througput methods only a subset of the features is
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Figure 2.1. A simpliﬁed representation of the cluster structure assumed by Block
Maxx. For this heatmap red depicts high expression and green shows low expression.
2.3 Block Maxx 51
informative, an unsupervised feature selection approach was implemented. The method
is based on agglomerative hierarchical clustering [135]. This makes it independent of the
number of clusters k. The quality of a selected subset of genes was rated by how well the
resulting dendrogram, as generated by hierarchical clustering, represents the patterns
hidden in the data. This can be assessed by the cophenetic correlation coeﬃcient[228].
Cophenetic Correlation
Cophenetic correlation rates how faithfully a dendrogram preserves the pairwise dis-
tances between the original unmodeled samples (data points). Given an original set of
samples X, which has been modeled using a hierarchical clustering method to produce
a dendrogram D, the cophenetic correlation can be deﬁned by comparing the euclidean
distance d2(xi, xj) between the ith and jth sample with the respective dendrogrammatic
distance. The dendrogrammatic distance t(i, j) between the model points of these sam-
ples is deﬁned as the height of the dendrogramm node at which the two points are ﬁrst
joined together. Denotig the average of the d2(i, j) by d and the average of the t(i, j) by
t, the cophenetic correlation coeﬃcient c is deﬁned by:
c =
∑
i<j(d2(i, j)− d)(t(i, j)− t)√
[
∑
i<j(x(i, j)− x)2][(t(i, j)− t)2]
(2.3)
Optimal Gene Set
The variance of gene expression is often used to determine highly informative genes
[232]. Thus all genes are ordered in a decreasing manner, according to their expression
variance over all samples. The 5 genes with the highest variance are selected to generate
the associated dendrogramm of samples, which is rated using the cophenetic correlation
coeﬃcient. This is repeated iteratively, sequentially adding 5 more genes , till the cophe-
netic correlation coeﬃcient c no longer increases. The gene set resulting in the highest
cophenetic correlation coeﬃcient is used for all following calculations.
2.3.2 Basic Principles and Data Transformation
The Block Maxx approach assumes that the data matrix contains a structure with k
biclusters. Each bicluster is deﬁned by a subset of samples (columns), and a subset of
genes (rows). The grouped genes are consistently up- or down-regulated in the respec-
tive set of samples. A cluster can simultaneously contain up and- down-regulated genes.
Each sample is assigned to exactly one cluster. Genes can be consistently up-regulated
in one cluster, while being down-regulated in another cluster. Thus a gene can be a
member of up to 2 clusters. Genes that are not diﬀerentially expressed in any of the
sample clusters are assigned to a background cluster. The assignment to the background
cluster is handeled separately for up- and down-regulation. Meaning that while a gene
is consistently up-regulated (down-regulated) in one cluster, it is not necessarily consi-
tently down-regulated (up-regulated) in any of the other clusters. Assignment to the
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background is also performed for samples, if they do not show a consistent over- or
under-expression for any of the gene subsets deﬁned by the clustering. As the Block
Maxx approach is mainly based on the concept of diﬀerential expression, a numerical
representation for the up- and down-regulation of a gene in a specﬁfc sample has to be
deﬁned.
Gene Activiation Matrix
Given a data set (A) with m genes (F ) and n samples (S) the association of a gene with
a specﬁﬁc sample (aij) will be represented by a Gene Activation Score (GAS), instead
of the raw expression values. This GAS is based on the established Z score [87], which
indicates how many standard deviations an observation is above or below the mean for
a speciﬁc attribute. After calculating the row mean for a gene:
µi =
1
m
m∑
j=1
aij (2.4)
as well as the row wise standard deviation
σi =
√√√√ 1
m
m∑
j=1
(aij − µi) (2.5)
the z-normalized expression value can be assigned by:
a′ij =
aij − µi
σi
(2.6)
The z transformation normalizes each row to a mean of 0 and a standard deviation
of one. Since a gene can be up-regulated in one cluster and down-regulated in another
one, we deﬁne an up-regulation (Fup) and a down regulation (Fdown) representation for
each gene (feature) (F = (Fup, Fdown). This leads to an upregualtion Aup = A′ and a
down-regulation matrix Adown = −A′.
Both matrices (Aup and Adown) are than combined as:
A′′ =
[
Aup
Adown
]
(2.7)
For A′′ the matrix entries a′′ij are range scaled between 0 and 1, thus calculating the
ﬁnal Gene Activation Score (GAS) matrix A∗.
a∗ij =
a′′ij − a′′min
a′′max − a′′min
(2.8)
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For the GAS matrix A∗ the global mean (µ∗) over all matrix entries is deﬁned as
µ∗ =
0− A′′min
A′′max − A′′min
(2.9)
with the global standard deviation (σ∗) over all matrix entries being
σ∗ =
1− A′′min
A′′max − A′′min
(2.10)
Deﬁning a Background
To allow for the removal of genes/samples that can not be assigned clearly to a speciﬁc
cluster, we introduce the concept of a background. Thus the matrix A∗ is extended
by m
k
background genes (Fback) and nk background samples Sback. F
+ = F, Fback and
S+ = S, Sback. The background genes show an activation score of µ∗ for the set of S and
µ∗ + σ∗ for Sback. For the background genes Fback the genes F show an activation score
of µ∗.
A+ =

a∗11 a
∗
12 ... a
∗
1n ... µ
∗ + σ∗ ... µ∗ + σ∗
a∗21 a
∗
22 ... a
∗
2n ... µ
∗ + σ∗ ... µ∗ + σ∗
... ... ... ... ...
a∗m1 a
∗
m2 ... a
∗
mn ... µ
∗ ... µ∗
 (2.11)
Genes and samples that are more connected to the background than any of the real
clusters will be clustered together with the background samples/genes. Thus they are
removed from the detected cluster structure.
2.3.3 Graph Generation and Partitioning
To simultaneously partition genes and samples into k clusters, a spectral clustering
approach is used. The spectral clustering algorithm tries to ﬁnd clusters such that the
nodes in a graph are connected by highly weighted edges and the connections between
clusters are weak. Weak connections are represented by edges with low weights. The
goal is to identify these tightly coupled clusters, and to cut the inter cluster edges.
Spectral clustering achieves this goal by clustering the data, using eigenvectors of a
similarity/aﬃnity matrix derived from the data set. A biclustering variant of spectral
clustering, using the singular vectors of the data matrix, was described and applied by
Dhillon [224,225,226]. This approach, based on a bipartite graph representation of a
data set, was used to partition A+ into k clusters.
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Graph Model
The matrix A+ is a gene-by-condition matrix, where a+ij equals the Gene Expression
Scores (GAS). This can be represented as an undirected bipartite graph, with the weights
given by the Gene Activation scores. The graph is then deﬁned as G = F, S,E), where
F = {f1, f2, . . . , fm} and S = {s1, s2, . . . , sn} are two sets of vertices and E is the set
of edges {{fi, sj} : fi ∈ F+, sj ∈ S+}. S+ corresponds to the set of samples and F+
corresponds to the set of genes. These sets (F+ and S+) include the background genes
and samples. An edge signiﬁes the association between a condition and a gene. The
weight of the edge corresponds to a+ij. As the graph is supposed to be bipartite, there
are no edges between genes and no edges between conditions. To remove edges between
samples and genes, with a below average GAS, the entries a+ij ≤ µ∗ are set to 0. The
resulting bipartite graph can be represented by the following adjacency matrix:
M =
[
0 A+
A+T 0
]
(2.12)
Objective of Clustering
For an optimal partitioning the edge weight between members of a cluster should be
maximized, while minimizing the edge weight between the clusters. This objective can
be deﬁned by the normalized-cut (Ncut) [233]. To deﬁne the Ncut we ﬁrst introduce a
speciﬁc vertex weight function, where the weight of each vertex (V = (F, S) is equal to
the sum of the weights of edges that are incident on it:
weight(i) =
∑
r
Eir (2.13)
This leads us to the normalized-cut (NCut) objective [233]:
N(V1, V2) =
cut(V1, V2)∑
i∈V1
∑
r Eir
+
cut(V1, V2)∑
i∈V2
∑
r Eir
(2.14)
Graph Partitioning
Presenting the data as a bipartite graph allows for the application of spectral graph
theory [234], which can be used to partition the graph into clusters. Thus, since ﬁnding
the globally minimum solution to the NCut is NP-complete [233], an approximate solu-
tion can be found by the singular value decomposstion (SVD) of A+. The partitioning
algorithm, following reference [224], proceeds as follows:
1. Calculate A+ and form the matrix
An = D
−1/2
1 A
+D
−1/2
2 (2.15)
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with D1 and D2 diagonal matrices such that D1(i, i) =
∑
j A
+
ij and D2(j, j) =
∑
iA
+
ij
2. Calculate the singular value decomposition (SVD)
SV D(An) = U ∗ α ∗ V T (2.16)
and center each column of U and V to a columnwise mean of zero, by subtracting
the columnwise mean. This additional step diﬀers from the original approach described
in reference [224], as it is necessary to align the backgrounds of the genes and samples
with each other.
3. Construct the l-dimensional data set Z
As the l = k (or l = k − 1) singular vectors u2, u3, ..., ul+1, and v2, v3, ..., vl+1 often
contain k-modal information about the data set. Thus we can form the l-dimensional
data set
Z =
[
D
−1/2
1 U
D
−1/2
2 V
]
(2.17)
where U = [u2, ..., ul+1, and V = [v2, ..., vl+1].
4. Run the k-means algorithm on the l-dimensional data Z.
This obtains the desired k-way multipartitioning. Including the background cluster,
k-means is used to search for k + 1 clusters.
Genes (F = (Fup, Fdown) and samples (S) assigned to the same cluster, as obtained
by the k-means step, are considered a bicluster. Genes and samples clustered together
with the background genes (Fback) and background samples (Sback), were not considered
part of a bicluster. For the genes up- (Fup) and down-regulation (Fdown) representations
were considered separately.
2.3.4 Parameter Optimization
As not every singular vector of the data aﬃnity matrix (An) is informative, the choice
of the number of singular vectors l is critical to achieve a high quality clustering result.
Another important step is to deﬁne the optimal number of clusters k∗, a common problem
in unsupervised clustering approaches. Before setting these parameters, a measure of
cluster quality has to be deﬁned.
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Assessing Cluster Stability
To obtain a quality measure of the graph partitioning, which should reﬂect how well
separated and homogenous the clusters are, a subsampling scheme was applied. The
cluster stability was only assessed for the samples, a measure for the genes will be in-
troduced later. Each clusters quality was assessed by its reproducibility from a sample
subset of the entire data set. This clusterwise approach takes into consideration that
in a single clustering only a few clusters are highly stable, while the others prove to be
unstable. The data subsets used to test cluster stability are generated by bootstrap-
ping (sampling with replacement), for which duplicates are removed from the randomly
selected set. A clustering is calculated from this bootstrap subset, and each cluster is
compared to the most similar cluster from the original data set. The metric used to
deﬁne the similarity between two clusters is the Jaccard index. Given a set of entities
(samples) xn = x1, . . . , xn which are assigned to a set of disjoint cluster subsets, we can
deﬁne the Jaccard index for two clusters A and B as:
γ(A,B) =
|A ∩B|
|A ∪B| , A,B ⊆ xn. (2.18)
This deﬁnes the proportion of entities belonging to both clusters of all entities asigned
to at least one of both clusters. Given a set of B bootstrap iterations a clustering is
generated for each replicate. For a set of k clusters C = Ci, . . . , Ck from the original
clustering, the maximum similarity to each of the subset clusterings C∗b = C
∗
bj, . . . , C
∗
bk
is calculated for each of the original clusters:
γCib = maxγ(C
∗
b , Ci) (2.19)
This generates a sequence γCib , b = 1, . . . , B. Based on this sequence the mean Jaccard
index
γ¯Ci =
∑B
i=1 γC,i
B
(2.20)
serves as a stability measure. A cluster is considered as stable for γ¯Ci ≥ 0.75 The
stability for the entire clustering C is deﬁned as:
γ¯C =
∑k
i=1 γ¯Ci
k
(2.21)
A cluster (clustering) is considered as stable for γ¯Ci ≥ 0.75 (γ¯C ≥ 0.75).
Choosing k and the Number of Singular Vectors
The choice which eigenvectors or singular vectors to choose for data partitioning is still a
topic of much discussion in the ﬁeld of spectral clustering [235]. In this case the number
of singular vectors, used for a speciﬁc number of clusters k, is decided by the cluster
stability score of the samples. Either the ﬁrst 2 : (k) or the ﬁrst 2 : (k − 1) left and
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right singular vectors are used, depending on which choice shows the higher mean cluster
stability over all clusters. After choosing the singular vectors for each number of clusters
k, the optimal number of clusters k∗ needs to be determined. This was also done based
on the clusterwise stability. As reported in [229], a cluster can be considered as stable if
it shows a cluster stability score ≥ 0.75. Thus we choose the maximum number of k for
which all regular clusters, excluding the background cluster, (C1,...,k) show a clusterwise
stabililty score ≥ 0.75.
2.3.5 Gene Membership Score
As with assessing the cluster stability for the samples, the belonging and importance of a
gene to a cluster is quantiﬁed by the gene membership score (GMS). The GMS is based
on the same principles used to assess the clusterwise stability. During the bootstrap
iterations each cluster is assigned the same label as the most similar (samplewise) cluster
from the original data set. The genes in the cluster are also labeled accordingly. Thus
the GMS gives the percentage of times a gene was assigned a speciﬁc label.
GMSgc =
C∑
c=1
B (2.22)
The mgc are binary values with mgc = 1 g ∈ C
2.3.6 Comparisson and Visualization
To assess the usability of the Block Maxx approach, a previously published microarray
study of Burkitt`s Lymphoma and diﬀuse large-B-cell lymphoma was used [231]. This
data set was generated using Aﬀymetrix U133A gene chips for expression proﬁling of
220 mature aggressive B-cell lymphomas. On this data set Block Maxx was compared
to established algorithms. The PAM (partitioning around medoids) [135] method was
included as a standard clustering method. Further methods used for reference employ
strategies similar to those used by the Block Maxx approach (trimmed-k-means: out-
lier removal [175], unsupervised random forest clustering (PAM-RF): feature weighting
[174]). The biological/medical validity of the patient clusters was assessed by analysis of
survival time [164]. The survival time for the speciﬁc cluster was visualized using kaplan
meier curves, and statistical signiﬁcance of diﬀerences in survival time was assessesed
using the log-rank test. To validate if the gene membership scores actually reﬂect dif-
ferential expression, a Wilcoxon rank sum test (one tailed) was used. For each gene and
cluster combination the expression values between all samples in the cluster against all
samples not in the cluster were compared.
KEGG and Biocarta Association
Validation of the gene clusters was done using the DAVID functional annotation resource
[112,96]. Each clusters signiﬁcant enrichment of pathways (Biocarta and KEGG [110])
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was calculated. A cluster with signiﬁcantly enriched functional groups was rated as
biologically relevant.
Chapter 3
Results
3.1 Prediction of the Bronchiolitis Obliterans Syndrome
by Transcriptomics Analysis
The bronchial epithelial cell samples of 53 lung transplanted patients were obtained from
the airway mucosa using bronchial brushing [22]. The extracted RNA from 77 obtained
cell samples, taken at diﬀerent timepoints after lung transplantation, was replicated
by PCR and gene expression was measured using two-colour, whole-genome, cDNA
microarrays. For these RNA (labelled using Cy3) from an epithelial cell sample was co-
hybridized against reference RNA (labelled using Cy5) of the ﬁrst cell sample obtained
after LTx from the respective patient. The acquired expression proﬁles were preprocessed
and further computational analysis of BOS progression was performed.
3.1.1 Diﬀerentially Regulated Genes
After quality control and normalization the rank product test [104,94] was used to com-
pare BOS-positive against BOS-negative samples for all 10387 selected genes. We found
649 genes to be signiﬁcantly diﬀerentially expressed (441 up-regulated and 208 down-
regulated) at a p-value ≤ 0.05. The 20 most signiﬁcant genes from each group (up-
and down-regulated) are shown in Table 3.1 a) and 3.1 b) respectively. All diﬀerentially
regulated genes are shown in Appendix Table 1 and 2. Diﬀerential expression, as de-
tected by the rank product test, was validated for 5 genes (1 up-regulated: C15orf48 ; 4
down-regulated: ALDH3A1, SCGB3A2, HBA1 and SFTB) using quantitative real-time
PCR (qRT-PCR)(Table 3.2). For all genes the correlation between the microarray mea-
surements and the qRT-PCR results was considered signiﬁcant (Spearman rank corre-
lation test, p-value ≤ 0.05). All down-regulated genes met the respective FC threshold
(log2(FC) < log2(0.5)). For the up-regulated C15orf48 a tendency for up-regulation
was detected (FC > 1.74), but the FC threshold (log2(FC) > log2(2)) was not fully
met. The ordering of the microarray expression values, for each of the validated genes,
showed acceptably good concordance [213,212,168] with the qRT-PCR results (C-index
0.76− 0.92).
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Table 3.1. a) Genes signiﬁcantly up-regulated in BOS-positive samples
Gene symbol UniGene Gene name RP P FDR FC
1 SRGN Hs.1908 Serglycin 322 < 0.001 < 0.001 2.05
2 UPK1B Hs.271580 Uroplakin 1B 394 < 0.001 < 0.001 2.17
3 C15orf48 Hs.112242 Chromosome 15 open reading frame 48 446 < 0.001 < 0.001 2.1
4 LAPTM5 Hs.371021 Lysosomal protein transmembrane 5 468 < 0.001 < 0.001 1.87
5 CCL3L3 Hs.512304 Chemokine (C-C motif) ligand 3-like 3 478 < 0.001 < 0.001 1.88
6 FPGS Hs.335084 Folylpolyglutamate synthase 484 < 0.001 < 0.001 1.81
7 CCL3 Hs.514107 Chemokine (C-C motif) ligand 3 622 < 0.001 < 0.001 1.71
8 CCR1 Hs.301921 Chemokine (C-C motif) receptor 1 707 < 0.001 < 0.001 1.59
9 TPSAB1 Hs.405479 Tryptase alpha/beta 1 738 < 0.001 < 0.001 1.65
10 CCL2 Hs.303649 Chemokine (C-C motif) ligand 2 738 < 0.001 < 0.001 1.58
11 IL1B Hs.126256 Interleukin 1, beta 739 < 0.001 < 0.001 1.64
12 LY6D Hs.415762 Lymphocyte antigen 6 complex, locus D 752 < 0.001 < 0.001 1.6
13 MXD1 Hs.468908 MAX dimerization protein 1 763 < 0.001 < 0.001 1.66
14 FCER1G Hs.433300 Fc fragment of IgE, high aﬃnity I, receptor
for; gamma polypeptide
775 < 0.001 < 0.001 1.55
15 IFI30 Hs.14623 Interferon, gamma-inducible protein 30 776 < 0.001 < 0.001 1.58
16 SAA1 Hs.632144 Serum amyloid A1 778 < 0.001 < 0.001 1.4
17 CCNA1 Hs.417050 Cyclin A1 791 < 0.001 < 0.001 1.7
18 CENPN Hs.55028 Centromere protein N 807 < 0.001 < 0.001 1.54
19 HLA-G Hs.512152 Major histocompatibility complex, class I,
G
817 < 0.001 < 0.001 1.41
20 PLEK Hs.468840 Pleckstrin 818 < 0.001 < 0.001 1.45
Table 3.1. b) Genes signiﬁcantly down-regulated in BOS-positive samples
Gene symbol UniGene Gene name RP P FDR 1
FC
1 ALDH3A1 Hs.531682 Aldehyde dehydrogenase 3 family, member
A1
136 < 0.001 < 0.001 2.47
2 SCGB3A2 Hs.483765 Secretoglobin, family 3A, member 2 225 < 0.001 < 0.001 2.15
3 HBA1 Hs.449630 Hemoglobin, alpha 1 286 < 0.001 < 0.001 1.62
4 HBB Hs.523443 Hemoglobin, beta 294 < 0.001 < 0.001 1.57
5 MID1 Hs.27695 Midline 1 (Opitz/BBB syndrome) 395 < 0.001 < 0.001 1.77
6 SFTPC Hs.1074 Surfactant protein C 458 < 0.001 < 0.001 1.18
7 NCRNA00086 Hs.374414 Non-protein coding RNA 86 544 < 0.001 < 0.001 1.74
8 ZNF704 Hs.632067 Zinc ﬁnger protein 704 639 < 0.001 < 0.001 1.72
9 OLA1 Hs.157351 Obg-like ATPase 1 671 < 0.001 < 0.001 1.57
10 AHSP Hs.274309 Alpha hemoglobin stabilizing protein 699 < 0.001 < 0.001 1.82
11 VAV2 Hs.369921 Vav 2 guanine nucleotide exchange factor 762 < 0.001 < 0.001 1.58
12 PIPOX Hs.462585 Pipecolic acid oxidase 767 < 0.001 < 0.001 1.65
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13 CES1 Hs.558865 Carboxylesterase 1 (monocyte/-
macrophage serine esterase 1)
787 < 0.001 < 0.001 1.6
14 LTF Hs.529517 Lactotransferrin 795 < 0.001 < 0.001 1.37
15 SCGB1A1 Hs.523732 Secretoglobin, family 1A, member 1
(uteroglobin)
814 < 0.001 < 0.001 1.32
16 SFTPB Hs.512690 Surfactant protein B 830 < 0.001 < 0.001 1.23
17 TRMT61A Hs.525610 TRNA methyltransferase 61 homolog A
(S. cerevisiae)
864 < 0.001 < 0.001 1.62
18 F2RL2 Hs.42502 Coagulation factor II (thrombin) receptor-
like 2
876 < 0.001 < 0.001 1.59
19 APOBEC2 Hs.555915 Apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 2
895 < 0.001 < 0.001 1.41
20 ZNF700 Hs.528486 Zinc ﬁnger protein 700 937 < 0.001 < 0.001 1,41
RP, rank product; P, p-value ;FDR, false discovery rate; FC, mean fold change ; BOS, bronchiolitis
obliterans syndrome
Table 3.2. Correlation and Concordance between microarray and qRT-PCR
data.
Gene symbol Rho P (Spearman) FC C-index
C15ORF48 0.68 2.97× 10−5 1.74 0.76
ALDH3A1 0.95 < 2.2× 10−16 1
2.36
0.92
SCGB3A2 0.91 < 2.2× 10−16 1
7.02
0.86
HBA1 0.96 < 2.2× 10−16 1
5.6
0.92
SFTPB 0.92 < 2.2× 10−16 1
3.76
0.88
Rho, Spearman rank correlation coeﬃcient; FC, median fold change; P, p-value; C-index, concor-
dance index
3.1.2 Enriched KEGG pathways
Using functional enrichment analysis as implemented in the DAVID online resource [112],
I identiﬁed several functional groups (pathways as deﬁned in the KEGG database [110])
being signiﬁcantly highly enriched in the list of diﬀerentially expressed genes. A set of
6 KEGG pathways was identiﬁed by my analysis (Table 3.3). The list of diﬀerentially
expressed genes involved in the enriched pathways can be found in Table 3.4. The
KEGG Disease pathway map of systemic lupus erythematosus is shown in Figure 3.1.
To ﬁnd other genes that are functionally related to those genes conﬁrmed as KEGG
pathway members, but not yet known members of the enriched pathways, I clustered
all diﬀerentially expressed genes based on functional annotation. Using the funtional
classiﬁcation tool from DAVID [112] and prediﬁned quality settings (High), I selected
the clusters which showed a Gene Enrichment score (GE) ≥ 4 and contained at least
one member of the enriched KEGG pathways. Thus 6 genes clustered with conﬁrmed
members of the signiﬁcantly enriched KEGG pathways (Table 3.5). The genes from those
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clusters were selected to extend the list of pathway related genes ("pathway extension",
Table 3.6).
Table 3.3. Signiﬁcantly enriched KEGG pathways
KEGG Count FE P UniGene
hsa05322:Systemic
lupus erythematosus
18 4.03 1.01× 10−4 Hs.534322 Hs.467753 Hs.69771
Hs.437275 Hs.372679 Hs.477879
Hs.520048 Hs.008986 Hs.77424
Hs.534847 Hs.351279 Hs.46423
Hs.411472 Hs.485130 Hs.387679
Hs.171182
hsa05332:Graft-versus-
host disease
10 5.55 0.004 Hs.534322 Hs.512152 Hs.351279
Hs.77961 Hs.485130 Hs.387679
Hs.171182 Hs.520048 Hs.126256
hsa05320:Autoimmune
thyroid disease
9 5.74 0.01 Hs.534322 Hs.512152 Hs.351279
Hs.77961 Hs.485130 Hs.387679
Hs.171182 Hs.520048
hsa05330:Allograft
rejection
9 5.47 0.015 Hs.534322 Hs.512152 Hs.351279
Hs.77961 Hs.485130 Hs.387679
Hs.171182 Hs.520048
hsa04940:Type I dia-
betes mellitus
10 4.4 0.034 Hs.534322 Hs.512152 Hs.351279
Hs.77961 Hs.485130 Hs.387679
Hs.171182 Hs.520048 Hs.126256
hsa04612:Antigen pro-
cessing and presentation
12 3.56 0.046 Hs.14623 Hs.534322 Hs.434081
Hs.512152 Hs.418123 Hs.351279
Hs.77961 Hs.485130 Hs.387679
Hs.520048 Hs.534255
P, Bonferroni corrected p-value; FE, fold enrichment
Table 3.4. Diﬀerentially expressed genes directly involved in enriched KEGG
pathways
Gene symbol UniGene Gene name RP P FDR FC KEGG
IL1B Hs.126256 Interleukin 1, beta 739 < 0.001 < 0.001 1.64 hsa05332
hsa04940
IFI30 Hs.14623 Interferon, gamma-inducible
protein 30
776 < 0.001 < 0.001 1.58 hsa04612
HLA-G Hs.512152 Major histocompatibility
complex, class I, G
817 < 0.001 < 0.001 1.41 hsa04612
hsa05330
hsa05332
hsa04940
hsa05322
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FCGR3A Hs.372679 Fc fragment of IgG, low aﬃn-
ity IIIa, receptor (CD16a)
1001 < 0.001 < 0.001 1.23 hsa05322
C1QB Hs.8986 Complement component 1, q
subcomponent, B chain
1101 < 0.001 < 0.001 1,3 hsa05322
HIST1H2BK Hs.437275 Histone cluster 1, H2bk 1153 < 0.001 < 0.001 1.57 hsa05322
HLA-DQA1 Hs.387679 Major histocompatibility
complex, class II, DQ alpha 1
1161 < 0.001 < 0.001 1.31 hsa04612
hsa05330
hsa05332
hsa04940
hsa05322
HLA-DRA Hs.520048 Major histocompatibility
complex, class II, DR alpha
1277 < 0.001 < 0.001 1.4 hsa04612
hsa05330
hsa05332
hsa04940
hsa05322
H2AFX Hs.477879 H2A histone family, member
X
1346 < 0.001 < 0.001 1.52 hsa05322
FCGR1A Hs.77424 Fc fragment of IgG, high aﬃn-
ity Ia, receptor (CD64)
1355 < 0.001 < 0.001 1.32 hsa05322
HLA-DMA Hs.351279 Major histocompatibility
complex, class II, DM alpha
1407 < 0.001 0.001 1.22 hsa04612
hsa05330
hsa05332
hsa04940
hsa05322
HLA-DRB1 Hs.534322 Major histocompatibility
complex, class II, DR beta 1
1493 < 0.001 0.003 1.26 hsa04612
hsa05330
hsa05332
hsa04940
hsa05322
PSME2 Hs.434081 Proteasome (prosome,
macropain) activator sub-
unit 2 (PA28 beta)
1535 < 0.001 0.003 1.36 hsa04612
C4A Hs.534847 Complement component 4A
(Rodgers blood group)
1515 < 0.001 0.011 11.26 hsa05322
CFB Hs.69771 Complement factor B 1540 < 0.001 0.003 1.25 hsa05322
CD86 Hs.171182 CD86 molecule 1638 < 0.001 0.006 1.37 hsa05330,
hsa05332,
hsa04940,
hsa05322
HLA-DPB1 Hs.485130 Major histocompatibility
complex, class II, DP beta 1
1833 < 0.001 0.02 1.11 hsa04612
hsa05330
hsa05332
hsa04940
hsa05322
HIST1H4C Hs.46423 Histone cluster 1, H4c 1859 < 0.001 0.022 1.01 hsa05322
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C1QC Hs.467753 Complement component 1, q
subcomponent, C chain
1882 < 0.001 0.026 1.17 hsa05322
GRIN2A Hs.411472 Glutamate receptor,
ionotropic, N-methyl D-
aspartate 2A
1957 0.001 0.036 1.3 hsa05322
CTSL1 Hs.418123 Cathepsin L1 1973 0.002 0.039 1,2 hsa04612
HLA-B Hs.77961 Major histocompatibility
complex, class I, B
2012 0.002 0.045 1.13 hsa04612,
hsa05330
hsa05332
hsa04940
hsa05322
B2M Hs.534255 Beta-2-microglobulin 2031 0.002 0.049 1.12 hsa04612
RP, rank product; P, p-value ;FDR, false discovery rate; FC, mean fold change
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Table 3.5. Six functional gene groups identiﬁed by the functional classiﬁca-
tion tool
Gene Group 1 Enrichment Score: 15.48
UniGene Gene name
Hs.114948 cytokine receptor-like factor 1
Hs.204238 lipocalin 2
Hs.520989 ﬁbrinogen-like 2
Hs.591967 interleukin 18 binding protein
Hs.255462 microseminoprotein, beta-
Hs.21162 retbindin
Hs.439312 phospholipid transfer protein
Gene Group 2 Enrichment Score: 8.77
UniGene Gene name
Hs.512304 chemokine (C-C motif) ligand 3-like 3; chemokine (C-C motif) ligand 3-like 1
Hs.143961 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)
Hs.531668 chemokine (C-X3-C motif) ligand 1
Hs.32949 defensin, beta 1
Hs.57907 chemokine (C-C motif) ligand 21
Hs.514107 chemokine (C-C motif) ligand 3
Hs.77367 chemokine (C-X-C motif) ligand 9
Hs.131342 chemokine (C-C motif) ligand 26
Hs.789 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
Hs.943 interleukin 32
Hs.632586 chemokine (C-X-C motif) ligand 10
Gene Group 3 Enrichment Score: 6.78
UniGene Gene name
Hs.418123 cathepsin L1
Hs.151254 kallikrein-related peptidase 7
Hs.405479 tryptase alpha/beta 1; tryptase beta 2
Hs.252549 cathepsin Z
Hs.233389 carboxypeptidase, vitellogenic-like
Gene Group 4 Enrichment Score: 6.46
UniGene Gene name
Hs.69771 complement factor B
Hs.90708 granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)
Hs.151254 kallikrein-related peptidase 7
Hs.69771 complement component 2
Hs.405479 tryptase alpha/beta 1; tryptase beta 2
3.1 Prediction of the Bronchiolitis Obliterans Syndrome by Transcriptomics Analysis66
Gene Group 5 Enrichment Score: 6.15
UniGene Gene name
Hs.467753 complement component 1, q subcomponent, C chain
Hs.384598 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
Hs.534847 complement component 4A (Rodgers blood group)
Hs.8986 complement component 1, q subcomponent, B chain
Hs.534847 complement component 4B (Chido blood group)
Hs.69771 complement component 2
Gene Group 6 Enrichment Score: 4.54
UniGene Gene name
Hs.1011 protein Z, vitamin K-dependent plasma glycoprotein
Hs.512587 macrophage stimulating 1 (hepatocyte growth factor-like)
Hs.151254 kallikrein-related peptidase 7
Hs.224698 protein C (inactivator of coagulation factors Va and VIIIa)
Hs.405479 tryptase alpha/beta 1; tryptase beta 2
The members of signiﬁcantly enriched KEGG pathways are marked in bold. The genes clustered
together with members of signiﬁcantly enriched KEGG pathways are written in italic.
Table 3.6. Pathway extension: diﬀerentially expressed genes functionally
linked to enriched KEGG pathways
Gene symbol UniGene Gene name RP P FDR FC
TPSAB1 Hs.405479 Tryptase alpha/beta 1 738 < 0.001 < 0.001 1.59
CTSZ Hs.252549 Cathepsin Z 1387 < 0.001 < 0.001 1.44
SERPING1 Hs.384598 Serpin peptidase inhibitor,
clade G (C1 inhibitor), mem-
ber 1
1543 < 0.001 0.003 1.24
CPVL Hs.233389 Carboxypeptidase,
vitellogenic-like
1662 < 0.001 0.007 1.18
GZMA Hs.90708 Granzyme A (granzyme 1,
cytotoxic T-lymphocyte-
associated serine esterase
3)
1681 < 0.001 0.008 1.08
KLK7 Hs.151254 Kallikrein-related peptidase 7 1792 < 0.001 0.015 1.37
RP, rank product; P, p-value ;FDR, false discovery rate; FC, median fold change
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Figure 3.1. The disease pathway map of Systemic Lupus Erythematosus as represented
in the KEGG Disease database. In the list of genes signiﬁcantly deregulated in the
BOS+ samples, genes belonging to this particular pathway were found to be signiﬁcantly
enriched. Those genes are marked by stars (blue = up-regualted and green = down-
regulated) in the pathway map [110] .
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3.1.3 Analysis of BOS-free Progression by Random Survival For-
est Modelling
An integrative random survival forest (RSF) model to predict BOS-free progression was
constructed and the performance was rated by the out-of-bag (OOB) concordance index
(C-index). The model incorporates all signiﬁcantly deregulated genes which were mem-
bers of a signiﬁcantly enriched KEGG pathway, the signiﬁcantly diﬀerentially expressed
genes clustered together with members of signiﬁcantly enriched KEGG pathways by the
functional classiﬁcation tool from DAVID ("pathway extension genes") and the FEV1
score as the clinical representation of BOS. This integrative approach (genes and FEV1)
showed a concordance error (1 - C-index) of 0.29 (Figure 3.2). To make sure that the
observed eﬀects on BOS-free progression are not due to potential confounding factors,
Cox proportional hazard models were calculated. The time after lung transplantation
(LTx) showed no signiﬁcant inﬂuence on BOS-free time (Hazard Ratio (HR) 1.00 95%,
conﬁdence interval (CI) 0.99-1.00, p-value 0.292). Microbial infection (HR 0.84 95%, CI
0.55-1.27, p-value 0.4) and the total number of acute rejections before sampling (HR
0.88 95%, CI 0.29-2.63, p-value 0.816) showed no signiﬁcant inﬂuence on BOS-free time.
The patient-speciﬁc attributes age at LTx, transplant type and gender had no signiﬁcant
inﬂuence on BOS-free time after LTx (Table 2.1).
3.1.4 Model Analysis of the Random Survival Forest for BOS-
free Progression
Random forests (RF) and random survival forests (RSF) are sometimes considered to
be black-boxes, which is due to them being an ensemble combination of a large number
of decision or survival trees. Luckily several methods are available to make the analysis
and interpretation of these ensemble methods feasible. The ﬁrst such approach presented
here is the importance of the variables according to the generated random survival forest
model.
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Variable Importance
The variable importance (VIMP) of each gene/clinical parameter was assessed by the
random survival forest (RSF) and is shown in Table 3.7 and Figure 3.2. According to
our RSF model 10 features/genes were potentially informative (VIMP > 0, Table 3.7
and Figure 3.2). Of those, 6 were considered signiﬁcantly informative, with a VIMP
higher than the absolute value of the lowest negative-scoring variable [197]: kallikrein
7 (KLK7), HLA class II histocompatibility antigen, DM alpha chain (HLA.DMA),DR
alpha chain (HLA.DRA), cathepsin Z (CTSZ) and major histocompatibility complex,
class II, DQ alpha 1 (HLA.DQA1). The correlation of each potentially informative
gene or clinical feature with BOS free time was additionally tested by univariate Cox
proportional hazard models (Table 3.8).
Marginal Plots
The relationship between a predictor variable and an individuals predicted survival,
according to to an random survival forest model, can be visualized using marginal plots.
For this the predicted BOS-free progression rate, as predicted for each observation at
the median follow up time, was plotted against the features respective values (Figure
3.3).
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Figure 3.2. The ﬁrst plot shows the out-of-bag (OOB) concordance error rates of the
random survival forest (RSF) for the ﬁrst b trees. The second plot shows the variable
importance (VIMP) for predictors (genes and clinical features). Positive (blue) values
represent informative variables, while negative values (red) represent uninformative ones.
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Table 3.7. The predictors order according to variable importance (VIMP)
as obtained from the random survival forest model
Gene symbol VIMP Relative VIMP
KLK7 0.045 1
HLA.DMA 0.034 0.756
FEV1 0.032 0.711
HLA.DRA 0.011 0.244
CTSZ 0.011 0.244
HLA.DQA1 0.010 0.222
GRIN2A 0.007 0.156
PSME2 0.003 0.067
CFB 0.002 0.044
TPSAB1 0.002 0.044
HLA.DPB1 0.000 0.0000
B2M -0.001 -0.022
H2AFX -0.001 -0.022
CTSL1 -0.001 -0.022
FCGR3A -0.001 -0.022
FCGR1A -0.001 -0.022
C4A -0.001 -0.022
HLA.DRB1 -0.001 -0.022
SERPING1 -0.002 -0.044
GZMA -0.003 -0.067
CPVL -0.004 -0.089
HLA.B -0.004 -0.089
HIST1H2BK -0.005 -0.111
IFI30 -0.005 -0.111
HLA.G -0.005 -0.111
C1QC -0.005 -0.111
C1QB -0.005 -0.111
HIST1H4C -0.005 -0.111
CD86 -0.007 -0.156
IL1B -0.007 -0.156
VIMP, variable importance
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Table 3.8. Univariate analysis of features selected as informative by random
survival forest
FN FC P (Wilcoxon) HR (95% CI) P (Cox)
KLK7 (Kallikrein
7)
1
1.04 0.21 2.06 (0.81 - 5.28) 0.21
HLA.DMA (HLA
class II histocom-
patibility antigen,
DM alpha chain)
2.27 9.74× 10−12 1.52 (0.99 - 2.33) 0.055
FEV1 (Clinical
Parameter)
86.3
92.8 0.159 0.92 (0.88 - 0.96) 4.42× 10−4
HLA.DRA (HLA
class II histocom-
patibility antigen,
DR alpha chain)
2.24 3.83× 10−13 1.9 (1.13 - 3.19) 0.015
CTSZ (Cathepsin
Z)
1.63 2.33× 10−5 2.39 (1.21 - 4.73) 0.012
HLA.DQA1
(Major histo-
compatibility
complex, class II,
DQ alpha 1)
2.82 < 2.2× 10−16 1.5 (1.05 - 2.14) 0.027
GRIN2A (Glu-
tamate recep-
tor, ionotropic,
N-methyl D-
aspartate 2A)
1.1 0.4583 2.01 (0.75 - 5.4) 0.166
PSME2 (Protea-
some (prosome,
macropain) acti-
vator subunit 2
(PA28 beta))
1.32 2.23× 10−6 1.11 (0.52 - 2.33) 0.793
CFB (Com-
plement factor
B)
1.27 0.008 1.34 (0.79 - 2.29) 0.276
TPSAB1
(tryptase al-
pha/beta 1)
1.29 0.01 1.62 (1.05 - 2.5) 0.03
FN, feature name; P, p-value; FC, median fold change; HR, hazard ratio; CI, conﬁdence interval
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(b) HLA class II histocompatibil-
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(c) Forced expiratory volume in
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(d) HLA class II histocompatibil-
ity antigen, DR alpha chain
−2.0 −1.5 −1.0 −0.5 0.0 0.5 1.0
30
40
50
60
70
80
log2(ratio) (CTSZ)
pr
ed
ict
ed
 fr
ee
do
m
 fr
om
 B
O
S 
(%
)
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
(e) Cathepsin Z
−3 −2 −1 0 1 2
30
40
50
60
70
80
log2(ratio) (HLA.DQA1)
pr
ed
ict
ed
 fr
ee
do
m
 fr
om
 B
O
S 
(%
)
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
(f) Major histocompatibility
complex, class II, DQ alpha 1
Figure 3.3. The marginal plots show the predicted survival, as predicted by the random
survival forest (RSF) model, at the median follow up time against the log2 expression-
ratio of the respective gene. Ratio denotes the fold-wise expression change between each
sample and the ﬁrst sample obtained from the respective patient, for both microarray
and qRT-PCR results. For FEV1 the relative percentage of the best FEV1 observed
after lung transplantation (baseline) is given.
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Risk Groups
To get an overview of how the random survival forest (RSF) model partitions the data
set, I made use of the proximity information from the RSF model. After transformation
of the proximity into a distance (1 − proximity), the samples taken before BOS on-
set (BOS-negative and BOS-unclassiﬁed) were clustered into two groups. Both groups
showed a signiﬁcant diﬀerence in BOS free time (p-value 2.27 × 10−4, log-rank test)
(Figure 3.4a), and were accordingly labelled as high-risk and low-risk respectively. An
FEV1 score of ≤ 90% (BOS 0-p) was less, but signiﬁcantly (p-value 0.046, log-rank test),
associated with a decrease in BOS free time (Figure 3.4b). Diﬀerential expression be-
tween both groups (high-risk and low-risk) was assesed for each potentially informative
gene or clinical parameter (VIMP > 0), as detected by the RSF model, by means of a
Wilcoxon rank sum test (Table 3.8). The expression diﬀerences were visualized using
a heatmap (Figure 3.5). In the case of cathepsin Z (CTSZ), signiﬁcant diﬀerential ex-
presssion between the high risk and low risk groups (p-value 2.33×10−05, Wilcoxon rank
sum test), was conﬁrmed (Table 3.9) on the qRT-PCR level (Spearman rank correlation
test, p-value 0.045 and Wilcoxon rank sum test, p-value 1.17× 10−5). See Figure 3.6 for
the diﬀerential expression of cathepsin Z (CTSZ) between random survival forest based
clusters, for microarray and qRT-PCR.
Table 3.9. Correlation and concordance between microarray and qRT-PCR
data for cathepsin Z.
Gene symbol Rho P (Spearman) FC P (Wilcoxon) C-index
CTSZ 0.43 0.045 1.7 1.17× 10−5 0.68
Rho, Spearman rank correlation coeﬃcient; P, p-value; C-index, concordance index
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Figure 3.4. Kaplan-Meier analysis of bronchiolitis obliterans syndrome (BOS)-free time
in relation to genomic (random survival forest (RSF)) and diagnostic (FEV1, BOS 0-p)
based risk groups. a) The clustering of the samples according to my random survival
forest (RSF) model revealed two groups with a signifcant diﬀerence in BOS-free time
(p-value 2.27 × 10−4, log-rank test). b) A forced expiratory volume in 1 sec (FEV1)
less than or equal to 90 percent signature (BOS 0-p) was associated with signiﬁcantly
shorter BOS-free time (p-value 0.045, log-rank test).
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Figure 3.5. Correlation-based heatmap: The heatmap shows the gene expression
change between the clusters (high-risk/low-risk) obtained from the random survival
forest (RSF) proximity values. The peaks were clustered according to the Pearson
correlation coeﬃcient, using the average distance method [236,237].
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Figure 3.6. Diﬀerential expression of cathepsin Z (CTSZ) between random
survival forest (RSF) based clusters, for microarrays and qRT-PCR. A sig-
niﬁcant up-regulation for cathepsin Z (CTSZ) was detected for the cluster, as obtained
from the random survival forest (RSF) proximity values, associated with a high BOS
risk (p-value 2.27 × 10−4, log-rank test). This was shown by the microarrays (a) (p-
value 2.33× 10−5, Wilcoxon rank sum test) and b) the qRT-PCR (p-value 1.17× 10−5,
Wilcoxon rank sum test) Ratio denotes the fold expression change between each sample
and the ﬁrst sample obtained from the respective patient, for both microarray and qRT-
PCR results. a) Expression ratios are from microarray hybridization. Samples where
expression has been measured as well by qRT-PCR are shown in red, those where this
has not been possible in blue. b) Expression ratios from qRT-PCR, as measured for
samples shown in red in a).
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Interaction Between Variables
In addition to estimating the variable importance (VIMP) of the features of interest,
RSFs can also be used to rate interactions between those features. There are two types
of interesting pairwise interactions to be discovered from such an RSF model. Variables
which show the same information with regard to BOS prediction (redundancy) and
those with complementary interaction. Complementary in the sense that the combined
information from both variables leads to an improvement in the prediction of BOS-free
progression. In a tree structure complementary means that after splitting on one vari-
able an additional split on a speciﬁc complementary variable further down the tree leads
to an improvement in prediction performance. The interaction for a pair of variables is
analysed using the concept of a joint VIMP [195]. This joint VIMP is deﬁned as the
increase in OOB (out of bag) prediction error when both predictor variables are noised
up and the prediction error without noising up. Noising up refers to randomly choosing
a daughter node when splitting on the variable, instead of using the learned decision
rule. The sum of the two single variables VIMPs is called the additive importance. A
large absolute diﬀerence between the joint VIMP and the additive VIMP (|joint VIMP
− additive VIMP|) indicates a potential interaction between two variables [195]. Posi-
tive diﬀerences (joint Vimp > additive VIMP) reﬂect the idea that both variables are
redundant, while negative values (joint Vimp < additive VIMP) hint to a complemen-
tary interaction with respect to BOS progression. To obtain an interpretable interaction
score, the diﬀerences were normalised by Z score transformation [87] (Table 3.10). Min-
imum spanning trees, with nodes representing variables and the absolute values of the
interactions scores as edge adjacency weights, were calculated for positive and negative
interaction scores, separately (Figure 3.7). The ﬁrst tree graph a) helps to ﬁnd the
variables which best represent the set of predictive variables, while the second graph b)
allows for the detection of variables oﬀering complementary information to other predic-
tive variables. The connectivity of each node was assessed by its relative node strength
[210] (summed adjacency weight of the connected edges) as compared to the most con-
nected node. Nodes with a relative connectivity > 0.8 were considered hub nodes of their
respective graph. For a) the hub nodes were cathepsin Z (CTSZ) and the FEV1 score
(FEV). In tree graph b) kallikrein 7 (KLK 7) was considered a hub node. The protease
KLK7 was not a signiﬁcantly predictive variable when analysed independently of the
other selected features. This was shown both for correlation with BOS-free time and for
diﬀerential expression between the high risk and low risk clusters. In the multivariate
RSF model KLK7 was the most informative feature according to the VIMP measure of
variable importance. A random survival forest learned without KLK7 being part of the
selected feature set showed a concordance error of 33.17, which is a concordance error
increase of 4 percent when compared to the feature set including KLK7. The diﬀerence
of importance for KLK7 between univariate and multivariate assessment of KLK7 im-
portance already hints at showing complementary properties to other variables. This
hypothesis was validated by tree graph b). This graph shows KLK7 to be a hub node
of complementary information.
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Table 3.10. The pairwise interactions between the important predictors, as
detected by the random survival forest model.
Interaction Paired Additive Diﬀerence Interaction Score
HLA.DMA:FEV1 0.083 0.067 0.016 3.038
CTSZ:GRIN2A 0.030 0.019 0.011 2.100
GRIN2A:FEV1 0.047 0.038 0.009 1.725
CTSZ:HLA.DRA 0.030 0.022 0.007 1.350
CTSZ:HLA.DQA1 0.026 0.020 0.006 1.163
CTSZ:CFB 0.016 0.012 0.004 0.788
CTSZ:TPSAB1 0.015 0.011 0.004 0.788
CTSZ:HLA.DMA 0.048 0.045 0.004 0.788
CFB:HLA.DQA1 0.014 0.010 0.004 0.788
TPSAB1:HLA.DRA 0.016 0.013 0.003 0.600
KLK7:FEV1 0.082 0.079 0.003 0.600
GRIN2A:HLA.DRA 0.021 0.019 0.002 0.413
PSME2:HLA.DMA 0.037 0.037 0.001 0.225
CTSZ:FEV1 0.046 0.045 0.001 0.225
TPSAB1:FEV1 0.035 0.034 0.001 0.225
TPSAB1:PSME2 0.005 0.004 0.001 0.225
CFB:FEV1 0.036 0.035 0.001 0.225
HLA.DQA1:FEV1 0.043 0.042 0.001 0.225
GRIN2A:HLA.DMA 0.042 0.041 0.001 0.225
HLA.DRA:HLA.DMA 0.045 0.045 0.000 0.038
GRIN2A:KLK7 0.053 0.053 0.000 0.038
CFB:HLA.DMA 0.035 0.035 0.000 0.038
HLA.DQA1:HLA.DRA 0.021 0.021 0.000 0.038
CFB:HLA.DRA 0.011 0.013 -0.001 -0.150
PSME2:FEV1 0.036 0.037 -0.001 -0.150
CFB:KLK7 0.045 0.046 -0.001 -0.150
CFB:GRIN2A 0.007 0.009 -0.001 -0.150
HLA.DQA1:GRIN2A 0.016 0.017 -0.001 -0.150
HLA.DQA1:PSME2 0.012 0.013 -0.001 -0.150
TPSAB1:HLA.DQA1 0.010 0.011 -0.002 -0.338
GRIN2A:PSME2 0.009 0.011 -0.002 -0.338
PSME2:KLK7 0.047 0.049 -0.002 -0.338
CTSZ:KLK7 0.054 0.057 -0.002 -0.338
TPSAB1:CFB 0.001 0.004 -0.003 -0.525
TPSAB1:HLA.DMA 0.032 0.035 -0.003 -0.525
HLA.DRA:FEV1 0.042 0.046 -0.004 -0.713
HLA.DQA1:HLA.DMA 0.041 0.044 -0.004 -0.713
CFB:PSME2 -0.001 0.004 -0.005 -0.900
TPSAB1:GRIN2A 0.004 0.009 -0.005 -0.900
CTSZ:PSME2 0.009 0.015 -0.006 -1.088
TPSAB1:KLK7 0.041 0.047 -0.006 -1.088
PSME2:HLA.DRA 0.009 0.014 -0.006 -1.088
HLA.DRA:KLK7 0.050 0.057 -0.007 -1.275
HLA.DQA1:KLK7 0.042 0.055 -0.013 -2.400
KLK7:HLA.DMA 0.067 0.080 -0.013 -2.400
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a) Minimum Spanning tree of the positive interaction scores
Figure 3.7. Minimum spanning trees of the pair wise interaction scores (positive: re-
dundant and negative: complementary). The edge weights are given by the absolute
values of the interaction scores, while the number next to each node shows the rela-
tive node weight (summed weight of the connected edges) as compared to the most
connected node. This level of connectivity is visualized by node size and node color
(from green:lowest to red:highest). Nodes marked red were considered hub nodes of
their respective graph.
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b) Minimum Spanning tree of the negative interaction scores
Figure 3.7 (continued)
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3.2 Prediction of the Bronchiolitis Obliterans Syndrome
by Proteome Proﬁling
The broncholaveolar lavage ﬂuid (BALF) of 82 lung transplanted patients was sampled
by bronchoalveolar lavage (BAL) [21]. The proteome constitutents from 146 obtained
samples, taken at diﬀerent time points after lung transplantation, were isolated using
superparamagnetic particles (MB-WCX,Bruker Daltonics, Bremen, Germany) and anal-
ysed by a linear MALDI-TOF mass spectrometer (MicroﬂexLT, Bruker Daltonics). The
acquired proﬁle spectra were then preprocessed using the PROcess R-package [129],
before further computational analysis of BOS pathogenesis was performed.
3.2.1 MALDI-TOF Proﬁles 1-100 kDa
The peak number in the total mean normalized spectrum was 256 for the 1-10 kDa mass
range and 39 for 10-100 kDa mass range with more than 90 percent of all detectable peaks
below m/z 20,000. After quality control (Chapter 2.2.1), for each of the mass ranges all
spectra of 2 samples (BOS-negative and BOS-unclassiﬁed) were excluded from further
analysis.
3.2.2 BOS-Speciﬁc Proteome Alterations
In the mass range between 1-10 kDa, 23 MALDI-TOF MS peaks (4 peaks, 10-100 kDa)
showed signiﬁcant intensity changes after the ﬁrst postoperational year as shown in Table
3.11 and 3.13 (10-100 kDa, Table 3.12 and 3.14). Bronchoalveolar lavage ﬂuid (BALF)
samples for which an FEV1 ≤ 80% became persistent within one year after bronchoscopy,
were called BOS-positive. An FEV1 below the International Society for Heart and Lung
Transplantation (ISHLT) criteria for BOS (FEV1 ≤ 80% of baseline) was considered
persistent, if all consecutive FEV1 measurements over a period of at least one year also
showed an FEV1 ≤ 80%. Samples were classiﬁed as BOS-negative, if they were taken
at least three years before an persistent decrease of FEV1 below 80%. Samples not
complying with these strict criteria were labelled as BOS-unclassiﬁed. Comparing BOS-
positive proﬁles to negative ones, 24 peaks were found to be diﬀerentially regulated in
the 1-10 kDa mass range (7 peaks, 10-100 kDa). Those diﬀerentially regulated peaks
are shown in Table 3.15 and 3.17 (10-100 kDa, Table 3.16 and 3.18). Of all diﬀerentially
regulated masses (1-10 kDa, Table 3.11, 3.13, 3.15 and 3.17), 13 showed a signiﬁcant
diﬀerence in regulation between BOS-positive and BOS-negative at the time of sampling
and after the ﬁrst year post transplantation (Figure 3.9).
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Table 3.11. a) Masses with increased intensity after the ﬁrst year posttrans-
plantation (1-10 kDa)
Peak ranking Da RP FDR P Protein identity
3086.90 49 < 0.01 < 0.001 Serum albumin(ALBU_HUMAN,AA25-51) a
7 1309.32 b 53 < 0.01 < 0.001 Hemoglobin-beta(HBB_HUMAN,AA33-42) a
5 3277.08 b 54 < 0.01 < 0.001 Hemoglobin beta(HBB_HUMAN,AA2-32) a
1195.90 58 < 0.01 < 0.001 Hemoglobin-beta(HBB_HUMAN,AA34-42) a
2135.83 59 0.02 < 0.001 Unidentiﬁed mass
3329.27 60 0.02 < 0.001 Unidentiﬁed mass
6798.43 62 0.02 < 0.001 Unidentiﬁed mass
2023.00 63 0.02 < 0.001 Complement C3f fragment(CO3_HUMAN,AA1304-1320) c
2429.70 65 0.03 0.001 Serum albumin (ALBU_HUMAN,AA25-45) a
Table 3.12. b) Masses with increased intensity after the ﬁrst year posttrans-
plantation (10-100 kDa)
Peak ranking Da RP FDR P Protein identity
15154.85 9 < 0.01 < 0.001 Hemoglobin alpha chain a
a Protein identiﬁed in MS/MS experiment.
b Peak of random forest biomarker panel.
c Exact mass match with the ExPasy TagIdent tool (SIB, Basle, Switzerland).
d Exact mass match to previously identiﬁed bronchoalveolar lavage ﬂuid component [238]
Da, dalton; RP, rank product; P, p-value; FDR, false discovery rate; Peak ranking (random forest) ,
classiﬁcation of samples as BOS+ or BOS- by random forest; BOS, bronchiolitis obliterans syndrome
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Table 3.13. a) Masses with decreased intensity after the ﬁrst year posttrans-
plantation (1-10 kDa)
Peak ranking Da RP FDR P Protein identity
1 7921.44 b 45 < 0.01 < 0.001 Clara cells 10k Da secretory protein
(UTER_HUMAN,AA22-91) a,c
4372.60 46 < 0.01 < 0.001 Unidentiﬁed mass
5593.04 48 < 0.01 < 0.001 Unidentiﬁed mass
1435.54 48 < 0.01 < 0.001 Histatin-3(HIS3_HUMAN,AA33-43) a
1288.20 49 < 0.01 < 0.001 Histatin-3(HIS3_HUMAN,AA34-43) a,c
1336.29 50 < 0.01 < 0.001 Histatin-3(HIS3_HUMAN,AA20-30) a
4 3372.41 b 55 < 0.01 < 0.001 Neutrophil defensin 2 (DEF2_HUMAN,AA66-94) c,d
5946.94 56 < 0.01 < 0.001 Unidentiﬁed mass
6953.22 58 0,01 < 0.001 Unidentiﬁed mass
7987.27 58 0.01 < 0.001 Unidentiﬁed mass
2666.31 60 0.01 < 0.001 Vimentin(VIME_HUMAN,AA444-466) a
1563.85 60 0.01 < 0.001 Histatin-3(HIS3_HUMAN,AA32-42) a
9755.57 62 0.02 0.001 Unidentiﬁed mass
2 3443.58 b 63 0.03 0.002 Neutrophil defensin 1 (DEF1_HUMAN,AA65-94) c,d
Table 3.14. b) Masses with decreased intensity after the ﬁrst year posttrans-
plantation (10-100 kDa)
Peak ranking Da RP FDR P Protein identity
13183.97 8 < 0.01 < 0.001 SP-A1 precursor a
12720.94 9 < 0.01 < 0.001 Transthyretin, chain A a
24007.62 9 < 0.01 < 0.001 Unidentiﬁed mass
a Protein identiﬁed in MS/MS experiment.
b Peak of random forest biomarker panel.
c Exact mass match with the ExPasy TagIdent tool (SIB, Basle, Switzerland).
d Exact mass match to previously identiﬁed bronchoalveolar lavage ﬂuid component [238]
Da, dalton; RP, rank product; P, p-value; FDR, false discovery rate; Peak ranking (random forest) ,
classiﬁcation of samples as BOS+ or BOS- by random forest; BOS, bronchiolitis obliterans syndrome
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Table 3.15. Masses with increased intensity in BOS-positive samples (1-10
kDa)
Peak ranking Da RP FDR P Protein identity
6 4136.65 b 34 < 0.01 < 0.001 Unidentiﬁed mass
2 3372.41 b 38 0.01 < 0.001 Neutrophil defensin 2 (DEF2_HUMAN,AA66-94) c,d
4 3443.58 b 42 0.03 < 0.001 Neutrophil defensin 1 (DEF1_HUMAN,AA65-94) c,d
3 3202.54 b 43 0.03 < 0.001 Unidentiﬁed mass
Table 3.16. Masses with increased intensity in BOS-positive samples (10-100
kDa)
Peak ranking Da RP FDR P Protein identity
13183.97 7 0.01 < 0.001 SP-A1 precursor a
a Protein identiﬁed in MS/MS experiment.
b Peak of random forest biomarker panel.
c Exact mass match with the ExPasy TagIdent tool (SIB, Basle, Switzerland).
d Exact mass match to previously identiﬁed bronchoalveolar lavage ﬂuid component [238]
Da, dalton; RP, rank product; FDR, false discovery rate; Peak ranking (random forest) , classiﬁca-
tion of samples as BOS+ or BOS- by random forest; BOS, bronchiolitis obliterans syndrome
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Table 3.17. Masses with decreased intensity in BOS-positive samples (1-10
kDa)
Peak ranking Da RP FDR P Protein identity
4372.60 31 < 0.01 < 0.001 Unidentiﬁed mass
1 7921.44 a 35 < 0.01 < 0.001 Clara cells 10 kDa secretory protein a
(UTER_HUMAN,AA22-91) a,c
5593.04 35 < 0.01 < 0.001 Unidentiﬁed mass
1435.54 36 < 0.01 < 0.001 Histatin-3(HIS3_HUMAN,AA33-43) a
1288.20 37 < 0.01 < 0.001 Histatin-3(HIS3_HUMAN,AA34-43) a,c
9965.00 46 < 0.01 < 0.001 Unidentiﬁed mass
7612.20 47 < 0.01 < 0.001 Unidentiﬁed mass
2186.62 48 < 0.01 < 0.001 Unidentiﬁed mass
1563.85 48 < 0.01 < 0.001 Histatin-3(HIS3_HUMAN,AA32-42) a
5 3277.08 a 48 < 0.01 < 0.001 Hemoglobin beta(HBB_HUMAN,AA2-32) a
2470.53 50 < 0.01 < 0.001 Hemoglobin alpha(HBA_HUMAN,AA108-142) a
3476.35 52 0.01 < 0.001 Unidentiﬁed mass
7 1309.32 a 53 0.01 < 0.001 Hemoglobin-beta(HBB_HUMAN,AA33-42) a
3329.27 53 0.01 0.001 Unidentiﬁed mass
6927.00 55 0.02 0.001 Unidentiﬁed mass
2062.73 55 0.02 0.001 Unidentiﬁed mass
1170.14 59 0.04 0.003 Galanin-like peptide(GALP_HUMAN,AA15-26) a
7987.27 59 0.04 0.003 Unidentiﬁed mass
5946.94 60 0.04 0.003 Unidentiﬁed mass
10021.78 60 0.04 0.003 Unidentiﬁed mass
Table 3.18. Masses with decreased intensity in BOS+ samples (10-100 kDa)
Peak ranking Da RP FDR P Protein identity
15154.84 7 < 0.01 < 0.001 Hemoglobin alpha chain a
15860.68 7 < 0.01 < 0.001 Clara cells 10 kDa secretory protein a,c
17474.04 8 < 0.01 < 0.001 Unidentiﬁed mass
14675.63 9 < 0.01 < 0.001 Lysozyme c a
10807.78 9 < 0.01 < 0.001 Calgranulin A a
14299.55 11 0.01 0.001 Unidentiﬁed mass
a Protein identiﬁed in MS/MS experiment.
b Peak of random forest biomarker panel.
c Exact mass match with the ExPasy TagIdent tool (SIB, Basle, Switzerland).
d Exact mass match to previously identiﬁed bronchoalveolar lavage ﬂuid component [238]
Da, dalton; RP, rank product; P, p-value; FDR, false discovery rate; Peak ranking (random forest) ,
classiﬁcation of samples as BOS+ or BOS- by random forest; BOS, bronchiolitis obliterans syndrome
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3.2.3 BOS Predictor Model
From the set of 45 unique peaks showing signiﬁcant intensity changes (Table 3.11, Table
3.13, Table 3.15 and Table 3.17) between 1-10 kDa, a panel of 7 peaks was selected for
the random forest (RF) bronchoalveolar lavage monitoring model (BALmon). These
peaks were ranked by variable importance according to their mean decrease in accuracy
(MDA) score (Table 3.19). Cross-validation of the predictor ascertained its performance
with accuracy: 0.81 (43/53), detection rate (sensitivity): 0.81 (13/16), false positive
rate (1 - speciﬁcity): 0.19 (7/37) and an area under curve (AUC) of 0.79 (Figure 3.8).
Figure 3.10 shows how individual peptide marker intensities change over time for BOS-
positive and BOS-negative samples. To make sure that the prediction performance was
not inﬂuenced by acute rejection or microbial infection, additional statistical tests were
performed. The RF score assigned to the BOS-negative and BOS-unclassifed samples
during cross-validation did not correlate signiﬁcantly with the total number of acute
rejection episodes until bronchoscopy (rho: 0.07 p-value: 0.459, Spearman correlation
test). There was no signiﬁcant diﬀerence in RF score for samples showing acute rejection
(p-value: 0.914, Wilcoxon rank test) or microbial infection (p-value: 0.769, Wilcoxon
rank test) at the time of bronchoscopy. The FEV1 value was signiﬁcantly lower for
samples showing acute rejection (p-value: <0.001, Wilcoxon rank test) but not microbial
infection (p-value: 0.22, Wilcoxon rank test). The FEV1 correlates signiﬁcantly with
the number of acute rejection episodes until bronchoscopy (rho: -0.28 p-value: 0.002,
Spearman rank correlation test).
Table 3.19. Peaks used to classify BOS+ and BOS- samples
Peak ranking Da MDA Protein identity
1 7921.44 0.11 Clara cells 10 kDa secretory protein (UTER_HUMAN,AA22-91) a,b,c
2 3443.58 0.10 Neutrophil defensin 1 (DEF1_HUMAN,AA65-94) a,b
3 3202.54 0.07 Unidentiﬁed mass
4 3372.41 0.03 Neutrophil defensin 2 (DEF2_HUMAN,AA66-94) a,b
5 3277.08 0.01 Hemoglobin beta(HBB_HUMAN,AA2-32) c
6 4136.65 0.01 Unidentiﬁed mass
7 1309.32 0.01 Hemoglobin-beta(HBB_HUMAN,AA33-42) c
a Exact mass match with the ExPasy TagIdent tool (SIB, Basle, Switzerland).
b Exact mass match to previously identiﬁed bronchoalveolar lavage ﬂuid component [238]
c Protein identiﬁed in MS/MS experiment.
Da, dalton; RP, rank product; FDR, false discovery rate; Peak ranking (random forest) , classiﬁca-
tion of samples as BOS+ or BOS- by random forest; BOS, bronchiolitis obliterans syndrome
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Figure 3.8. Receiver operating characteristics (ROC) curve of bronchoalveolar lavage
ﬂuid (BALF) classiﬁcation into bronchiolitis obliterans syndrome (BOS)-positive and -
negative condition by the BALmon biomarker panel. The random forest (RF) predictor,
using the BALmon biomarker panel, assigns a score (RF-score) between 0 (0% BOS-
negative) and 1 (100% BOS-positive) to all BALF samples. A sample that shows a higher
score than a predeﬁned cutoﬀ (RF-score ≥ 50%) is classiﬁed as BOS-positive. The ROC
curve is color-coded according to the level of the cutoﬀ and shows the detection rate
(sensitivity) against the false positive rate (1-speciﬁty) for all combinations. An area
under curve (AUC) of 0.79 was calculated.
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Figure 3.9. The Venn diagramm visualizes the overlap between peaks (1-10 kDa)
showing a signiﬁcant diﬀerence in regulation between BOS-positive and BOS-negative
at the time of sampling (BOS), after the ﬁrst year posttransplantation (Time) and the
ones selected for the ﬁnal random forest classiﬁer (RF). [238].
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Figure 3.10. Individual peptide marker intensity patterns over time after lung trans-
plantation.
The scatter plots show how individual peptide marker intensities change over time for
BOS-positive (red) and BOS-negative (green) samples.
Solid lines represent regression estimates as obtained by LOESS for local regression [239].
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3.2.4 Identiﬁcation of BALF Proteome Constitutents
Peaks were identiﬁed by mass spectrometry, diﬀerential signal likely related to diﬀer-
ential expression, was obtained from calculation. Thirty-four peaks were identiﬁed by
direct MALDI-TOF/TOF fragment ion searches, 44 additional mass assignments were
based on tryptic in-gel digestion of proteins and 4 additional exact peak masses corre-
sponded to previously identiﬁed BALF components. Five out of these 82 polypeptides,
could be assigned to predictor masses making up the ﬁnal BALmon (bronchoalveolar
lavage monitoring) random forest model (Table 3.19). The identiﬁed and signiﬁcantly
regulated peaks (mass range: 1-10kDa) that belong to the same functional protein group
or pathway showed a strong tendency to cluster together, as shown in Figure 3.11.
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Figure 3.11. Pearson correlation-based average-linkage hierarchical clustering of the
BOS biomarker candidates including identiﬁed, signiﬁcant and classiﬁer peaks. The
arrows mark signiﬁcant up- and down-regulation in BOS-positive samples. Peaks not
identiﬁed by MS/MS identiﬁcation are marked accordingly: * Exact mass match with
the ExPASy TagIdent tool (SIB, Basle, Switzerland).; + Exact mass match to previously
identiﬁed bronchoalveolar lavage ﬂuid component [238].
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3.2.5 BOS Risk Modelling
Patient-speciﬁc attributes (age at LTx, transplant type, gender and Diagnosis pretrans-
plantation) had no signiﬁcant inﬂuence (p-value > 0.05, univariate Cox proportional
hazard model) on BOS-free time after LTx (Table 2.3). A positive classiﬁcation result
(RF ≥ 50%) correlated with a signiﬁcant decrease in BOS-free time (p-value = 0.009,
log-rank test) as shown by the Kaplan-Meier plot in Figure 3.12a. This change did not
result from a sampling bias between the ﬁrst and later post-operational years (p-value
= 0.877, log-rank test) (Figure 3.12b). An FEV1 score of ≤ 90% (BOS 0-p) was signiﬁ-
cantly associated with a change in BOS-free time (p-value = 0.046, log-rank test) (Figure
3.12c). Combining both FEV1 and proteomic signatures (Figure 3.12d), it was possi-
ble to stratify patients with BOS 0-p signatures and positive RF-classiﬁcation results
into a group with inferior BOS-free time compared to the BOS 0-p group characterized
by negative RF-classiﬁcation results (p-value = 0.01, log-rank test). The former group
shows a short median BOS-free time of 769 days, while for the later group the rate
of freedom from BOS never fell below 50 percent. For the univariate Cox models, an
RF-score ≥ 50% and BOS 0-p showed signiﬁcant correlation with BOS-free time (Table
3.20). The time after LTx showed no signiﬁcant inﬂuence on BOS-free time (hazard ra-
tio (HR) 1.00,95%-conﬁdence interval (CI) 0.99-1.00, p-value 0.82). Microbial infection
(HR 0.82, 95%-CI 0.74-1.38, p-value 0.63), acute rejection (HR 0.91, 95%-CI 0.33-2.56,
p-value 0.86) and the total number of acute rejection episodes before sampling (HR 1.01,
95%-CI 0.74-1.38, p-value 0.95) also showed no signiﬁcant inﬂuence on BOS-free time.
In the multivariate Cox model using BOS 0-p and an RF-score ≥ 50% as factors, only
RF-prediction was an independent predictor of BOS progression (RF-score ≥ 50%: p
-value = 0.02, BOS 0-p: p-value = 0.08).
Table 3.20. Univariate Cox poportional hazard models
Hazard Ratio 95% Conﬁdence Interval p-value
BOS-0p 1.84 1.00-3.38 0.05
RF-score ≥ 50% 2.19 1.19-4.01 0.01
days after LTx 1 0.99-1.00 0.82
Table 3.21. Multivariate Cox proportional hazard model
Hazard Ratio 95% Conﬁdence Interval p-value
BOS-0p 1.71 0.93-3.16 0.08
RF-score ≥ 50% 2.07 1.12-3.82 0.02
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(a) Detection of a molecular BOS signature was
signiﬁcantly associated with shorter BOS-free time
(p-value = 0.009, log-rank test).
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(b) A a sampling bias between the ﬁrst (days af-
ter lung transplantation (LTx) ≤ 365) and later
post-operational years (days after lung transplan-
tation (LTx) > 365) did not signiﬁcantly inﬂuence
the results, as samples taken after the ﬁrst year
postoperative year showed no signiﬁcant change in
BOS-free time (p-value = 0.877, log-rank test).
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(c) A forced expiratory volume in 1 second (FEV1)
less than or equal to 90 percent signature (BOS-0p)
was associated with signiﬁcantly shorter BOS-free
time (p-value = 0.046, log-rank test).
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(d) Combining both FEV1 and biomarker signa-
tures resulted in a more distinct BOS-free time
diﬀerence than FEV1 or proteomic criteria alone
(p-value = 0.0004, log-rank test).
Figure 3.12. Kaplan-Meier analysis of bronchiolitis obliterans syndrome (BOS)-free
time in relation to the absence and presence of predictive factors. The diﬀerence between
the survival curves (red/green) was assessed by the log-rank test.
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3.2.6 ELISA Validation
The MALDI-TOF MS-based results were validated by ELISA for BALF CCP in 13 LTx
patients (8 BOS-positive,5 BOS-negative). A strong down-regulation (p-value = 0.009,
Wilcoxon rank test) of CCP was associated with BOS progression (Figure 3.13), which
is in accordance with the BALmon model. For this BOS progression was deﬁned as an
ISHLT BOS stage progression (BOS-0 -> BOS-1 -> BOS2 -> BOS3) in relation to the
previous sample.
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Figure 3.13. ELISA validation: A strong (p-value: 0.009, Wilcoxon rank test) down-
regulation of CCP was associated with BOS development which conﬁrms the results from
our proteomic data mining.
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3.3 Block Maxx
To assess and compare the performance of Block Maxx with several known unsupervised
clustering algorithms, a previously published microarray data set was used. This Burkitt
lymphoma data set consists of one color Aﬀymetrix gene expression proﬁles from 220
mature agressive B-cell lymphomas [231].
3.3.1 Gene Selection
To select the most informative genes from the set of genes on the chip, I performed
an unsupervised gene selection step. Thus I selected the set of genes which resulted
in the dendrogramm, as produced by agglomerative hierarchical clustering, showing the
highest concordance correlation (Chapter 2.3.1). This set of 1030 genes, showing the
highest variance, was used for all further calculations.
3.3.2 Clustering and Stability Analysis
Using the selected set of genes, clusterings were generated for diﬀerent unsupervised algo-
rithms (Block Maxx, PAM, PAM-RF (unsupervised random forest clustering) , trimmed-
k-means) and numbers of clusters (k = 2, . . . , 5). To evaluate the relative stability of
these detected clusters, a bootstrap validation scheme was applied (Table 3.22). The
optimal number of clusters for each algorithm (k∗) was chosen as the maximal number
of k, for which all (excluding the bakground clusters) clusterwise stabilities were higher
or equal to 0.75. The results, according to this criterion, were k∗ = 4 for Block Maxx
and k∗ = 3 in the case of trimmed-k-means. PAM and PAM-RF (unsupervised random
forest clustering) did not meet this threshold for any number of k.
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Table 3.22. Clusterwise stabilities
Algorithm Cluster 1 Cluster 2 Mean Back
Block Maxx 86.62 87.67 87.15 78.63
Trimmed-k-means 92.28 91.61 91.95 85.04
PAM 74.09 77.51 75.8
PAM-RF 73.48 79.44 76.46
Algorithm Cluster 1 Cluster 2 Cluster 3 Mean Back
Block Maxx 84.93 83.05 84.32 84.1 77.13
Trimmed-k-means 77.69 78.04 87 80.91 78.68
PAM 76.12 55.22 69.49 66.94
PAM-RF 78.02 70.99 79.1 76.04
Algorithm Cluster 1 Cluster 2 Cluster 3 Cluster 4 Mean Back
Block Maxx 85.62 82.9 80.27 84.58 83.34 76.4
Trimmed-k-means 71.57 53.34 66.07 75.03 66.5 78.07
PAM 47.29 67.47 73.04 47.99 58.95
PAM-RF 71.56 65.03 59.7 77.77 68.52
Algorithm Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Mean Back
Block Maxx 77.94 77.38 70.56 64.95 84.23 75.01 55.31
Trimmed-k-means 69.12 63.79 43.01 43.78 55.66 55.07 73.73
PAM 48.33 63.47 65.54 47.13 53.56 55.61
PAM-RF 77.76 68.44 47.48 51.33 74.93 63.99
Mean, mean clusterwise stability over all clusters; Back, the stability of the background cluster
generated by Block Maxx and trimmed-k-means
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3.3.3 Survival Analysis
In addition to stability, the ability of the procedure to generate clinically relevant tu-
mour subgroups was used as a performance criterion. Thus I analysed the correlation
of clustering patterns, as generated by the compared procedures, with clinical survival
data. Signiﬁcance was assessed using a log rank test and p-values below or equal to
0.05 were considered as signiﬁcant (Table 3.23). The survival rates were visualized by
Kaplan-Meier curves. For each number of k the results obtained from Block Maxx were
compared to the reference algorithm with the highest average (mean) clusterwise stabil-
ity (Figure 3.14). The Block Maxx algorithm showed signiﬁcant result for k = 3, . . . , 5,
trimmed-k-means for k = 3, . . . , 5 and PAM-RF (unsupervised random forest clustering)
for k = 2, . . . , 5. In the case of PAM none of the clusterings proved to be signiﬁcant.
Table 3.23. Clusterwise log rank test
Algorithm P (2 Clusters) P (3 Clusters) P (4 Clusters) P (5 Clusters)
BlockMAXX 0.098 0.039 0.009 0.038
trimmed-k-means 0.068 0.008 0.016 0.02
PAM 0.42 0.657 0.144 0.164
PAM-RF 0.049 0.007 0.009 0.013
P, p-value (log-rank-test)
3.3 Block Maxx 98
Figure 3.14. Kaplan Meier analysis of survival time in relation to the assignement to
a specﬁfc cluster. The diﬀerences between the survival curves was assesed by the log
rank test. The p-values for each log rank test are given in each ﬁgure and in Table 3.23.
(This is a multipage ﬁgure.)
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Figure 3.14 (continued)
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3.3.4 Visualization
Heatmap
For the number of clusters (k∗ = 4), detected as optimal for the Block Maxx algorithm,
the results were visualized as a heatmap. Since genes can be assigned to up to two
clusters, up-regulated in one and down-regulated in another, two respective heatmaps
were created (Figure 3.15). In the former genes were ordered according to their up-
regulation assignment, while in the later genes were order based on their down-regulation
clustering. Both heatmaps use the same sample clustering. The order of the samples is
also the same for both heatmaps.
Multidimensional Scaling
The pairwise euclidean distance between all clustered samples was visualized in two
dimensional space, using classical multidimensional scaling (MDS) [240,241,242]. The
data points were marked by numbers according to their cluster membership (Figure
3.16). For each number of clusters, the results from Block Maxx were compared to the
reference algorithm showing the highest average (mean) clusterwise stability.
3.3 Block Maxx 101
Event
Age
Stage
Histology
Molecular Diagnosis
MYC
Cluster
Lymphoma (upregulated genes)
Yes/Positive
No/Negative
NA
Cluster
cluster 1
cluster 2
cluster 3
cluster 4
cluster 0
MYC partners
IG−myc
non−IG−myc
no myc breakpoint
Molecular Diagnosis
mBL
non−mBL
intermediate
Histology
BL
atypical BL
DLBCL
unclassifiable
Stage
I−II
III−IV
Age
<60 Yr
>60 Yr
Event
Age
Stage
Histology
Molecular Diagnosis
MYC
Cluster
Lymphoma (downregulated genes)
Yes/Positive
No/Negative
NA
Cluster
cluster 1
cluster 2
cluster 3
cluster 4
cluster 0
MYC partners
IG−myc
non−IG−myc
no myc breakpoint
Molecular Diagnosis
mBL
non−mBL
intermediate
Histology
BL
atypical BL
DLBCL
unclassifiable
Stage
I−II
III−IV
Age
<60 Yr
>60 Yr
Figure 3.15. The heatmap visualizes the expression of all genes for each cluster.
Clusters and samples are ordered according to their cluster membership. Gray denotes
the background cluster. Since genes can be members of more than one cluster (up-
and down-regulation) two heatmaps were constructed. For these heatmaps red depicts
high expression and green shows low expression. (a) Genes were ordered according
to up-regulation membership. (b) Genes were clustered according to down-regulation
membership.
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(a) Block Maxx (2 Clusters)
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(b) Trimmed-k-means (2 Clusters)
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(c) Block Maxx (3 Clusters)
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(d) Trimmed-k-means (3 Clusters)
Figure 3.16. The plots visualize the euclidean distances between all samples in a
two dimensional space, using multidimensional scaling (0 = background). (This is a
multipage ﬁgure.)
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(e) Block Maxx (4 Clusters)
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(f) PAM-RF (4 Clusters)
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(g) Block Maxx (5 Clusters)
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(h) PAM-RF (5 Clusters)
Figure 3.16 (continued)
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3.3.5 Gene Membership
Functional analysis
As with the clustering of the samples, for which clinical relevance was used as a perfor-
mance criterion, the gene clustering was assessed for functional enrichment of pathways
from the KEGG and Biocarta data bases. This was done using the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID) [112]. The signiﬁcantly function-
ally enriched pathways for each cluster, up-regulation and down-regulation separately,
were reported (Table 3.24).
Table 3.24. Functionally enriched pathways
Cluster 1
Category Term Count FE P Regulation
KEGG hsa05012:Parkinson's disease 21 8.08 2× 10−11 up
KEGG hsa00190:Oxidative phospho-
rylation
21 7.92 1.48× 10−11 up
KEGG hsa05016:Huntington's dis-
ease
22 5.44 4.33× 10−9 up
KEGG hsa03040:Spliceosome 18 6.36 2.23× 10−8 up
KEGG hsa05010:Alzheimer's disease 18 4.86 1.18× 10−6 up
KEGG hsa03050:Proteasome 8 7.4 8.93× 10−4 up
KEGG hsa04260:Cardiac muscle con-
traction
9 5.55 0.002 up
KEGG hsa03010:Ribosome 9 4.11 0.012 up
BIOCARTA h_rabPathway:Rab GTPases
Mark Targets In The Endocy-
totic Machinery
4 45.27 0.002 down
BIOCARTA h_p38mapkPathway:p38
MAPK Signaling Pathway
4 16.46 0.022 down
Cluster 2
Category Term Count FE P Regulation
BIOCARTA h_rabPathway:Rab GTPases
Mark Targets In The Endocy-
totic Machinery
4 41.15 0.003 up
BIOCARTA h_p38mapkPathway:p38
MAPK Signaling Pathway
4 14.96 0.032 up
KEGG hsa05012:Parkinson's disease 22 7.88 8.44× 10−12 down
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KEGG hsa00190:Oxidative phospho-
rylation
21 7.37 6.84× 10−11 down
KEGG hsa05016:Huntington's dis-
ease
24 5.53 3.95× 10−10 down
KEGG hsa03040:Spliceosome 19 6.25 9.85× 10−9 down
KEGG hsa05010:Alzheimer's disease 18 4.52 3.88× 10−6 down
KEGG hsa03050:Proteasome 8 6.89 0.002 down
KEGG hsa04260:Cardiac muscle con-
traction
9 5.17 0.003 down
KEGG hsa03010:Ribosome 9 3.83 0.02 down
Cluster 3
Category Term Count FE P Regulation
KEGG hsa05012:Parkinson's disease 7 7.86 0.008 up
KEGG hsa05010:Alzheimer's disease 7 5.51 0.028 up
KEGG hsa00190:Oxidative phospho-
rylation
6 6.61 0.025 up
Cluster 4
Category Term Count FE P Regulation
KEGG hsa03010:Ribosome 11 5.48 0.003 up
KEGG hsa05012:Parkinson's disease 7 7.27 0.014 down
KEGG hsa05010:Alzheimer's disease 7 5.1 0.045 down
KEGG hsa00190:Oxidative phospho-
rylation
6 6.11 0.038 down
KEGG hsa03040:Spliceosome 6 5.72 0.038 down
FE, fold enrichment ; P, Benjamini-Hochberg False Discovery rate corrected p-value
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Stability and Signiﬁcance
To make sure that the obtained gene membership scores represent diﬀerential expression.
In addition to stability, a Wilcoxon rank sum test (one-tailed) was used. Expression
for all genes were compared between their cluster of membership and all samples not
assigned to this cluster. This was done separately for up- and down-regulation. To get
an impression how well the gene membership scores represent signiﬁcantly diﬀerential
expression, I plotted the gene membership scores against the Benjamini-Hochberg false
dicovery rate corrected p-values obtained from the Wilcoxon rank sum test (one-tailed)
(Figure 3.17). Genes assigned to the background, when the entire data set was used,
passed the 0.75 line in two cases. All of the background genes never passed the 0.95
line. A relation between gene membership and signiﬁcance was clearly visible in the
generated plots. Most of the genes with a gene membership score larger than the 0.75
threshold were signiﬁcant, while nearly all genes with a gene membership score larger
than 0.95 were signiﬁcant.
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Figure 3.17. The graphs show the relationship between the gene membership score
and the signiﬁcance of the expression diﬀerence when compared to other clusters. The
p-values were calculated by a Wilcoxon rank sum test (one-tailed) with multiple testing
correction according to Benjamini-Hochberg false discovery rate. The green dots rep-
resent the genes selected for the respective cluster when the entire data set was used,
while red dots represent genes assigned to the background (up- or down-regulation). The
black dots are genes that were assigned to another up- or down-regulation cluster. For
the p-values the green and red lines represent the 0.05 and 0.1 thresholds respectively.
In the case of the gene membership scores a red line signiﬁes a stability of 0.75, while
the green line represents a stability of 0.95. (This is a multipage ﬁgure.)
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Figure 3.17 (continued)
Chapter 4
Discussion
4.1 Bronchiolitis Obliterans Syndrome
Bronchiolitis obliterans (BO) is a disease for which no reliable prognostic marker has been
found yet [4]. It is a clinical manifestation of chronic rejection after lung transplantation
(LTx). BO is the major limiting factor for long-term survival after lung transplantation
[5,6,7], and manifests as a chronic bronchiolar inﬂammation accompanied by progres-
sive sub-mucosal ﬁbrosis leading to gradual obliteration of the bronchiolar lumen. The
resulting reduction in forced expiratory volume per second (FEV1) is deﬁned as the
bronchiolitis obliterans syndrome (BOS). As chronic lung transplant failure occurs more
frequently than in other organ transplants [4], molecular markers for early BO or BOS
detection are urgently required to adapt the patients immunosuppressive regimen when
airway damage is still minimal. This thesis demonstrates that bronchiolitis obliterans
syndrome (BOS) related changes can be discovered for gene expression in bronchial ep-
ithelial cells (microarray anaylsis) and from the proteome level in bronchoalveolar lavage
ﬂuid (BALF) as determined by mass spectrometric proﬁling. The detected patterns not
only reﬂect signiﬁcant diﬀerences between BOS-positive and BOS-negative samples, but
also show signiﬁcant correlation with BOS free time. These properties are essential for
biomarkers to ultimately supplement established diagnostic procedures [5]. A biomarker
panel was obtained by a machine learning approach (random forest), on the basis of a
carefully controlled BALF sampling process [243] and mass spectrometric sub-proteome
proﬁles with matrix assisted laser desorption ionization time-of-ﬂight (MALDI-TOF)
technology [244,76]. In addition to ﬁnding markers that are of putative clinical rele-
vance, I was also interested in a more systems-based approach. This might add to the
basic understanding of transplant injury and BOS pathogenesis. This approach was
based on gene expression analysis in combination with pathway based methods and
model analysis of a random survival forest (RSF) for BOS-free progression. The inte-
grative nature of this thesis lies in the idea that both genomics and proteomics data sets
were analysed in combination with clinical data. It has often been reported that mRNA
levels do not necessarily correlate with protein abundance [245,246,247199]. As the pro-
tein proﬁles were generated from BALF and gene expression was measured directly from
109
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bronchial epithelial cells, a further level of complexity was added to the integration of
both data types. This is due to the fact that BALF consisting of a mixture of bronchial
epithelial cells and immune cells such as macrophages, neutrophils and lymphocytes,
while bronchial brush specimens were shown to contain a relatively pure cell population
of more than 90 percent bronchial epithelial cells [22]. This was reported for lung trans-
plants showing no BOS. As inﬁltration by immune cells is a process that occurs in BOS,
a higher percentage of such cells is to be expected.
4.1.1 Clinical Application
Training a random forest classiﬁer on the MALDI-TOF mass spectra of BOS-positive
and BOS-negative samples, a panel of biomarker peptides was selected. As shown by
cross-validation, this classiﬁer panel was reliably able to diﬀerentiate between BOS-
positive and BOS-negative samples. Cross-validation of the predictor ascertained its
performance with accuracy: 0.81 (43/53), detection rate (sensitivity): 0.81 (13/16), false
positive rate (1 - speciﬁcity): 0.19 (7/37) and an area under curve (AUC) of 0.79. The
selected biomarker panel (BALmon) included hemoglobin (hemoglobin beta (HBB)), se-
cretoglobin (Clara Cell secretory protein (CCP)) and defensin (human neutrophil peptide
1 (HNP1) and human neutrophil peptide 2 (HNP2)) members. Thus the biomarker panel
only included proteins and protein families for which the results were shown to be consis-
tent between studies and sample types. This shows the reliability of my newly developed
feature selection approach combining rank product and random forest based method-
ologies. It also supports the idea that, to get reliable results, statistically signiﬁcant
ﬁndings should further be judged by their predictive performance [147]. As has already
been shown for the included markers CCP, HNP1 and HNP2 [248,238], the classiﬁcation
results were not inﬂuenced by acute rejection or microbial infection. The random forest
predictor score (RF-score) assigned to the BOS-negative and BOS-unclassiﬁed samples
during cross-validation did not correlate signiﬁcantly with the total number of acute
rejection episodes until bronchoscopy (rho: 0.07 p-value: 0.459, Spearman correlation
test). There was no signiﬁcant diﬀerence in RF-score for samples showing acute rejection
(p-value: 0.914, Wilcoxon rank test) or microbial infection (p-value: 0.769, Wilcoxon
rank test) at the time of bronchoscopy This is a distinct advantage when compared to
FEV1 based diagnostics. The FEV1 value was signiﬁcantly lower for samples showing
acute rejection (p-value: <0.001, Wilcoxon rank test) but not microbial infection (p-
value: 0.22, Wilcoxon rank test). The FEV1 correlates signiﬁcantly with the number of
acute rejection episodes until bronchoscopy (rho: -0.28 p-value: 0.002, Spearman rank
correlation test). The assumption that BOS (bronchiolitis obliterans syndrome) can be
predicted before its irreversible clinical symptoms manifest is evident in the well estab-
lished FEV1 based BOS 0-p [72,73] criterion, and on the proteome level by the random
forest model incorporating the biomarker panel BALmon. For the patient cohort of this
study, the BALmon-based classiﬁcation and the BOS 0-p criterion both showed signiﬁ-
cant diﬀerences in BOS-free time. The combination of both devices seems to suggest an
improved accuracy, characterized by a striking decrease in median BOS-free time after
positive classiﬁcation by both criteria. The biomarker panel further showed the ability
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to stratify the BOS 0-p group into two subgroups diﬀering signiﬁcantly in BOS-free time
(p-value = 0.01, log-rank test). Samples classiﬁed as BOS risk positive by only one of
both criteria, did not show a signiﬁcant decrease in BOS-free time. Many studies aim
to replace well-known and established clinical tools with emerging biomarker discovery
techniques. This study thus implies that it is favorable to follow an integrative ap-
proach by combining predictors from clinical parameters with those based on molecular
biomarkers, such as BALmon.
4.1.2 Systems-Based Approach
In addition to the search for genes and proteins diﬀerentially expressed in BOS-positive
samples, a more systems-based approach was performed for the transcriptome data.
For this several pathways were identiﬁed, which were signiﬁcantly overrepresented (en-
riched) among the list of diﬀerentially expressed genes. Several of these had already
been linked to the bronchiolitis obliterans syndrome, like "systemic lupus erythemato-
sus" [249,250,251,45], "graft vs. host disease" [252] or "allograft rejection" [253]. By
annotation based clustering several additional diﬀerentially expressed genes could be
functionally linked to the enriched pathways ("pathway extension"). Thus further anal-
ysis using a random survival forest (RSF) combining FEV1 diagnostics with known
pathway members and these extension genes. The model showed good performance of
BOS risk prediction and was able to identify two risk groups deﬁned by distinct molec-
ular patterns. It also allowed for the identiﬁcation of genes that are predictive of BOS
development.
4.1.3 Potential Biomarkers for the Bronchiolitis Obliterans Syn-
drome
In the following, I will describe several biomarkers that have been found to be associ-
ated with BOS, either from gene expression proﬁling and/or from mass-spectrometric
analysis. A summary of the discussed results is shown in Figure 4.1. It should be noted
that this analysis only yields mass over-charge (m/z) ratios for these biomarkers, and
they need to be identiﬁed by complex biochemical studies (Chapter 2.2.5).
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Figure 4.1. The green nodes represent genes and proteins that were shown by random
forest and random survival forest model analysis to be involved in BOS development.
Orange nodes show terms that link the selected genes and proteins to each other and to
BOS (red node). These links were obtained by literature search.
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Hemoglobins
I found a markedly reduced expression of hemoglobin (Hb) α (HbA) and β (HbB) chains
[254] in BOS-positive samples, as expressed by alveolar type 2 cells and Clara cells
[255,256,22,257,258]. The signiﬁcantly lower hemoglobin gene expression in bronchial
epithelial cells was also conﬁrmed at the BALF proteome level by MALDI-TOF pro-
ﬁling. The presence of the HbB protein in BALF was formerly reported in reference
[259]. These ﬁndings were further supported by the down-regulation of the AHSP
(alpha-hemoglobin-stabilizing protein) gene in Bos-positive samples [260,261,262,263].
The alpha-hemoglobin-stabilizing protein (AHSP) serves as a molecular chaperone for
free hemoglobin α chains. Current scientiﬁc evidence suggests AHSP participation in
hemoglobin synthesis and a possible role in neutralization of the toxic eﬀects caused by
excess accumulation of free alpha-hemoglobin subunits. Hemoglobins have been shown
to play a role in various processes, including gas exchange [264] and protection against
oxidative stress [265]. Hb down-regulation was previously correlated with diverse lung
diseases [26,259], such as idiopathic pulmonary ﬁbrosis (IPF)[257]. Oxidative stress oc-
curs in pulmonary ﬁbrosis [266,267], where cells are damaged by reactive oxygen species,
and has been linked to BOS development and progression [268,269,270]. Up-regulation
of HbA and HbB was observed in BALF after the ﬁrst year post lung transplantation.
The up-regulated gene expression of HbA and HbB genes in bronchial epithelial cells
was shown to be linked to lung transplantation (LTx) [22], hypoxia in alveolar epithelial
cells [258] and in response to oxidative stress in hepatocytes [265]. A down-regulation of
hemoglobins in lung transplants that are aﬀected by BOS could thus further facilitate
cell damage by oxidative stress.
Secretoglobins
Another protein expressed in Clara cells [271], is the Clara cell secretory protein (uteroglobin
or secretoglobin (SCGB) 1A1). Clara cell secretory protein (CCP) is a low-molecular-
weight protein secreted into the alveoli in large quantities by Clara cells [272,273]. Clara
cells, the primary site of xenobiotic detoxiﬁcation, form an abundant population of non-
ciliated secretory cells within the bronchiolar epithelium of the mammalian lung. They
serve as a progenitor pool for bronchial epithelial steady-state maintenance and regener-
ation after lung injury. Clara cells also provide nonmucinous proteins to the extracellular
lining ﬂuid, among them the Clara cell secretory protein (CCP). This protein, one of the
most abundant respiratory-tract derived proteins, is suggested to have immunosuppre-
sive and antiprotease properties [274,275,276,277]. Alterations in Clara cell function are
often assumed to play a signiﬁcant role in lung function decrease in airway diseaes, and
CCP is known to be deregulated in a number of diseases that damage the lung epithelium
[26,25]. This study conﬁrmed the down-regulation of CCP for the bronchiolitis obliter-
ans syndrome [278,238], as the CCP gene was found to be signifcantly down-regulated
in BOS-positive samples at both the transcriptomic and proteomic level. Further a
signiﬁcant down-regulation was observed in BALF after the ﬁrst year post lung trans-
plantation. While on its own CCP is not a reliable predictor for development of BOS
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[279], it showed promising performance when combined with other biomarkers as shown
in reference [238], and by my BALmon classifer model. The study in [238] predicted
BOS using CCP in combination with Lysozyme, for which I found Lysozyme (Lyz) gene
expression up-regulated in BOS-postive cell samples and Lysozyme c down-regulated
in the BOS-positive BALF samples [280,281]. Secretoglobin (SCGB) 3A2 [282], like
CCP a member of the secretoglobin family, also showed a decreased gene expression
level in BOS-positive samples. The members of the SCGB gene superfamily, found
only in mammals, are all cytokine-like secreted proteins of 10 kDa. The SCGB3A2
(secretoglobin, family 3A, member 2) [282,16,283], which is predominently expressed in
the pulmonary airway epithelium, shows anti-inﬂammatory and growth factor activities.
Using pulmonary ﬁbroblasts isolated from adult mice [283], it was shown to inhibit the
TGFβ-induced diﬀerentiation of ﬁbroblasts to myoﬁbroblasts. This diﬀerentiation is a
hallmark of the ﬁbrotic process. Thus a down-regulation of SCGB3A2 might result in
increased ﬁbrosis in BOS aicted patients. The SCGB3A1 (secretoglobin, family 3A,
member 1), as opposed to the other analysed secretoglobin family members, showed
a signiﬁcantly increased gene expression level in BOS-positive samples. It was shown
in [282] that SCGB3A1 also exhibits a diﬀerent localization pattern than CCP and
SCGB3A2. While CCP and SCGB3A1 gene expression serve as a molecular marker
for Clara cells distributed throughout the conducting airway epithelium, SCGB3A1 is
highly expressed in a subset of airway epithelial cells located primarily in the bronchi
[282]. This might serve as possible explanation for the opposing patterns of diﬀerential
expression in BOS-positive samples.
Pulmonary Surfactant
Pulmonary surfactant [284], a surface-active lipoprotein complex (phospholipoprotein),
is formed by type II alveolar cells. This complex was originally known for its role reducing
surface tension at the air liquid layer. Recent discoveries revealed surfactant proteins
as an important component of the lung immune host defense. In this thesis, surfactant
protein A (SPA) [285] was found to be down-regulated on the protein level after the ﬁrst
year post lung transplantation. The down-regulation of SPA has already been linked
to BOS in reference [286]. In contrary to reference [286], I found an up-regulation of
SPA in BOS-positive BALF samples. Its diﬀerential expression was detected only on
the protein level, as surfactant protein A was not part of the gene set measured by the
microarrays that had been used in our study. Several other genes from the surfactant
family were found to be down-regulated in BOS-postive samples: surfactant protein B
(SPB) [287], surfactant protein C (SPC) [288] and surfactant protein D (SPD) [289]. As
a part of the innate immune system, the Surfactant proteins A and D regulate innate
immune cells of the immunologic enviroment of the lung [290,291]. This allows them to
modulate an extreme inﬂammatory reponse, which could otherwise result in a reduced
gas exchange by lung damage [284]. The signiﬁcant deregulation of surfactant protein D
could not be conﬁrmed on the protein level by a recent study [279]. Conﬂicting reports
and results of diﬀerential surfactant expression in patients aicted by BOS prevent a
clear conclusion concerning their role in BOS development [286,279].
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Defensins
Defensins are part of a large family of peptides, which were ﬁrst known for their broad
spectrum of activity against bacteria, fungi and viruses [292]. Recent studies expanded
on their role in promotion of innate and adaptive immune reponses, recruitment of in-
ﬂammatory cells as well as anti-inﬂammatory eﬀects [292]. Two members of the alpha-
defensin category (human neutrophil peptide (HNP) 1-2, or alpha defensin (DEF) 1-2)
were found to be up-regulated in BOS-positive BALF samples. Conversely both HNP
1 and 2 were found to be signiﬁcantly down-regulated in BALF samples after the ﬁrst
year post lung transplantation. HNPs were previously shown to exhibit BOS-related
changes but are believed to be involved in other respiratory conditions as well [293,294].
Up-regulation of these two proteins, neutrophil alpha defensin 1 (DEF1 or HNP1) and
neutrophil alpha defensin 2, has already been reported in the references [248,238]. Mem-
bers of the HNP family are constitutively expressed and packaged in azurophil granules
of neutrophiles from which they are released in large quantities during neutrophil acti-
vation [292]. In both studies [248,238] the HNP levels did not correlate with episodes
of acute rejection, cytomegalovirus or fungal infection. This is in line with chronic ob-
structive pulmonary disease (COPD) and idiopathic pulmonary ﬁbrosis (IPF), other
diseases with elevated HNP levels, for which infection is not a predominant clinical ﬁnd-
ing [295,296,248]. Human neutrophil peptides have also been linked to the pathogenesis
of acute lung injury [297], which shows acute inﬂammation with neutrophil iniﬁltration,
ﬁbroproliferation with hyaline membranes and varying degrees of interstitial ﬁbrosis
[298]. In a mouse model the eﬀects caused by α-defensins were shown to be mediated by
signal transduction through low-density lipoprotein-related receptor (LRP), for which
the LRP5 (low-density lipoprotein-related protein 5) gene showed a signiﬁcantly lower
expression level in BOS-positive bronchial epithelial cell samples. Other than for HNP
1-3, the diﬀerential expression of human neutrophil peptide 4 (HNP4 or DEF4) was not
reported in [248,238]. I found that, HNP4 (DEFA4) gene expression was signiﬁcantly
down-regulated in bronchial epithelial cells of BOS-positive samples. The gene expres-
sion of defensin beta 1 (DEFB1) a member of the β-defensins (hBDs), was up-regulated
in BOS-positive samples. The hBDs are expressed by mucosal epithelial cells, and are
secreted from these cells into the surrounding lining ﬂuid [292]. They support the initial
host defense against infection and the maintenance of epithelial integrity [292]. The up-
regulated level of defensin beta 2 in the bronchoalveolar lavage of lung transplants has
already been linked to the bronchiolitis oblitenans syndrome [299]. The up-regulated
gene expression of defensin beta 1(DEFB1) thus further supports the theory that β-
defensins play a role in BOS progression.
Histatins
Histatins [300], as secreted by human salivary glands [301], are a group of proteins
found in saliva [302] and bronchoalveolar lavage ﬂuid [11] and are a part of human
airway surface liquid (ASL) [303]. They show strong antimicrobial activity, especially
strong antifungal properties and stimulate wound closure of both oral and non-oral
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cells [304,305]. The analysed BOS-positive BALF samples showed a signiﬁcant down-
regulation of histatin-3. Despite a speciﬁc role of histatins in BOS development and
progression being unknown, this ﬁnding still adds to the current topics in BOS research.
This is due to the circumstance that lung allograft airway colonization by fungal as-
pergillus species and pseudomonas aeruginosa have been associated with BOS [68,306].
Histatin-3 also showed a signiﬁcant down-regulation after the ﬁrst year post lung trans-
plantation. This, together with the accompanying down-regulation of the human neu-
trophil peptides (HNP1 and HNP2), is in line with an increased susceptibility of the
pulmonary allograft to infection [307]. In a gene expression study histatins were found
only in parotid and submandibular glands [308], suggesting a speciﬁty to salivary secre-
tions. Thus, while the ﬁndings are interesting in the context of lung transplantation,
further research will be necessary to explain the presence and function of histatins in
lung ﬂuids.
Calgranulins
For calgranulin A (S100A8), which was suspected as a potential BOS biomarker in ref-
erence [238], a signiﬁcant down-regulation was found in BOS-positive BALF samples.
Calgranulin A is a member of the S100 family [309] of calcium binding proteins. These
are expressed in multiple cells, including activated macrophages, monocytes and neu-
trophils. So far altered expression of S100 family members has also been linked to cystic
ﬁbrosis [310], COPD [311], idiopathic ﬁbrosis [312] and lung cancer [11,313]. In alveolar
epithelial cells gene expression of S100A8 samples was found to be signiﬁcantly up-
regulated, together with S100P [314], S100A10 [315,313] and S100A11 [316]. S100A8, a
pro-inﬂammatory mediator in acute and chronic inﬂammation [311,317,318], promotes
phagocyte migration [319,320,321] and inﬁltration of granulocytes [322,323] to the sites
of tissue damage [324]. It also supports antifungal activities [325], and eight members
of the S100 family, including S100A8, show diﬀerential gene expression in bronchial
epithelial cells after pseudomonas aeruginosa exposure [326]. S100A12 (calgranulin C),
another pro-inﬂammatory protein member of the S100 family, showed signiﬁcantly lower
gene expression in BOS-positive epithelial cell samples. In references [311,259] S100A12
was shown to be more associated with acute lung inﬂammation, while chronic inﬂam-
mation is mainly mediated by S100A8/A9. Thus the transcriptomic down-regulation
of S100A12 would still be in line with BOS being deﬁned by chronic inﬂammation and
rejection processes [327].
Aldehyd Dehydrogenases
Both ALDH3A1 (aldehyde dehydrogenase 3 family , member A1) and ALDH3B2 (alde-
hyde dehydrogenase 3 family, member B2) were found to show a signiﬁcantly decreased
gene expresion level in BOS-positive epithelial cell samples. The enzymes encoded by
these genes belong to the aldehyde dehydrogenase family and are constitutively expressed
in the lung [328]. Aldehyde dehydrogenase, which oxidizes mainly aromatic and long
chain aliphatic aldehydes, is the second enzyme of the major oxidative pathway of alcohol
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metabolism. It protects organisms from aldehydes from food and air pollution, and was
reported to be a tumor stem cell-associated marker in lung cancer [329,330,331]. Further
these enzymes fullﬁll several noncatalytic duties, including antioxodative functions and
structural roles [331]. As cell damage from oxidative stress is linked to BOS development
and progression [268,269,270], the down-regulation of ALDH3A1 might partially explain
an increased susceptibility to oxidative stress-induced cell damage. While ALDH3A1
and ALDH3B2 gene expression was down-regulated in BOS-positive samples, the ex-
pression of ALDH3B2 has already been reported to be up-regulated in transplanted
lungs [22]. The same regulation pattern was also found in this thesis for hemoglobins
that oﬀer protection against oxidative stress [265]
HLA
Among the genes identiﬁed as informative for BOS progression by the random survival
forest model (RSF) were several HLA (human leukocyte antigens) genes. The HLA
genes were the unifying element between the signiﬁcantly enriched pathways. Allore-
activity directed toward HLA antigens has already been reported to play a role in the
pathogenesis of BOS. The exclusively α-subunit HLA genes (HLA-DMA,HLA-DRA and
HLA-DQA1), as selected by the RSF model, were all part of the HLA class II group.
Class II HLA antigens are expressed in cilliated bronchial epithelial cells [332,333,334].
During chronic rejection this expression is known to be up-regulated [335,336,337]. A
signiﬁcantly up-regulated gene expression of the HLA Class II genes was conﬁrmed for
BOS-positive samples and correlated signiﬁcantly with an elevated risk of BOS develop-
ment. While a clear consensus on the the role of HLA mismatching as a risk factor for
chronic lung allograft rejection has not yet been reached [338], several studies supple-
ment this idea [60]. In total this thesis further supplements the idea of HLA involvement
in BOS risk and progression.
Proteases
Among the genes selected by the RSF model were the proteases (peptidases) tryptase
alpha/beta 1 (TPSAB1), kallikrein 7 (KLK7) and cathepsin Z (CTSZ). Proteases be-
long to a group of enzyme families that catalyse protein breakdown. Their activity and
expression is governed by several regulative mechanisms that prevent uncontrolled pro-
teolytic action. Proteases play a role in the control of several extracellular and cellular
processes. These extracellular processes include extracellular matrix turnover and re-
sponses to tissue injury and healing. In the cells they are able regulate gene expression,
cell diﬀerentiation and proliferation, or induce cell death through limited proteolysis
[339].
Tryptases and Mast Cells
A cell type that is especially rich in proteases are mast cells. The mast cell peptidases
are stored in and released from secretory granules. Most of the proteolytic enzymes
selectively concentrated in the secretory granules of human mast cells show trypsin-
4.1 Bronchiolitis Obliterans Syndrome 118
or chemotrypsin like activities [340]. Among these are tryptases alpha and beta, pro-
teases that in humans are both encoded by the same TPSAB1 gene [341]. Tryptases are
known to stimulate ﬁbroblast proliferation [342,343]. The expression of the TPSAB1
gene was signiﬁcantly up-regulated in BOS-positive cell samples and in samples deﬁned
as high risk by the RSF model. It was also shown that an increase of TPSAB1 ex-
pression correlated signiﬁcantly with a decrease in BOS free time. In a previous study,
elevated tryptase levels in BAL were linked to the development of ﬁbrosis in idiopathic
bronchiolitis obliterans organizing pneumonia (BOOP) [344]. The presence of tryptases
is a reliable marker for mast cell activation[341]. Mast cells have already been linked
to most inﬁltrative ﬁbrotic lung diseases [345,346,344] and show the ability to produce
ﬁbrogenic cytokines [347]. While mast cells are not able to induce ﬁbrosis on their
own [348], their close morphologic and functional relationship with ﬁbroblasts further
supports their primary involvement in ﬁbrosis [349,350].
Kallikrein 7 and Epithelial-Mesenchymal Transition
Gene expression of the protease kallikrein 7 (KLK7) [351] was signiﬁcantly up-regulated
in BOS-positive bronchial epithelial cell samples. Kallikrein 7 is a chymotrypsin-like se-
creted serine protease that is known to catalyze the degradation of intercellular adhesive
structures in the corniﬁed layer of the skin [352]. KLK7 expression was rated as the
most informative feature of the multivariate random survival forest (RSF) model. An
up-regulation of KLK7 expression was only predictive of BOS development when con-
sidered in combination with other genes. The RSF based model analysis revealed such
BOS speciﬁc interactions with human leukocyte antigens (HLA-DMA, HLA-DRA and
HLA-DQA1) and the tryptase TPSAB1. As already shown for TPSAB1, KLK7 has also
been linked to ﬁbrosis. A recent study demonstrated that active kallikrein 7 is involved
in extracellular matrix degradation and shows the ability to cleave ﬁbronectin [353]. An-
other study showed that KLK7 induces epithelial-mesenchymal transition-like changes in
prostate cacrinoma cells [352]. Mesenchymal cells are known to migrate into the airspace
after acute lung injury, where they deposit connective tissue macromolecules [354]. The
occurence of epithelial-mesenchymal transition (EMT) in lung alveolar epithelial cells
has been proposed as a mechanism to explain the increased ﬁbroblast numbers, collagen
overproduction and ﬁbrosis ocurring in chronic obstructive pulmonary disease (COPD),
asthma and pulmonary ﬁbrosis [355]. It was also suggested that for bronchiolitis oblit-
erans EMT could serve as a potential link between injury caused by inﬂammation and
airway remodelling as driven by TGF-β [355]. In this study [355] TGF-β induced remod-
elling was linked to an reduced expression of epithelial markers as well as an increased
expression of vimentin and ﬁbronectin. In the BOS-positive cell samples, as obtained
from bronchial epithelial brushing, several diﬀerentially expressed genes might support
the idea of EMT occurence. These include the up-regulated IL1B (Interleukin 1, beta),
FGFBP1 (ﬁbroblast growth factor binding protein 1), LRFN5 (leucine rich repeat and
ﬁbronectin type III domain containing 5), ACTG2 (actin, gamma 2, smooth muscle, en-
teric), PCOLCE2 (procollagen C-endopeptidase enhancer 2) and KRT8 (keratin 8) [356].
A down-regulated gene expression was detected for the cadherin-related family mem-
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ber 1 (CDHR1), which is a member of the cadherin superfamily of calcium-dependent
cell-cell adhesion molecules. The down-regulation of epithelial cadherin (E-cadherin),
another member of the cadherin superfamily, has already been linked to EMT in several
studies [355,357]. During EMT, epithelial cells lose their epithelial properties and gain
mesenchymal ones. These mesenchymal properties include the production of metallopro-
teinases [355] . Two metalloproteinase coding genes (ADAM metallopeptidase domain 9
(ADAM9) and Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type
IV collagenase) (MMP9)) were found to be up-regulated in BOS-positive samples. EMT
does not seem to occur in lung transplants not suﬀering from BOS, as on the protein
level vimentin was found to be down-regulated in BALF samples taken after the ﬁrst
year post transplantation. Vimentin is a type III intermediate ﬁlament (IF) protein and
the major cytoskeletal component of mesenchymal cells. Vimentin [358], which plays
a role in organ rejection [359] and airway remodeling after lung transplantation [355],
serves as a biomarker of mesenchymally derived cells or cells undergoing EMT. Vimentin
silencing leads to a change in mesenchymal cell shape [360].
Cathepsin Z and Integrins
Gene expression of the lysosomal cysteine protease cathepsin Z (CTSZ), which is also
known as cathespin X (CTSX), was signiﬁcantly up-regulated in BOS-positive bronchial
epithelial cell samples. It was also shown that expression of the CTSZ gene was sig-
niﬁcantly up-regulated in samples deﬁned as high risk by the random survival forest
(RSF) model. An increase of CTSZ expression correlated signiﬁcantly with a decrease
in BOS free time. CTSZ gene expression was rated as one of the most informative fea-
tures of the multivariate RSF model. The RSF based model analysis revealed that the
expression of CTSZ best represents the BOS speciﬁc inﬂuence of the human leukocyte
antigens (HLA-DRA and HLA-DQA1), tryptase alpha/beta 1 (TPSAB1) and comple-
ment factor B (CFB). The carboxypeptidase cathepsin Z shows unique properties that
set it apart from other cysteine proteases [361]. Cathepsin Z expression is restricted
to cells of the immune system, such as dendrictic cells, macrophages and monocytes
[362]. Cathepsin Z modulates the activity of the β2-integrin receptor LFA-1 (Lympho-
cyte function-associated antigen 1) by sequential cleavage of the C-terminal amino acids
of the β2 intergin subunit [363,364]. Integrins are heterodimers containing two distinct
α and β chains. The common integrin β2 chain (CD18) of all integrins is the protein
product of the ITGB2 (integrin beta chain beta 2) gene. The integrin receptor LFA-1
is formed by the combination of β2 and the alpha L chain (CD11a/CD18, αLβ2). The
modulation of LFA-1 by CTSZ causes cytoskeletal rearrangement and increased migra-
tion of T lymphocytes [363,364]. This is interesting, since T lymphocyte inﬁltration is
commonly described as being linked to BOS development [4]. It was shown in reference
[365] that cathepsin Z possesses the ability to activate the β2-integrin receptor Mac-1
(Macrophage-1 antigen, CD11b/CD18, αMβ2)) [366]. This MAC-1 activation promotes
the adhesion of monocytes and macrophages to ﬁbrinogen and regulates phagocyto-
sis [363,364]. The participation of ﬁbrinogen in the immune and inﬂammatory rep-
sonse depends on the speciﬁc interaction with leukocyte integrin surface receptors. In
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macrophages, neutrophils, monocytes and several lmyphocyte subsets the main ﬁbrino-
gen receptors are MAC-1 [367] and inactivated-C3b (iC3b) receptor 4 (CR4) [368]. The
later receptor (CD11c/CD18,αxβ2) is formed by the combination of β2 and the integrin
alpha X chain protein. This protein is encoded by the Integrin, alpha X (complement
component 3 receptor 4 subunit) (ITGAX,CD11c) gene. Gene expression of ITGAX was
found to be signiﬁcantly up-regulated in the BOS-positive bronchial brushing samples.
As BOS is a condition of intraluminal airway ﬁbrosis [4] these ﬁndings might prove to
be very important for the understanding of BOS pathogenesis.
4.2 Block Maxx
In this thesis, a novel approach for biclustering of gene expression data was presented.
This algorithm (Block Maxx) focuses on the discovery of a set of sample clusters deﬁned
by the consistent up- and down-regulation of a subset of genes. The method uses spec-
tral bipartite graph partitioning as its framework. This framework was extended by a
background model, to allow for the removal of genes and samples that represent noise
and can not be clearly assigned to a speciﬁc cluster. The algorithm also allows for a
cluster to be deﬁned by a mixture of up-regulated and down-regulated genes. So far,
methods modelling the data as a bipartite graph were only able to ﬁnd clusters deﬁned
by gene expression up-regulation. The algorithm was applied to a publicly available
B-cell lymphoma microarray data set [231] and revealed four stable patient clusters.
A bootstrap resampling scheme was used to rank the genes in accordance with their
clusterwise importance (gene membership score). The ranking was shown to represent
signiﬁcant diﬀerential gene expression between the detected clusters. This establishes
the cluster membership score as a reliable way to rate gene importance in a bicluster
setting. The obtained clustering of the lymphomas also revealed interesting insights
into the biology of B-cell lymphomas. The clusters were ordered according to decreasing
survival time. Several pathways and gene sets were found signiﬁcantly enriched in the
lists of genes associated with the respective clusters. The ﬁrst and second cluster, as
well as the third and fourth cluster, show opposite patterns of gene expression (Figure
3.15). Genes up-regulated in the ﬁrst cluster are down-regulated in the second cluster,
while genes down-regulated in the ﬁrst cluster are up-regulated in the second. The same
principle applies to the third and fourth cluster. They consequently present opposite
patterns of pathway or gene-set enrichment (Table 3.24). The patients in these four
clusters also show a signiﬁcant diﬀerence in survival time, where the patients in the
ﬁrst and fourth clusters have the best and worst prognosis of all patients, respectively.
The Biocarta "Rab" pathway is overrepresented in the down-regulated genes of the ﬁrst
cluster and in the up-regulated genes of the second cluster. Interestingly, overexpression
of Rab genes has been associated with hematological malignancies [369,370], and this
correlates with the worse prognosis of the second group, which presents up-regulation
of this pathway, as compared to the ﬁrst cluster. The Biocarta "p38 MAPK" signaling
pathway, a known signaling event associated with several tumors, such as breast cancers
[371], is also down-regulated and up-regulated in the ﬁrst and second cluster, respec-
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tively, suggesting a protective role of the inhibition of this pathway also in lymphoma.
Particularly interesting is the diﬀerentially regulation of oxidative phosphorylation in
the ﬁrst and second cluster, as well as in third and fourth cluster. It is known that
diﬀerent cancers, and even cancer subgroups, are selective in the means of producing en-
ergy, varying from glycolytic to oxidative types [372]. Interestingly, the KEGG pathway
"oxidative phosphorylation" is overrepresented in the up-regulated genes of the ﬁrst and
third clusters and in the down-regulated genes of the second and fourth clusters. This
ﬁnding suggests two diﬀerent subgroups of lymphoma based on their ability to produce
energy from oxidative phosphorylation.
4.3 Outlook
This study revealed that the clinical implementation of a predictor model such as BAL-
mon, based on proteomic markers, could ultimately supplement established diagnostic
procedures. Validation on a separate patient cohort using multiplexed enzyme-linked
immunosorbent assay and multiple reaction monitoring mass spectrometry will be per-
formed. This will also allow to conﬁrm BOS-related changes detected on the gene ex-
pression level in the proteome of BALF samples. For the Block Maxx algorithm, an R
package will be made available. This will allow the community to employ Block Maxx
in an easy and open source fashion. Block Maxx will also be extended to allow for semi
supervised clustering. Semi-supervised clustering refers to a group of machine learning
methods that can make use of a combination of labeled and unlabeled data. Normally
a large amount of unlabeled data and a small amount of labeled data. For this the
bipartite graph model will be extended to allow edges between samples that are already
known to belong to the same clinically deﬁned group.
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Table 1. Genes signiﬁcantly up-regulated in BOS-positive samples
Gene symbol Entrez ID UniGene RP P FDR Mean FC Median FC
SRGN 5552 Hs.1908 322 <0.001 <0.001 2.05 1.77
UPK1B 7348 Hs.271580 394 <0.001 <0.001 2.17 1.3
C15orf48 84419 Hs.112242 446 <0.001 <0.001 2.1 1.89
LAPTM5 7805 Hs.371021 468 <0.001 <0.001 1.87 2.84
CCL3L3 414062 Hs.512304 478 <0.001 <0.001 1.88 1.91
FPGS 2356 Hs.335084 484 <0.001 <0.001 1.81 1.66
CCL3 6348 Hs.514107 622 <0.001 <0.001 1.71 1.4
CCR1 1230 Hs.301921 707 <0.001 <0.001 1.59 1.23
TPSAB1 7177 Hs.405479 738 <0.001 <0.001 1.65 1.67
CCL2 6347 Hs.303649 738 <0.001 <0.001 1.58 1.6
IL1B 3553 Hs.126256 739 <0.001 <0.001 1.64 1.32
LY6D 8581 Hs.415762 752 <0.001 <0.001 1.6 1.69
MXD1 4084 Hs.468908 763 <0.001 <0.001 1.66 1.45
FCER1G 2207 Hs.433300 775 <0.001 <0.001 1.55 1.95
IFI30 10437 Hs.14623 776 <0.001 <0.001 1.58 1.62
SAA1 6288 Hs.632144 778 <0.001 <0.001 1.4 1.03
CCNA1 8900 Hs.417050 791 <0.001 <0.001 1.7 1.39
CENPN 55839 Hs.55028 807 <0.001 <0.001 1.54 1.43
HLA-G 3135 Hs.512152 817 <0.001 <0.001 1.41 1.59
PLEK 5341 Hs.468840 818 <0.001 <0.001 1.45 1.31
HIST1H1C 3006 Hs.7644 821 <0.001 <0.001 1.58 1.88
PSAP 5660 Hs.523004 823 <0.001 <0.001 1.49 1.46
TREM1 54210 Hs.283022 834 <0.001 <0.001 1.59 1.44
CD52 1043 Hs.276770 846 <0.001 <0.001 1.51 1.5
SPP1 6696 Hs.313 868 <0.001 <0.001 1.45 1.48
SOCS3 9021 Hs.527973 879 <0.001 <0.001 1.56 1.54
TMPRSS13 84000 Hs.266308 885 <0.001 <0.001 1.54 1.6
TNFAIP6 7130 Hs.437322 905 <0.001 <0.001 1.63 1.35
S100A8 6279 Hs.416073 912 <0.001 <0.001 1.18 1.09
G0S2 50486 Hs.432132 924 <0.001 <0.001 1.48 1.23
CCL18 6362 Hs.143961 927 <0.001 <0.001 1.61 1.44
PLUNC 51297 Hs.211092 928 <0.001 <0.001 1.03 1.02
DDX5 1655 Hs.279806 934 <0.001 <0.001 1.29 1.32
AQP9 366 Hs.104624 937 <0.001 <0.001 1.45 1.2
RNASE1 6035 Hs.78224 959 <0.001 <0.001 1.3 1.17
FCGR3A 2214 Hs.372679 1001 <0.001 <0.001 1.23 1.29
HAUS8 93323 Hs.404088 1007 <0.001 <0.001 1.51 1.59
CD53 963 Hs.443057 1012 <0.001 <0.001 1.44 1.45
LGALS1 3956 Hs.445351 1017 <0.001 <0.001 1.38 1.54
C8orf4 56892 Hs.591849 1022 <0.001 <0.001 1.51 1.57
RAD51L3 5892 Hs.631757 1025 <0.001 <0.001 1.57 1.47
MRC1L1 414308 Hs.461247 1030 <0.001 <0.001 1.15 1.29
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CXCR4 7852 Hs.593413 1039 <0.001 <0.001 1.39 1.47
IL1R2 7850 Hs.25333 1059 <0.001 <0.001 1.5 1.2
ADAM9 8754 Hs.591852 1063 <0.001 <0.001 1.55 1.55
CXCL9 4283 Hs.77367 1068 <0.001 <0.001 1.13 1.33
FGFBP1 9982 Hs.1690 1072 <0.001 <0.001 1.46 1.35
MDM4 4194 Hs.497492 1073 <0.001 <0.001 1.59 1.93
HN1 51155 Hs.532803 1080 <0.001 <0.001 1.59 1.57
IDO1 3620 Hs.840 1095 <0.001 <0.001 1.29 1.02
C1QB 713 Hs.8986 1101 <0.001 <0.001 1.3 1.37
HRASLS 57110 Hs.36761 1101 <0.001 <0.001 1.6 1.54
CORO6 84940 Hs.143046 1112 <0.001 <0.001 1.51 1.49
OLR1 4973 Hs.412484 1123 <0.001 <0.001 1.41 1.36
BCL2A1 597 Hs.227817 1127 <0.001 <0.001 1.44 1.34
DAPK2 23604 Hs.237886 1137 <0.001 <0.001 1.43 1.46
SELL 6402 Hs.82848 1142 <0.001 <0.001 1.04 1.04
LCP1 3936 Hs.381099 1143 <0.001 <0.001 1.32 1.42
FHL1 2273 Hs.435369 1152 <0.001 <0.001 1.47 1.54
HIST1H2BK 85236 Hs.437275 1153 <0.001 <0.001 1.57 1.5
LANCL1 10314 Hs.13351 1154 <0.001 <0.001 1.37 1.12
FAM26F 441168 Hs.381220 1155 <0.001 <0.001 1.45 1.34
ADM 133 Hs.441047 1161 <0.001 <0.001 1.48 1.31
HLA-DQA1 3117 Hs.387679 1161 <0.001 <0.001 1.31 1.02
ATP6V1F 9296 Hs.78089 1162 <0.001 <0.001 1.47 1.27
GJA4 2701 Hs.296310 1168 <0.001 <0.001 1.47 1.5
MARCO 8685 Hs.67726 1178 <0.001 <0.001 1.27 1.31
C1orf38 9473 Hs.10649 1187 <0.001 <0.001 1.35 1.54
IL32 9235 Hs.943 1203 <0.001 <0.001 1.45 1.35
YWHAZ 7534 Hs.492407 1210 <0.001 <0.001 1.23 1.11
EPSTI1 94240 Hs.546467 1218 <0.001 <0.001 1.23 1.25
GOLGA5 9950 Hs.104320 1218 <0.001 <0.001 1.55 1.42
CSF2RB 1439 Hs.592192 1222 <0.001 <0.001 1.34 1.13
AIF1 199 Hs.76364 1223 <0.001 <0.001 1.34 1.54
SAG 6295 Hs.32721 1231 <0.001 <0.001 1.57 1.36
FPR1 2357 Hs.753 1236 <0.001 <0.001 1.3 1.39
BCL3 602 Hs.31210 1237 <0.001 <0.001 1.5 1.45
LRFN5 145581 Hs.136893 1249 <0.001 <0.001 1.35 1.63
LYZ 4069 Hs.524579 1252 <0.001 <0.001 1.25 1.21
CST1 1469 Hs.123114 1256 <0.001 <0.001 1.37 1.33
GPR109A 338442 Hs.524812 1266 <0.001 <0.001 1.28 1.27
C3AR1 719 Hs.591148 1270 <0.001 <0.001 1.45 1.31
STXBP2 6813 Hs.515104 1270 <0.001 <0.001 1.4 1.06
A2M 2 Hs.212838 1271 <0.001 <0.001 1.19 1.09
DEFB1 1672 Hs.32949 1273 <0.001 <0.001 1.52 1.53
IFITM1 8519 Hs.458414 1274 <0.001 <0.001 1.22 1.02
HLA-DRA 3122 Hs.520048 1277 <0.001 <0.001 1.4 1.81
AKR1A1 10327 Hs.474584 1292 <0.001 <0.001 1.45 1.51
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CYP27B1 1594 Hs.524528 1294 <0.001 <0.001 1.52 1.56
BST2 684 Hs.118110 1294 <0.001 <0.001 1.35 1.36
ASS1 445 Hs.160786 1303 <0.001 <0.001 1.41 1.34
NGFRAP1 27018 Hs.448588 1303 <0.001 <0.001 1.44 1.34
ACTG2 72 Hs.516105 1313 <0.001 <0.001 1.36 1.4
SERPINB3 6317 Hs.227948 1318 <0.001 <0.001 1.24 1.31
SERPINB4 6318 Hs.123035 1318 <0.001 <0.001 1.11 1.25
LITAF 9516 Hs.459940 1320 <0.001 <0.001 1.42 1.41
IL1RN 3557 Hs.81134 1330 <0.001 0.001 1.34 1.24
H2AFX 3014 Hs.477879 1346 <0.001 0.001 1.52 1.41
C12orf44 60673 Hs.9911 1350 <0.001 0.001 1.46 1.39
TFF3 7033 Hs.82961 1354 <0.001 0.001 1.17 1.39
FCGR1A 2209 Hs.77424 1355 <0.001 0.001 1.32 1.29
LCP2 3937 Hs.304475 1357 <0.001 0.001 1.41 1.36
LYZL6 57151 Hs.97477 1358 <0.001 0.001 1.42 1.22
NCF2 4688 Hs.587558 1358 <0.001 0.001 1.25 1.53
PPPDE2 27351 Hs.570455 1362 <0.001 0.001 1.44 1.4
STK40 83931 Hs.471768 1364 <0.001 0.001 1.52 1.6
GPR109B 8843 Hs.458425 1364 <0.001 0.001 1.42 1.57
UCP2 7351 Hs.80658 1364 <0.001 0.001 1.37 1.29
MAF 4094 Hs.134859 1365 <0.001 0.001 1.4 1.45
SPRR1B 6699 Hs.1076 1367 <0.001 0.001 1.36 1.21
CDV3 55573 Hs.518265 1372 <0.001 0.001 1.3 1.6
SLC2A3 6515 Hs.419240 1378 <0.001 0.001 1.38 1.41
CSTA 1475 Hs.518198 1379 <0.001 0.001 1.34 1.48
IGSF1 3547 Hs.22111 1384 <0.001 0.001 1.49 1.52
GMFG 9535 Hs.5210 1386 <0.001 0.001 1.3 1.09
CTSZ 1522 Hs.252549 1387 <0.001 0.001 1.44 1.31
TM4SF5 9032 Hs.184194 1392 <0.001 0.001 1.48 1.4
GUCY1B2 2974 Hs.411573 1393 <0.001 0.001 1.43 1.62
PTPRH 5794 Hs.179770 1393 <0.001 0.001 1.52 1.28
MT1F 4494 Hs.513626 1402 <0.001 0.001 1.38 1.22
LOC100130288 100130288 Hs.120196 1404 <0.001 0.001 1.36 1.75
HLA-DMA 3108 Hs.351279 1407 <0.001 0.001 1.22 1.44
TSPAN13 27075 Hs.364544 1412 <0.001 0.001 1.4 1.68
FAM96A 84191 Hs.439548 1413 <0.001 0.001 1.45 1.61
C11orf9 745 Hs.473109 1416 <0.001 0.001 1.44 1.45
STX10 8677 Hs.43812 1425 <0.001 0.001 1.5 1.35
RPL21 6144 Hs.381123 1435 <0.001 0.001 1.29 1.08
WBP5 51186 Hs.533287 1440 <0.001 0.001 1.45 1.4
WFDC2 10406 Hs.2719 1443 <0.001 0.001 1.33 1.31
GGH 8836 Hs.78619 1449 <0.001 0.002 1.44 1.57
ATOX1 475 Hs.125213 1450 <0.001 0.002 1.35 1.2
POLR2L 5441 Hs.441072 1459 <0.001 0.002 1.31 1.4
MTHFD2 10797 Hs.469030 1461 <0.001 0.002 1.38 1.51
RGS16 6004 Hs.413297 1466 <0.001 0.002 1.46 1.34
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APOBEC3B 9582 Hs.226307 1468 <0.001 0.002 1.48 1.47
ALOX5AP 241 Hs.507658 1472 <0.001 0.002 1.23 1.03
TNFRSF1B 7133 Hs.256278 1472 <0.001 0.002 1.28 1.24
GPSM3 63940 Hs.520046 1475 <0.001 0.002 1.33 1.42
MFNG 4242 Hs.517603 1483 <0.001 0.002 1.42 1.6
CCNB2 9133 Hs.194698 1485 <0.001 0.002 1.45 1.42
HLA-DRB1 3123 Hs.534322 1493 <0.001 0.002 1.26 1.44
MMP9 4318 Hs.297413 1499 <0.001 0.002 1.33 1.39
MAZ 4150 Hs.23650 1500 <0.001 0.002 1.38 1.36
MUC12 10071 Hs.489355 1507 <0.001 0.003 1.42 1.37
HCST 10870 Hs.117339 1508 <0.001 0.003 1.39 1.44
RARRES1 5918 Hs.131269 1515 <0.001 0.003 1.27 1.13
GSTM4 2948 Hs.348387 1519 <0.001 0.003 1.41 1.4
EMCN 51705 Hs.152913 1522 <0.001 0.003 1.41 1.25
LOC100289478 100289478 Hs.121915 1522 <0.001 0.003 1.4 1.21
SLA 6503 Hs.75367 1524 <0.001 0.003 1.31 1.21
S100P 6286 Hs.2962 1526 <0.001 0.003 1.23 1.05
CCNL1 57018 Hs.4859 1526 <0.001 0.003 1.14 1.08
TMSB4X 7114 Hs.522584 1531 <0.001 0.003 1.33 1.34
VNN2 8875 Hs.293130 1531 <0.001 0.003 1.14 1.22
PSME2 5721 Hs.434081 1535 <0.001 0.003 1.36 1.55
HSD17B6 8630 Hs.524513 1536 <0.001 0.003 1.4 1.39
MTHFS 10588 Hs.459049 1539 <0.001 0.003 1.43 1.38
CFB 629 Hs.69771 1540 <0.001 0.003 1.25 1.03
CXCL10 3627 Hs.632586 1543 <0.001 0.003 1.15 1.01
SERPING1 710 Hs.384598 1543 <0.001 0.003 1.24 1.27
FCAMR 83953 Hs.145519 1544 <0.001 0.003 1.45 1.45
CAV1 857 Hs.74034 1554 <0.001 0.003 1.11 1.06
CORO1A 11151 Hs.415067 1558 <0.001 0.003 1.17 1.14
KIF5A 3798 Hs.151219 1562 <0.001 0.004 1.41 1.29
CREB3L1 90993 Hs.405961 1562 <0.001 0.004 1.27 1.18
LOC645638 645638 Hs.463652 1565 <0.001 0.004 1.3 1.28
EPR1 8475 Hs.514527 1570 <0.001 0.004 1.4 1.38
SERPINA3 12 Hs.534293 1571 <0.001 0.004 1.39 1.42
L1CAM 3897 Hs.522818 1575 <0.001 0.004 1.2 1.24
UNC93A 54346 Hs.567508 1576 <0.001 0.004 1.42 1.34
CD44 960 Hs.502328 1577 <0.001 0.004 1.4 1.4
ITGAX 3687 Hs.248472 1577 <0.001 0.004 1.25 1.05
GCAT 23464 Hs.54609 1578 <0.001 0.004 1.34 1.39
MRPS35 60488 Hs.311072 1580 <0.001 0.004 1.28 1.61
NDST3 9348 Hs.480596 1582 <0.001 0.004 1.37 1.56
PIN1 5300 Hs.465849 1585 <0.001 0.004 1.28 1.29
ZPBP 11055 Hs.388841 1586 <0.001 0.004 1.48 1.48
CPZ 8532 Hs.78068 1587 <0.001 0.004 1.4 1.37
MRPL14 64928 Hs.311190 1589 <0.001 0.004 1.4 1.47
EHHADH 1962 Hs.429879 1590 <0.001 0.004 1.3 1.18
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IGLJ3 28831 Hs.449585 1590 <0.001 0.004 1.31 1.15
CD300A 11314 Hs.9688 1593 <0.001 0.004 1.3 1.32
IFI27 3429 Hs.532634 1594 <0.001 0.005 1.02 1.13
SYCP1 6847 Hs.112743 1594 <0.001 0.005 1.26 1.64
PAFAH1B3 5050 Hs.466831 1597 <0.001 0.005 1.35 1.17
RARRES3 5920 Hs.17466 1599 <0.001 0.005 1.22 1.52
TSTA3 7264 Hs.404119 1600 <0.001 0.005 1.34 1.23
LSP1 4046 Hs.56729 1606 <0.001 0.005 1.27 1.01
MUC2 4583 Hs.315 1606 <0.001 0.005 1.24 1.3
LOC100287697 100287697 Hs.326822 1608 <0.001 0.005 1.39 1.43
SH2D3C 10044 Hs.306412 1609 <0.001 0.005 1.33 1.42
HAS3 3038 Hs.592069 1609 <0.001 0.005 1.34 1.57
KIF23 9493 Hs.270845 1614 <0.001 0.005 1.44 1.38
FCER2 2208 Hs.465778 1616 <0.001 0.005 1.4 1.37
TRNP1 388610 Hs.355747 1619 <0.001 0.005 1.32 1.11
CMPK2 129607 Hs.7155 1620 <0.001 0.006 1.21 1.46
PRDX3 10935 Hs.523302 1622 <0.001 0.006 1.34 1.59
FPR2 2358 Hs.99855 1623 <0.001 0.006 1.27 1.13
DIRAS3 9077 Hs.194695 1625 <0.001 0.006 1.32 1.5
C19orf53 28974 Hs.231616 1628 <0.001 0.006 1.3 1.28
UBE2C 11065 Hs.93002 1630 <0.001 0.006 1.36 1.31
CYTH4 27128 Hs.170944 1632 <0.001 0.006 1.29 1.18
CD86 942 Hs.171182 1638 <0.001 0.006 1.37 1.57
SIRPA 140885 Hs.581021 1644 <0.001 0.006 1.27 1.09
MRPL54 116541 Hs.356578 1645 <0.001 0.006 1.22 1.09
UBE2L6 9246 Hs.425777 1645 <0.001 0.006 1.27 1.15
ROBLD3 28956 Hs.632483 1651 <0.001 0.007 1.4 1.2
RPL13 6137 Hs.410817 1652 <0.001 0.007 1.32 1.34
PLIN2 123 Hs.3416 1655 <0.001 0.007 1.21 1.21
RLBP1 6017 Hs.1933 1656 <0.001 0.007 1.39 1.39
RASGRP4 115727 Hs.130434 1656 <0.001 0.007 1.37 1.3
AGXT 189 Hs.144567 1657 <0.001 0.007 1.29 1.18
SLC16A2 6567 Hs.75317 1660 <0.001 0.007 1.34 1.44
PROC 5624 Hs.224698 1661 <0.001 0.007 1.42 1.36
CPVL 54504 Hs.233389 1662 <0.001 0.007 1.18 1.42
MT1G 4495 Hs.433391 1666 <0.001 0.007 1.27 1.05
CCDC6 8030 Hs.591360 1668 <0.001 0.007 1.39 1.38
SEC13 6396 Hs.166924 1669 <0.001 0.007 1.4 1.33
GLO1 2739 Hs.268849 1669 <0.001 0.007 1.26 1.14
BOLA2 552900 Hs.444600 1671 <0.001 0.007 1.38 1.27
TRMT2B 79979 Hs.496501 1673 <0.001 0.007 1.3 1.23
KRT8 3856 Hs.533782 1675 <0.001 0.008 1.33 1.47
C1QTNF2 114898 Hs.110062 1677 <0.001 0.008 1.42 1.37
RGS1 5996 Hs.75256 1678 <0.001 0.008 1.27 1.37
GZMA 3001 Hs.90708 1681 <0.001 0.008 1.08 1.05
MSN 4478 Hs.87752 1683 <0.001 0.008 1.26 1.27
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C19orf70 125988 Hs.356626 1685 <0.001 0.008 1.26 1.39
DHX9 1660 Hs.191518 1687 <0.001 0.008 1.23 1.35
IL18BP 10068 Hs.591967 1689 <0.001 0.008 1.39 1.28
MUC4 4585 Hs.369646 1691 <0.001 0.008 1.26 1.25
PCOLCE2 26577 Hs.8944 1692 <0.001 0.008 1.19 1.35
CHRNB4 1143 Hs.624178 1694 <0.001 0.008 1.38 1.59
LOC100288376 100288376 Hs.519523 1698 <0.001 0.009 1.19 1.24
CCS 9973 Hs.502917 1698 <0.001 0.009 1.42 1.34
TTC13 79573 Hs.424788 1699 <0.001 0.009 1.35 1.53
GK 2710 Hs.1466 1701 <0.001 0.009 1.37 1.43
PPP1R9A 55607 Hs.21816 1704 <0.001 0.009 1.29 1.44
RPL27A 6157 Hs.523463 1705 <0.001 0.009 1.3 1.13
CXCL1 2919 Hs.789 1705 <0.001 0.009 1.21 1.19
SALL1 6299 Hs.135787 1713 <0.001 0.01 1.28 1.27
GLUL 2752 Hs.518525 1716 <0.001 0.01 1.23 1.21
ISG20 3669 Hs.459265 1717 <0.001 0.01 1.29 1.29
IFITM3 10410 Hs.374650 1717 <0.001 0.01 1.19 1.06
FAM96B 51647 Hs.9825 1718 <0.001 0.01 1.31 1.2
PCNT 5116 Hs.474069 1719 <0.001 0.01 1.3 1.27
PDYN 5173 Hs.22584 1721 <0.001 0.01 1.36 1.26
ASAH1 427 Hs.527412 1722 <0.001 0.01 1.07 1.18
SAT1 6303 Hs.28491 1724 <0.001 0.01 1.32 1.21
RAMP2 10266 Hs.514193 1727 <0.001 0.011 1.31 1.26
ZNF555 148254 Hs.47712 1728 <0.001 0.011 1.38 1.33
VSIG4 11326 Hs.8904 1731 <0.001 0.011 1.01 1.13
LOXL1 4016 Hs.65436 1737 <0.001 0.012 1.34 1.32
SPAG11A 653423 Hs.559506 1739 <0.001 0.012 1.39 1.32
ALPI 248 Hs.37009 1742 <0.001 0.012 1.34 1.38
STAT4 6775 Hs.80642 1746 <0.001 0.012 1.13 1.22
OAZ2 4947 Hs.74563 1748 <0.001 0.012 1.33 1.22
CYBA 1535 Hs.513803 1754 <0.001 0.012 1.29 1.17
PRDX4 10549 Hs.83383 1755 <0.001 0.013 1.32 1.48
PTMS 5763 Hs.504613 1762 <0.001 0.013 1.33 1.09
SLC24A6 80024 Hs.286194 1763 <0.001 0.013 1.32 1.62
MS4A4A 51338 Hs.325960 1764 <0.001 0.013 1.22 1.41
RDH10 157506 Hs.244940 1764 <0.001 0.013 1.23 1.31
CLPP 8192 Hs.515092 1769 <0.001 0.013 1.3 1.37
SCGB3A1 92304 Hs.62492 1772 <0.001 0.014 1.16 1.12
MYL6 4637 Hs.632717 1774 <0.001 0.014 1.3 1.55
ARSA 410 Hs.88251 1774 <0.001 0.014 1.35 1.39
BLOC1S1 2647 Hs.94672 1775 <0.001 0.014 1.3 1.3
LOC100288550 100288550 Hs.448226 1776 <0.001 0.014 1.28 1.25
LOC100288974 100288974 Hs.102310 1776 <0.001 0.014 1.36 1.24
KCNJ15 3772 Hs.411299 1776 <0.001 0.014 1.31 1.17
CD37 951 Hs.166556 1777 <0.001 0.014 1.19 1.09
WIPF1 7456 Hs.128067 1780 <0.001 0.014 1.27 1.4
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DNTTIP2 30836 Hs.85769 1782 <0.001 0.014 1.13 1.3
TUBB4 10382 Hs.110837 1785 <0.001 0.014 1.38 1.36
RABAC1 10567 Hs.11417 1792 <0.001 0.015 1.28 1.37
GPR182 11318 Hs.483909 1792 <0.001 0.015 1.29 1.29
ACSL1 2180 Hs.406678 1792 <0.001 0.015 1.18 1.36
KLK7 5650 Hs.151254 1792 <0.001 0.015 1.37 1.34
PPEF2 5470 Hs.290873 1792 <0.001 0.015 1.31 1.18
SOD3 6649 Hs.2420 1795 <0.001 0.015 1.34 1.28
IER3 8870 Hs.591785 1795 <0.001 0.015 1.14 1.35
TNNI1 7135 Hs.320890 1796 <0.001 0.016 1.4 1.2
ESPL1 9700 Hs.153479 1802 <0.001 0.016 1.41 1.4
UBB 7314 Hs.356190 1803 <0.001 0.016 1.27 1.39
SLC22A1 6580 Hs.117367 1803 <0.001 0.016 1.39 1.43
NFKBIB 4793 Hs.9731 1805 <0.001 0.017 1.41 1.32
VMO1 284013 Hs.122561 1806 <0.001 0.017 1.2 1.32
C1orf194 127003 Hs.446962 1806 <0.001 0.017 1.26 1.24
DUSP2 1844 Hs.1183 1809 <0.001 0.017 1.29 1.25
RASAL1 8437 Hs.528693 1814 <0.001 0.018 1.31 1.08
LOC100288209 100288209 Hs.601492 1817 <0.001 0.018 1.24 1.46
COX7A2 1347 Hs.70312 1821 <0.001 0.019 1.18 1.54
NCKAP1L 3071 Hs.182014 1822 <0.001 0.019 1.23 1.42
LCN2 3934 Hs.204238 1823 <0.001 0.019 1.24 1.08
S100A11 6282 Hs.417004 1823 <0.001 0.018 1.25 1.3
ATP1A3 478 Hs.515427 1826 0.001 0.019 1.14 1.25
CDCA8 55143 Hs.524571 1828 0.001 0.019 1.36 1.32
HLA-DPB1 3115 Hs.485130 1833 0.001 0.02 1.11 1.68
LGALS9 3965 Hs.81337 1834 0.001 0.02 1.32 1.36
STOML2 30968 Hs.3439 1835 0.001 0.02 1.32 1.36
CCL5 6352 Hs.514821 1835 0.001 0.02 1.22 1.1
CD1A 909 Hs.1309 1836 0.001 0.02 1.29 1.29
NRG2 9542 Hs.408515 1836 0.001 0.02 1.33 1.16
FUT3 2525 Hs.169238 1839 0.001 0.02 1.22 1.25
DMBT1 1755 Hs.279611 1840 0.001 0.02 1.33 1.04
PTTG1 9232 Hs.350966 1843 0.001 0.021 1.34 1.11
CYCS 54205 Hs.437060 1843 0.001 0.021 1.25 1.38
SYNGR2 9144 Hs.464210 1849 0.001 0.022 1.3 1.47
RPL29 6159 Hs.425125 1850 0.001 0.021 1.29 1.31
SURF4 6836 Hs.512465 1850 0.001 0.021 1.29 1.35
CAMK2N1 55450 Hs.197922 1851 0.001 0.021 1.34 1.28
CD3D 915 Hs.504048 1854 0.001 0.022 1.15 1.06
B9D1 27077 Hs.462445 1855 0.001 0.022 1.25 1.13
POLR2I 5438 Hs.47062 1857 0.001 0.022 1.16 1.12
C1orf96 126731 Hs.585011 1859 0.001 0.022 1.38 1.32
HIST1H4C 8364 Hs.46423 1859 0.001 0.022 1.01 1.12
ATP5G2 517 Hs.524464 1861 0.001 0.023 1.26 1.16
CAV2 858 Hs.212332 1866 0.001 0.023 1.16 1.33
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TCEB2 6923 Hs.172772 1867 0.001 0.024 1.27 1.26
PTGS1 5742 Hs.201978 1868 0.001 0.024 1.35 1.31
AP1M1 8907 Hs.71040 1869 0.001 0.024 1.31 1.3
PPFIA3 8541 Hs.413748 1871 0.001 0.024 1.33 1.19
CDK5R1 8851 Hs.500015 1873 0.001 0.024 1.08 1.36
ATP8B3 148229 Hs.306212 1873 0.001 0.024 1.32 1.3
TSPO2 222642 Hs.357392 1877 0.001 0.025 1.29 1.43
ADCK1 57143 Hs.413208 1878 0.001 0.025 1.34 1.46
FGR 2268 Hs.1422 1878 0.001 0.025 1.09 1.18
SMPDL3B 27293 Hs.123659 1880 0.001 0.025 1.41 1.32
C1QC 714 Hs.467753 1882 0.001 0.026 1.17 1.25
ZNF131 7690 Hs.535804 1883 0.001 0.026 1.36 1.27
GALNT13 114805 Hs.470277 1883 0.001 0.026 1.26 1.36
FBP1 2203 Hs.494496 1884 0.001 0.026 1.11 1.14
ECHS1 1892 Hs.76394 1887 0.001 0.026 1.31 1.31
CD163 9332 Hs.504641 1889 0.001 0.026 1.14 1.26
TTYH3 80727 Hs.440899 1893 0.001 0.027 1.37 1.33
AGER 177 Hs.534342 1897 0.001 0.028 1.26 1.18
ACP5 54 Hs.1211 1900 0.001 0.028 1.18 1.28
CNPY1 285888 Hs.146751 1901 0.001 0.028 1.28 1.18
FLJ40852 285962 Hs.17589 1901 0.001 0.028 1.31 1.42
LAP3 51056 Hs.570791 1901 0.001 0.028 1.07 1.04
C19orf56 51398 Hs.108969 1903 0.001 0.028 1.19 1.21
PDAP1 11333 Hs.632296 1904 0.001 0.028 1.35 1.48
STOM 2040 Hs.253903 1904 0.001 0.028 1.34 1.17
CAPN14 440854 Hs.468059 1904 0.001 0.028 1.25 1.49
NEFM 4741 Hs.458657 1906 0.001 0.029 1.26 1.39
CEACAM6 4680 Hs.466814 1907 0.001 0.029 1.2 1.21
AMPD1 270 Hs.89570 1911 0.001 0.03 1.26 1.27
MRPL18 29074 Hs.416998 1911 0.001 0.03 1.35 1.39
BTG1 694 Hs.255935 1916 0.001 0.03 1.31 1.34
NIPSNAP1 8508 Hs.173878 1916 0.001 0.03 1.28 1.26
CCL26 10344 Hs.131342 1918 0.001 0.03 1.3 1.14
TUBB3 10381 Hs.511743 1918 0.001 0.03 1.31 1.28
LGALS2 3957 Hs.531776 1921 0.001 0.031 1.28 1.32
FGL2 10875 Hs.520989 1922 0.001 0.031 1.05 1.29
MBNL1 4154 Hs.201858 1922 0.001 0.031 1.29 1.4
RPSA 3921 Hs.449909 1925 0.001 0.032 1.22 1.21
LMX1B 4010 Hs.129133 1926 0.001 0.032 1.36 1.38
KIF9 64147 Hs.373947 1928 0.001 0.032 1.26 1.28
ASF1B 55723 Hs.26516 1930 0.001 0.032 1.33 1.42
CCL21 6366 Hs.57907 1930 0.001 0.032 1.36 1.34
DCTN6 10671 Hs.158427 1931 0.001 0.032 1.3 1.34
NDST1 3340 Hs.222055 1933 0.001 0.033 1.35 1.32
FAM100A 124402 Hs.513313 1934 0.001 0.033 1.32 1.12
NDUFA2 4695 Hs.534333 1934 0.001 0.033 1.25 1.14
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LMAN2 10960 Hs.75864 1935 0.001 0.033 1.25 1.2
AIP 9049 Hs.412433 1938 0.001 0.033 1.28 1.44
VIP 7432 Hs.53973 1939 0.001 0.033 1.34 1.17
SRR 63826 Hs.461954 1940 0.001 0.034 1.33 1.4
CHCHD8 51287 Hs.475387 1942 0.001 0.034 1.31 1.3
LOC401397 401397 Hs.117929 1943 0.001 0.034 1.27 1.41
DSE 29940 Hs.458358 1945 0.001 0.034 1.23 1.26
NOP10 55505 Hs.14317 1946 0.001 0.034 1.25 1.23
GCM1 8521 Hs.28346 1948 0.001 0.035 1.33 1.19
AKR1B1 231 Hs.521212 1948 0.001 0.035 1.18 1.22
ETF1 2107 Hs.483494 1949 0.001 0.035 1.22 1.15
NDUFA7 4701 Hs.333427 1952 0.001 0.035 1.17 1.28
NMI 9111 Hs.54483 1953 0.001 0.036 1.24 1.27
LGI3 203190 Hs.33470 1954 0.001 0.036 1.3 1.35
GSS 2937 Hs.82327 1954 0.001 0.036 1.34 1.25
HERC1 8925 Hs.210385 1955 0.001 0.036 1.2 1.4
GRIN2A 2903 Hs.411472 1957 0.001 0.036 1.3 1.28
MEOX1 4222 Hs.438 1962 0.001 0.037 1.24 1.35
CPN1 1369 Hs.2246 1968 0.002 0.038 1.37 1.34
GPNMB 10457 Hs.190495 1968 0.002 0.038 1.15 1.24
MRPL41 64975 Hs.44017 1969 0.002 0.038 1.18 1.34
ZNF701 55762 Hs.235167 1971 0.002 0.038 1.33 1.38
PSMB8 5696 Hs.180062 1972 0.002 0.039 1.18 1.25
CTSL1 1514 Hs.418123 1973 0.002 0.039 1.2 1.32
FAM135B 51059 Hs.126024 1977 0.002 0.04 1.24 1.28
FOXF2 2295 Hs.484423 1980 0.002 0.04 1.21 1.23
GPR87 53836 Hs.591292 1981 0.002 0.04 1.29 1.18
BDNF 627 Hs.502182 1983 0.002 0.041 1.19 1.17
CEP78 84131 Hs.374421 1984 0.002 0.041 1.28 1.17
SLC16A1 6566 Hs.75231 1985 0.002 0.041 1.21 1.14
C3orf14 57415 Hs.47166 1986 0.002 0.041 1.27 1.27
PLAUR 5329 Hs.466871 1986 0.002 0.041 1.28 1.21
S100A10 6281 Hs.143873 1987 0.002 0.041 1.25 1.41
TEK 7010 Hs.89640 1988 0.002 0.041 1.16 1.12
PRAC 84366 Hs.116467 1989 0.002 0.041 1.16 1.04
TIMM8B 26521 Hs.279915 1992 0.002 0.042 1.23 1.42
BIN2 51411 Hs.14770 1992 0.002 0.042 1.15 1.07
BACH1 571 Hs.154276 1994 0.002 0.042 1.13 1.05
TWF2 11344 Hs.436439 1994 0.002 0.042 1.22 1.19
SLC6A6 6533 Hs.529488 1995 0.002 0.042 1.3 1.19
APOL1 8542 Hs.114309 1996 0.002 0.043 1.23 1.08
PLK4 10733 Hs.172052 1997 0.002 0.043 1.3 1.32
HSD3B7 80270 Hs.460618 1997 0.002 0.043 1.29 1.33
PLTP 5360 Hs.439312 1999 0.002 0.043 1.28 1.25
NDUFA13 51079 Hs.534453 1999 0.002 0.043 1.26 1.21
GSTM5 2949 Hs.75652 2001 0.002 0.043 1.34 1.29
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MT1E 4493 Hs.534330 2001 0.002 0.043 1.21 1.22
MYBL2 4605 Hs.179718 2005 0.002 0.044 1.34 1.38
OLFM1 10439 Hs.522484 2006 0.002 0.044 1.29 1.19
POLD4 57804 Hs.523829 2006 0.002 0.044 1.24 1.39
FUT10 84750 Hs.458713 2011 0.002 0.045 1.28 1.35
GPER 2852 Hs.20961 2011 0.002 0.045 1.26 1.27
HLA-B 3106 Hs.77961 2012 0.002 0.045 1.13 1.29
TMEM48 55706 Hs.476525 2013 0.002 0.045 1.33 1.41
ESRRA 2101 Hs.110849 2016 0.002 0.046 1.2 1.22
NCF4 4689 Hs.474781 2018 0.002 0.046 1.26 1.26
ATG2A 23130 Hs.370671 2019 0.002 0.047 1.36 1.35
TCP10L 140290 Hs.42034 2020 0.002 0.047 1.28 1.46
BRPF3 27154 Hs.520096 2021 0.002 0.047 1.29 1.25
SALL4 57167 Hs.517113 2021 0.002 0.047 1.35 1.33
MAGEA6 4105 Hs.441113 2022 0.002 0.047 1.33 1.19
EPB41L4B 54566 Hs.591901 2022 0.002 0.047 1.16 1.17
LOC100288413 100288413 Hs.363087 2024 0.002 0.047 1.34 1.22
C12orf65 91574 Hs.319128 2025 0.002 0.048 1.31 1.28
KDM5D 8284 Hs.80358 2025 0.002 0.048 1.24 1.33
SLC6A4 6532 Hs.134662 2026 0.002 0.048 1.21 1.1
NDUFA1 4694 Hs.534168 2029 0.002 0.049 1.19 1.36
DNMT1 1786 Hs.202672 2030 0.002 0.049 1.34 1.31
B2M 567 Hs.534255 2031 0.002 0.049 1.12 1.04
KPNA2 3838 Hs.594238 2031 0.002 0.049 1.26 1.34
TMEM40 55287 Hs.475502 2032 0.002 0.049 1.17 1.23
CDC25B 994 Hs.153752 2033 0.002 0.049 1.27 1.29
LOC644838 644838 Hs.145561 2035 0.002 0.05 1.34 1.23
FABP4 2167 Hs.391561 2035 0.002 0.05 1.09 1.21
SPRYD3 84926 Hs.343334 2036 0.002 0.05 1.25 1.37
SSNA1 8636 Hs.530314 2037 0.002 0.05 1.31 1.27
TBC1D23 55773 Hs.477003 2037 0.002 0.05 1.24 1.11
RP, rank product; P, p-value ;FDR, false discovery rate; FC, fold change
Table 2. Genes signiﬁcantly down-regulated in BOS-positive samples
Gene symbol Entrez ID UniGene RP P FDR 1
MeanFC
1
MedianFC
ALDH3A1 218 Hs.531682 136 <0.001 <0.001 2.47 2.85
SCGB3A2 117156 Hs.483765 225 <0.001 <0.001 2.15 1.87
HBA1 3039 Hs.449630 286 <0.001 <0.001 1.62 2.37
HBB 3043 Hs.523443 294 <0.001 <0.001 1.57 3.17
MID1 4281 Hs.27695 395 <0.001 <0.001 1.77 1.85
SFTPC 6440 Hs.1074 458 <0.001 <0.001 1.18 1.31
NCRNA00086 399668 Hs.374414 544 <0.001 <0.001 1.74 1.74
ZNF704 619279 Hs.632067 639 <0.001 <0.001 1.72 1.76
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OLA1 29789 Hs.157351 671 <0.001 <0.001 1.57 2
AHSP 51327 Hs.274309 699 <0.001 <0.001 1.82 1.26
VAV2 7410 Hs.369921 762 <0.001 <0.001 1.58 1.7
PIPOX 51268 Hs.462585 767 <0.001 <0.001 1.65 1.74
CES1 1066 Hs.558865 787 <0.001 <0.001 1.6 1.83
LTF 4057 Hs.529517 795 <0.001 <0.001 1.37 1.92
SCGB1A1 7356 Hs.523732 814 <0.001 <0.001 1.32 1.4
SFTPB 6439 Hs.512690 830 <0.001 <0.001 1.23 1.84
TRMT61A 115708 Hs.525610 864 <0.001 <0.001 1.62 1.87
F2RL2 2151 Hs.42502 876 <0.001 <0.001 1.59 1.48
APOBEC2 10930 Hs.555915 895 <0.001 <0.001 1.41 1.69
ZNF700 90592 Hs.528486 937 <0.001 <0.001 1.15 1.53
SLC25A36 55186 Hs.144130 943 <0.001 <0.001 1.35 1.43
RTBDN 83546 Hs.21162 950 <0.001 <0.001 1.48 1.6
HFE2 148738 Hs.632436 966 <0.001 <0.001 1.49 1.51
MUC5AC 4586 Hs.534332 969 <0.001 <0.001 1.3 1.09
CXorf57 55086 Hs.274267 978 <0.001 <0.001 1.45 1.71
APBB1 322 Hs.372840 984 <0.001 <0.001 1.5 1.47
WNT6 7475 Hs.29764 992 <0.001 <0.001 1.42 1.85
C14orf132 56967 Hs.6434 993 <0.001 <0.001 1.42 1.42
TBC1D8 11138 Hs.442657 1006 <0.001 <0.001 1.51 1.64
CORO2B 10391 Hs.551213 1007 <0.001 <0.001 1.43 1.56
ZMAT1 84460 Hs.496512 1029 <0.001 <0.001 1.29 1.37
CAMK2G 818 Hs.523045 1069 <0.001 <0.001 1.41 1.49
CDHR1 92211 Hs.137556 1089 <0.001 <0.001 1.47 1.64
SFTPD 6441 Hs.253495 1092 <0.001 <0.001 1.24 1.57
HYDIN 54768 Hs.461229 1100 <0.001 <0.001 1.37 1.25
MST1 4485 Hs.512587 1114 <0.001 <0.001 1.31 1.12
PRKAR2A 5576 Hs.631923 1119 <0.001 <0.001 1.46 1.5
IFIT1 3434 Hs.20315 1124 <0.001 <0.001 1.38 1.33
LOC100130872 100130872 Hs.302963 1129 <0.001 0.001 1.39 1.67
RAB3B 5865 Hs.123072 1132 <0.001 0.001 1.47 1.61
WDR19 57728 Hs.438482 1142 <0.001 0.001 1.37 1.25
ALDH3B2 222 Hs.87539 1144 <0.001 0.001 1.19 1.37
NELL2 4753 Hs.505326 1148 <0.001 0.001 1.39 1.09
CDKN1C 1028 Hs.106070 1153 <0.001 0.001 1.41 1.07
S100A12 6283 Hs.19413 1154 <0.001 0.002 1.24 1.12
MPL 4352 Hs.82906 1166 <0.001 0.002 1.44 1.44
KCNMB4 27345 Hs.525529 1184 <0.001 0.002 1.42 1.7
PTPN14 5784 Hs.193557 1190 <0.001 0.002 1.44 1.51
GSTA3 2940 Hs.102484 1197 <0.001 0.002 1.42 1.33
NUP210 23225 Hs.475525 1202 <0.001 0.002 1.44 1.56
C1orf173 127254 Hs.531182 1202 <0.001 0.002 1.31 1.43
CRLF1 9244 Hs.114948 1212 <0.001 0.002 1.32 1.25
DLGAP2 9228 Hs.113287 1213 <0.001 0.002 1.37 1.52
NLGN4X 57502 Hs.21107 1214 <0.001 0.002 1.39 1.82
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SLC35D3 340146 Hs.369703 1227 <0.001 0.002 1.45 1.44
NRG1 3084 Hs.453951 1236 <0.001 0.002 1.39 1.51
RGS22 26166 Hs.120021 1243 <0.001 0.002 1.33 1.55
ZNF233 353355 Hs.466891 1246 <0.001 0.003 1.44 1.47
LRP5 4041 Hs.6347 1246 <0.001 0.003 1.35 1.27
LOC440248 440248 Hs.531509 1254 <0.001 0.003 1.15 1.51
ATOH8 84913 Hs.135569 1258 <0.001 0.003 1.36 1.38
TMEM146 257062 Hs.631842 1275 <0.001 0.003 1.21 1.2
CX3CR1 1524 Hs.78913 1277 <0.001 0.003 1.38 1.21
SNCAIP 9627 Hs.426463 1281 <0.001 0.003 1.46 1.4
C12orf66 144577 Hs.505871 1284 <0.001 0.003 1.44 1.34
USP6 9098 Hs.448851 1299 <0.001 0.003 1.26 1.4
ALAS2 212 Hs.522666 1306 <0.001 0.004 1.43 1.04
CCDC66 285331 Hs.476399 1310 <0.001 0.004 1.26 1.38
GSTA2 2939 Hs.94107 1312 <0.001 0.004 1.34 1.32
COL7A1 1294 Hs.476218 1317 <0.001 0.004 1.4 1.25
DNAH5 1767 Hs.212360 1322 <0.001 0.004 1.25 1.36
CACNA1C 775 Hs.118262 1357 <0.001 0.004 1.37 1.42
NOX4 50507 Hs.371036 1358 <0.001 0.004 1.36 1.47
LOC100287743 100287743 Hs.129095 1359 <0.001 0.004 1.41 1.67
ACSS1 84532 Hs.529353 1362 <0.001 0,004 1.3 1.53
FLRT3 23767 Hs.41296 1371 <0.001 0,004 1.35 1.4
AKR1C2 1646 Hs.567256 1372 <0.001 0,005 1.27 1.06
SNX13 23161 Hs.487648 1390 <0.001 0,005 1.29 1.27
NPIPL3 23117 Hs.611072 1390 <0.001 0,005 1.12 1.66
NAP1L5 266812 Hs.12554 1395 <0.001 0,005 1.4 1.61
ZNF703 80139 Hs.288042 1402 <0.001 0,006 1.3 1.3
TP53INP1 94241 Hs.492261 1406 <0.001 0,006 1.32 1.39
C1orf168 199920 Hs.437655 1410 <0.001 0,006 1.25 1.21
C18orf10 25941 Hs.436636 1413 <0.001 0,006 1.38 1.38
PRR15L 79170 Hs.368260 1428 <0.001 0,007 1.3 1.17
METRN 79006 Hs.533772 1438 <0.001 0,008 1.13 1.32
KRCC1 51315 Hs.469254 1440 <0.001 0,008 1.38 1.33
SNTB1 6641 Hs.46701 1441 <0.001 0,008 1.36 1.32
SLC29A1 2030 Hs.25450 1454 <0.001 0,008 1.42 1.58
DNAH7 56171 Hs.97403 1460 <0.001 0,008 1.24 1.2
PLEKHG1 57480 Hs.189781 1461 <0.001 0,008 1.18 1.7
MBLAC2 153364 Hs.64004 1474 <0.001 0,009 1.39 1.49
MCF2L2 23101 Hs.208267 1474 <0.001 0,009 1.2 1.27
DNAH3 55567 Hs.526500 1478 <0.001 0,009 1.23 1.58
DSC1 1823 Hs.567260 1479 <0.001 0,009 1.25 1.3
NRCAM 4897 Hs.21422 1486 <0.001 0,009 1.37 1.49
C12orf4 57102 Hs.302977 1488 <0.001 0,009 1.32 1.25
RNPC3 55599 Hs.632423 1492 <0.001 0,009 1.19 1.37
NKAIN1 79570 Hs.470259 1499 <0.001 0,010 1.34 1.5
WIF1 11197 Hs.284122 1504 <0.001 0,010 1.33 1.29
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SNRPN 6638 Hs.592473 1504 <0.001 0,010 1.16 1.31
CYP1B1 1545 Hs.154654 1512 <0.001 0,011 1.41 1.23
FBXL3 26224 Hs.508284 1514 <0.001 0,011 1.29 1.17
C4A 720 Hs.534847 1515 <0.001 0,011 1.26 1.31
RBM18 92400 Hs.415842 1522 <0.001 0,011 1.25 1.28
C21orf7 56911 Hs.222802 1523 <0.001 0,011 1.29 1.37
FAM120A 23196 Hs.372003 1524 <0.001 0,011 1.4 1.52
NAT10 55226 Hs.577281 1524 <0.001 0,011 1.32 1.4
CDC42SE2 56990 Hs.508829 1525 <0.001 0,011 1.39 1.36
DENND5B 160518 Hs.118166 1535 <0.001 0,012 1.33 1.37
WDSUB1 151525 Hs.20848 1540 <0.001 0,012 1.33 1.28
PPY 5539 Hs.558368 1549 <0.001 0,013 1.26 1.34
ZNF439 90594 Hs.528731 1552 <0.001 0,014 1.19 1.28
SLC6A20 54716 Hs.413095 1554 <0.001 0,014 1.3 1.36
PON3 5446 Hs.440967 1554 <0.001 0,013 1.25 1.32
FAM83A 84985 Hs.379821 1555 <0.001 0,013 1.29 1.4
HSD17B13 345275 Hs.284414 1570 <0.001 0,015 1.22 1.25
GPCPD1 56261 Hs.636359 1571 <0.001 0,015 1.24 1.44
OXTR 5021 Hs.2820 1572 <0.001 0,015 1.29 1.33
ANAPC16 119504 Hs.426296 1573 <0.001 0,015 1.19 1.46
FOLR1 2348 Hs.73769 1579 <0.001 0,015 1.13 1.17
PTCD2 79810 Hs.126906 1579 <0.001 0,015 1.34 1.44
PPP2CA 5515 Hs.105818 1586 <0.001 0,016 1.31 1.29
LOC100288779 100288779 Hs.11729 1587 <0.001 0,016 1.29 1.25
SNRPN 6638 Hs.632166 1588 <0.001 0,016 1.36 1.41
CXXC4 80319 Hs.12248 1595 <0.001 0,017 1.3 1.37
ZNF771 51333 Hs.148584 1597 <0.001 0,017 1.26 1.31
CHRFAM7A 89832 Hs.510853 1598 <0.001 0,017 1.19 1.24
ARGLU1 55082 Hs.508644 1598 <0.001 0,017 1.15 1.31
SESN1 27244 Hs.591336 1607 <0.001 0,018 1.32 1.17
MLLT11 10962 Hs.75823 1615 <0.001 0,019 1.32 1.51
HDAC10 83933 Hs.26593 1615 <0.001 0,019 1.31 1.51
ACY3 91703 Hs.126265 1617 <0.001 0,019 1.28 1.43
PRKCA 5578 Hs.531704 1619 <0.001 0,019 1.3 1.35
VSTM2L 128434 Hs.517029 1641 <0.001 0,021 1.22 1.28
RNLS 55328 Hs.149849 1651 <0.001 0,022 1.25 1.32
SLC25A37 51312 Hs.596025 1653 <0.001 0,022 1.25 1.24
C18orf16 147429 Hs.559280 1654 <0.001 0,022 1.36 1.4
ABCA13 154664 Hs.226568 1655 <0.001 0,022 1.16 1.32
LOC440354 440354 Hs.552700 1657 <0.001 0,022 1.32 1.32
FXYD2 486 Hs.413137 1662 <0.001 0,023 1.29 1.13
PM20D2 135293 Hs.356247 1664 <0.001 0,023 1.31 1.42
JHDM1D 80853 Hs.308710 1666 <0.001 0,023 1.2 1.44
LOC100132004 100132004 Hs.434447 1670 <0.001 0,024 1.31 1.33
SLC22A9 114571 Hs.502772 1673 <0.001 0,024 1.32 1.31
CYP4X1 260293 Hs.439760 1676 <0.001 0,025 1.26 1.28
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TNS3 64759 Hs.520814 1678 <0.001 0,025 1.23 1.35
FAM111B 374393 Hs.186579 1680 <0.001 0,025 1.33 1.4
NRP1 8829 Hs.131704 1680 <0.001 0,025 1.27 1.17
SEZ6L2 26470 Hs.6314 1681 <0.001 0,025 1.23 1.45
GOLGA8A 23015 Hs.182982 1687 <0.001 0,026 1.24 1.31
DEFA4 1669 Hs.591391 1687 <0.001 0,026 1.24 1.1
CLEC3B 7123 Hs.476092 1689 <0.001 0,026 1.1 1.13
CX3CL1 6376 Hs.531668 1689 <0.001 0,026 1.19 1.24
MPP6 51678 Hs.533355 1694 <0.001 0,027 1.38 1.25
CXorf42 158801 Hs.442518 1694 <0.001 0,027 1.35 1.37
PDXP 57026 Hs.632762 1700 <0.001 0,028 1.31 1.35
MGC39584 441058 Hs.130535 1702 <0.001 0,028 1.33 1.44
LOC100286909 100286909 Hs.445414 1705 <0.001 0,028 1.16 1.22
ATRN 8455 Hs.276252 1710 <0.001 0.029 1.22 1.37
MSMB 4477 Hs.255462 1718 <0.001 0.031 1.08 1.34
SESTD1 91404 Hs.30977 1719 <0.001 0.031 1.22 1.37
CDK5RAP1 51654 Hs.435952 1724 <0.001 0.031 1.29 1.35
LGALS3 3958 Hs.531081 1724 <0.001 0.031 1.11 1.28
GMPR 2766 Hs.484741 1728 <0.001 0.031 1.23 1.28
KIAA1407 57577 Hs.477159 1742 <0.001 0.034 1.19 1.15
CYP24A1 1591 Hs.89663 1744 <0.001 0.034 1.24 1.31
USP51 158880 Hs.40061 1747 <0.001 0.035 1.33 1.45
RAI2 10742 Hs.446680 1751 <0.001 0.035 1.27 1.32
ALCAM 214 Hs.591293 1752 <0.001 0.036 1.31 1.22
ODF2L 57489 Hs.149360 1754 <0.001 0.036 1.15 1.2
TMX3 54495 Hs.440534 1755 <0.001 0.036 1.2 1.17
PPP3R1 5534 Hs.280604 1755 <0.001 0.036 1.2 1.35
MUC5B 727897 Hs.523395 1757 <0.001 0.036 1.12 1.04
C1orf111 284680 Hs.97784 1766 <0.001 0.038 1.34 1.26
SIPA1L2 57568 Hs.268774 1768 <0.001 0.039 1.29 1.32
RAPGEFL1 51195 Hs.632254 1770 <0.001 0.039 1.29 1.28
SMYD1 150572 Hs.516176 1775 <0.001 0.040 1.12 1.33
VAT1L 57687 Hs.461405 1778 <0.001 0.040 1.21 1.31
LOC100130522 100130522 Hs.352602 1781 <0.001 0,041 1.32 1.37
AGTR1 185 Hs.477887 1783 <0.001 0.041 1.28 1.26
CD3G 917 Hs.2259 1783 <0.001 0.041 1.34 1.22
C1QL2 165257 Hs.433493 1785 <0.001 0.041 1.29 1.23
STK33 65975 Hs.501833 1789 <0.001 0.042 1.19 1.17
GABRE 2564 Hs.22785 1795 <0.001 0.043 1.21 1.31
NHLRC2 374354 Hs.594372 1795 <0.001 0.043 1.23 1.27
HDAC8 55869 Hs.310536 1796 <0.001 0.043 1.32 1.49
CBLN2 147381 Hs.569851 1796 <0.001 0.043 1.22 1.08
FAM110B 90362 Hs.154652 1798 <0.001 0.043 1.31 1.23
KCNJ16 3773 Hs.463985 1803 <0.001 0,044 1.19 1.43
LOC645195 645195 Hs.536063 1807 <0.001 0.045 1.33 1.26
IQGAP1 8826 Hs.430551 1809 <0.001 0.046 1.25 1.17
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PROZ 8858 Hs.1011 1812 <0.001 0.046 1.16 1.24
CLK1 1195 Hs.433732 1815 <0.001 0.046 1.17 1.34
PAN2 9924 Hs.273397 1815 <0.001 0.046 1.29 1.27
FLJ31104 441072 Hs.482141 1816 <0.001 0.046 1.28 1.36
C5orf4 10826 Hs.519694 1817 <0.001 0.046 1.28 1.23
SEMA5A 9037 Hs.27621 1819 0.001 0.047 1.13 1.05
ZNF592 9640 Hs.79347 1820 0.001 0.047 1.31 1.23
POLR3B 55703 Hs.62696 1823 0.001 0.048 1.28 1.45
LGR6 59352 Hs.497402 1824 0.001 0.048 1.21 1.25
VNN1 8876 Hs.12114 1825 0.001 0.049 1.01 1.1
AGA 175 Hs.207776 1826 0.001 0.049 1.24 1.27
STIM2 57620 Hs.135763 1828 0.001 0.049 1.29 1.24
LOC388152 388152 Hs.405809 1829 0.001 0.049 1.22 1.26
LOC100287465 100287465 Hs.507676 1830 0.001 0.049 1.34 1.27
P2RY13 53829 Hs.546396 1830 0.001 0.049 1.12 1.23
ABCC3 8714 Hs.463421 1830 0.001 0.049 1.28 1.13
RP, rank product; P, p-value ;FDR, false discovery rate; FC,fold change
